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Preface 
The purpose of this book is to review all types of pituitary adenoma and describe the
symptoms, epidemiology, diagnosis, management, outcome and complications of 
them. 
Pituitary adenomas are typically benign, slow-growing tumors that arise from cells in 
the pituitary gland. The pituitary gland lies below the optic system, primarily the optic
chiasm, and below the optic nerves and optic tracts. Thus, pituitary adenomas, the
most common tumors of the hypophysis, can compress optic system and some of the
main symptoms and signs in patients are visual. Therefore, measurement of visual 
acuity, visual fields, ophthalmoscopy and the use of Optical Coherence Tomography 
has a significant role in diagnosis and periodic evaluation of the patient. 
Pituitary adenomas are classified based on hormone secretory products. But non-
functioning adenomas are endocrine-inactive tumors. Because of physiologic effects of
excess hormones, the functioning tumors present earlier than non-functioning
adenomas. On the other hand, the mass effect from large pituitary adenomas may lead 
to the pressure symptoms, such as headaches, visual field defects, cranial nerve 
deficits, hypopituitarism, pituitary apoplexy or stalk effect.
The molecular mechanisms underlying the development and progression of pituitary 
adenoma have not yet been clearly defined. However, immunohistochemistry and 
ultrastructural analysis developed new insights into the pathogenesis of these tumors. 
The finding of specific serum markers in patients with pituitary adenoma will help 
physicians in the accurate diagnosis and specific treatment of patients in the future. 
Diagnostic MRI of the sellar region constitutes one of the most challenging subjects in 
neurooncology. T1- and T2-weighted MRI in coronal and sagittal planes with and 
without paramagnetic contrast medium is the method of choice for imaging of the 
pituitary gland and the perisellar area. 
During the past two decades, a number of new procedures for radiation dose delivery
and fractionation have become extensively accessible. The most important progress
has been in the use of stereotactic procedures to make radiotherapy targeting
relatively simple and very precise. This has permitted the application of single fraction 
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high-dose irradiation entitled stereotactic radiosurgery for brain tumors which can be 
given as an adjuvant or as a specific treatment modality for pituitary adenomas in 
patients who have had recurrence after microsurgery, or if complete tumor removal 
has not been possible. 
Finally, visual testing, endocrine evaluation and MRI are three main tools in the pre 
and post treatment assessment of patients with pituitary adenoma. Considering all 
modalities of treatment (medical, surgical, or radiotherapy) selected for management 
of patients, visual assessment together with endocrine and imaging is essential in short 
and long term evaluation of tumors of the hypophysis. 
I want to thank Ms Maja Bozicevic for helping me trough the process, InTech for 
giving me opportunity to work as an Editor and Prof. Ed Laws for his support. 
 
Vafa Rahimi-Movaghar, MD 
Associate professor of Neurosurgery 
Vice-Chairman of Sina Trauma and Surgery Research Center, Department of 
Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, 
Iran 
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Pituitary Adenomas and Ophthalmology 
Santiago Ortiz-Perez and Bernardo Sanchez-Dalmau 
Hospital Clinic, University of de Barcelona, Ophthalmology department 
Spain 
1. Introduction 
Pituitary gland, also called hypophysis, is a neuroendocrine organ placed in the “sella 
turcica” in the skull base. This gland consists of 2 main areas, the anterior and medial part 
constitute the adenohypophysis, the posterior part is called neurohypophysis. Pituitary 
gland is in charge of the internal constancy, homeostasis and reproductive function; this is 
why pituitary abnormalities cause a wide spectrum of signs and symptoms.  
Pituitary adenomas are a common pathology; they represent about 10% of all intracranial 
tumours and between 50-80% of pituitary tumours. Necropsy and imaging studies estimate 
an incident of 20-25% of pituitary adenomas in general population; however, only about 1/3 
of them are clinically evident (Asa & Ezzat, 2009). The majority of these tumours have 
monoclonal origin (mutation of a single gonadotropic cell), but there are still some 
discrepancies about the pathogenesis of these neoplasms. The most common mutations 
seem in other human neoplasms are not frequent in pituitary adenomas, and only a 
minimum proportion of them are associated to other genetic disorders, such as MEN1 
syndrome (multiple endocrine neoplasms type 1)  or the Carney complex, due to mutations 
of the genes MEN1 and PRKAR1A (protein kinase A regulatory subunit 1A) respectively 
(Beckers & Daly, 2007). Hormones and growth factors involve in normal pituitary function 
can be also related to the growth of these tumours, although evident connection with the 
pathogenesis has not been demonstrated. 
Symptoms related to pituitary tumours are secondary to several factors. On the one hand, 
many of them are non-secreting tumours, they can be asymptomatic or cause compression 
symptoms if they are big enough; on the other hand, other are secreting tumours and they can 
cause clinical syndromes derivate from the hormone activity in different target organs. 
Hormones secreting by these tumours are the same that the physiologic hypophysis 
produces. According to frequency, the most frequent tumours are prolactin (PRL)-secreting 
pituitary adenomas, non secreting pituitary adenomas are in second position, growth 
hormone (GH)-secreting tumours in third, adrenocorticotropic hormone (ACTH)-secreting 
tumours in fourth, and the rarest are thyroid stimulating hormone (TSH)-secreting 
adenomas. There are also tumour secreting different combinations of hormones, mainly GH 
and PRL (Table 1). In cases of fast growing or big tumours affecting surrounding structures, 
chiasmatic or cavernous sinus syndrome can be seen.  
Two types of adenomas can be described depending on the size of the tumour, 
macroadenomas with more than 1 centimeter and microadenomas measuring less than 1 cm 
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in size (figure 1). A low percentage of tumours have a malign behaviour producing 
metastases, central nervous system invasion and even death; nevertheless, this is very 
uncommon and the majority of the problems related to these tumours are due to the 
morbidity that they produce. 
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Table 1. Pituitary cells, hormones, tumours and associated clinical syndromes (Asa & Ezzat, 
2002) 
 
Fig. 1. Magnetic resonance imaging showing a pituitary macroadenoma. 
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The wide spectrum of clinical syndromes including endocrinological, cardiovascular, 
neurological, ophthalmological, determine the needed of a multidisciplinary management 
between different specialists. Early diagnosis is very important in order to establish a proper 
therapeutic plan and achieve the best prognosis for these patients. 
In this review, a comprehensive description about the ophthalmological syndromes 
associated to pituitary adenomas is presented. The suspicion of these syndromes by the 
doctors facing patients with pituitary tumours will allow earlier diagnostic and better 
treatments for them. Despite the general ophthalmic examination including visual field 
tests, we describe the Optical Coherence Tomography (OCT) as a new tool that must be 
performed in all these patients.  
2. Ophthalmic manifestations of pituitary adenomas 
The most common neuro-ophthalmological syndrome associated to pituitary adenomas is 
due to compression of the central part of the optic chiasm; this produces the classic 
bitemporal hemianopia in the visual field. That was the onset manifestation in up to 80% of 
pituitary adenomas several years ago, but nowadays, the advantages in the hormone 
detection tests and neuroimaging have changed this trend, and headache and systemic 
clinical syndromes related to hormone production are the commonest onset manifestations. 
Neuro-ophthalmological manifestations are the debut syndrome in less than 10% of cases 
(Table 2); they are due to the anatomical relations between the gland and the optic chiasm, 
the optic nerves and the III, IV and VI nerves in the cavernous sinus.  
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 14 70 34 6 
Klauber et al 
(51; 1967-74)  45 69 47  
Wray (100; 
1974-76) 21 24 31 19 4 
Anderson et al 
(200; 1976-1981) 70 46 9 2 1 
EOM: extraocular muscle 
Table 2. Debut signs and symptoms in pituitary adenoma patients (Chhabra & Newman, 
2006)  
2.1 Anatomy of the pituitary area (Rouvière & Delmas, 1996) 
Optic nerves enter the intracranial space through the optic foramen in the sphenoid bones, 
after 8-15 mm up and backwards they join together to constitute the optic chiasm. There are 
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optic chiasm, this is extremely important with respect to the visual deficits caused by 
tumours in the suprasellar region. In 75-80% of people optic chiasm is placed just above the 
diaphragma sellae; when the intracranial optic nerve is shorter than about 12 mm (about 10% 
of people), the optic chiasm is positioned anteriorly, or “pre-fixed”, and it sits above the 
tuberculum sellae, when the intracranial optic nerve is long, over 18 mm (10-15% of people), 
the chiasm is positioned posteriorly to the dorsum sellae or “post-fixed” (Chhabra & 
Newman, 2006; Miller N, et al, 2008). 
Fibers running from the nasal retinal nerve cells (about 53% of fibers) cross in the chiasm to 
join the fibers from the temporal retinal nerve cells of the opposite side. However, as they 
enter the chiasm, some ventral crossed fibers, primarily from the inferonasal retinal of the 
contralateral eye and serving the superotemporal portion of the contralateral visual field, 
where historically believed to loop anteriorly 1 to 2 mm into the terminal portion of the 
opposite optic nerve before turning posteriorly to continue through the chiasm and into the 
optic tract. This loop is called Willebrand’s Knee (Miller N, et al, 2008; Muñoz-Negrete & 
Rebolleda, 2002). There is some controversy about the real anatomical existence of this 
structure, however Willebrand’s knee clearly exists from a clinical point of view, as it is 
described below. In cases of chiasm compression the crossed fibers are more likely to be 
damaged as they support the same quantity of pressure in less space (Kosmorsky, et al, 
2008). This is the reason for the bitemporal hemianopia (crossed nasal fibers compression) as 
the more frequent syndrome in cases of chiasm compression. Fibers leave the chiasm 
backwards in both sides of the hypophysis as the optic tracts; in cases of pre-fixed chiasms is 
more likely to see damaged of these tracts.  
The pituitary gland lies between the two paired cavernous sinuses. An abnormally growing 
adenoma will expand in the direction of least resistance and eventually compress the 
cavernous sinus (figure 2). The cavernous sinus receives blood via the ophthalmic vein 
through the superior orbital fissure and from superficial cortical veins, and is connected to 
the basilar plexus of veins posteriorly. The internal carotid artery (carotid siphon), and 
cranial nerves III, IV, V1, V2 and VI all pass through this blood filled space. The cavernous 
sinus drains by two channels, the superior and inferior petrosal sinuses, ultimately into the 
internal jugular vein. These nerves, with the exception of V2, pass through the cavernous 
sinus to enter the orbital apex through the superior orbital fissure. The maxillary nerve, 
division V2 of the trigeminal nerve travels through the lower portion of the sinus and exits 
via the foramen rotundum (Miller N, et al, 2008; Frank, et al, 2006). 
2.2 Clinical syndromes 
There are different syndromes that can be seen in cases of pituitary adenomas: 
2.2.1 Anterior chiasmal syndrome 
This is more common in post-fixed chiasms. The compression in the anterior angle of the 
optic chiasm affect the Willbrandt’s knee fibers and produces temporal and superior visual 
field defects affecting one or both eyes. In cases of non-centred tumours the anterior junction 
syndrome of Traquair (junctional scotoma) can be observed, characterized by advanced 
visual field loss affecting the visual field centre in one eye and (possibly subtle) defects 
respecting the vertical midline in the fellow eye (Muñoz-Negrete & Rebolleda, 2002). 
 




Fig. 2. Anatomy of the cavernous sinus and surrounding structures. Relation between the 
pituitary gland and the chiasm, cranial nerves and internal carotid arteries. 
2.2.2 Central chiasmal syndrome  
This is the most frequent syndrome; the damage involving mainly the crossed fibers 
produces bitemporal hemianopia with possible central visual field affectation (figure 3). 
This syndrome is seen in lesions that damage the body of the optic chiasm. 
 
Fig. 3. Visual field showing a bitemporal hemianopia. 
2.2.3 Inferior chiasmal syndrome  
If the compression affects predominantly the inferior part of the chiasm the visual field 
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2.2.4 Superior chiasmal syndrome 
Compression of the superior part of the chiasm is not a frequent condition in cases of 
pituitary adenomas; it is more likely to see this clinical picture in other tumours arising from 
the base of the brain, mainly the craniopharyngioma. In these cases the visual field defects 
are temporal and inferior. 
2.2.5 Posterior chiasmal syndrome  
More frequent in pre-fixed chiasms. It produces characteristic bitemporal hemianopic 
scotomas in the visual field.  
2.2.6 Lateral chiasmal syndrome 
This syndrome can be observed in tumours compressions or carotid pathology that pushes 
the chiasm laterally. Contralateral homonymus quadrantanopic or hemianopic defects can 
be assessed; much less frequent is the binasal hemianopia in these cases.  
2.2.7 Optic tract compression  
This is also more frequent in cases of post-fixed chiasms. Contralateral homonymus defects 
can be observed. Optic tract damage is more frequent in other neurological conditions, such 
as vascular processes, demyelinating diseases or trauma. Another pupillary phenomenon 
that is sometimes associated with lesions of the optic tract that produce a complete or nearly 
complete homonymus hemianopia is pupillary hemiakinesia (hemianopic pupillary reaction 
or Wernicke’s pupil) (Miller N, et al, 2008).  
2.2.8 Neuro-ophthalmological signs and symptoms associated with the chiasmal 
syndrome 
The presence of visual field defect can associate different manifestations, such as the 
hemifield slide phenomenon that produces fluctuating diplopia with no oculomotor 
impairment due to anomalous retinal correspondence. It is also common a disturbance of 
depth perception. These two phenomenons are associated to bitemporal hemianopia (Chhabra 
& Newman, 2006; Miller N, et al, 2008). 
2.2.9 Ocular motility disorders  
Patients with pituitary pathology can refer diplopia related to the mentioned hemifield slide 
phenomenon, or due to cranial nerves damage in the cavernous sinus; the most frequently 
affected is the third nerve leading to an eyelid ptosis, pupillary dilation, and ocular motility 
disorders (figure 4). The rarest of those syndromes is the VI nerve palsy.  
2.2.10 Nystagmus  
In cases of tumours of the diencephalon and chiasmal regions the rare phenomenon of the 
“see-saw” nystagmus may occur. This condition is characterized by synchronous alternating 
elevation and incyclotorsion of one eye and depression and excyclotorsion of the opposite 
eye. The pathogenesis of this phenomenon is not well understood but it is thought to be 
related to perception impairment connected with hemianopia (Chhabra & Newman, 2006) 
 




Fig. 4. Patient affected by a III nerve palsy. Observe the eyelid ptosis due to affectation of the 
levator muscle. These patients also have pupillary dilation and extraocular movements 
impairment 
or damage to the interstitial nucleus of Cajal or adjacent structures of the tumour (Miller, et 
al, 2008). In cases of big tumours compressing the brainstem is also possible, although 
exceptional, the presence of nystagmus. 
2.2.11 Colour vision impairment  
This can be observed as a sign of visual pathway damage in different conditions, including 
cases of pituitary adenomas.  
2.2.12 Photophobia  
Some authors suggest that persistent photophobia of unknown aetiology should arise the 
suspicion of pituitary pathology (Kawasaki & Purvin, 2002). 
2.2.13 Pituitary apoplexy  
Defined as a sudden neurologic impairment, usually due to a vascular process. It is 
characterized by a sudden onset of headache, visual symptoms, altered mental status, and 
hormonal dysfunction due to acute hemorrhage or infarction of a pituitary gland. An existing 
pituitary adenoma is usually present. The incidence of this phenomenon has been described 
up to 10% in some series (Wakai, 1981). The visual symptoms may include both visual acuity 
impairment and visual field impairment from involvement of the optic nerve or chiasm and 
ocular motility dysfunction from involvement of the cranial nerves traversing the cavernous 
sinus (more frequent III nerve). Other less common symptoms are related to possible 
brainstem damage, such as light-near dissociation or convergence retraction nystagmus.  
2.2.14 Funduscopy  
Most of the cases show normal optic discs in fundus examination. If altered, it can be a diffuse 
atrophy, or more typically the “band” or “bow-tie” atrophy that occupies a more or less 
horizontal band across the disc with relative sparing of the superior and inferior portions 
where the majority of spared temporal fibers enter (figure 5). Some cases can develop 
papilledema, this is more frequently associated with suprachiasmal tumours that can invade 
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Fig. 5. Schematic representation of retinal nerve fibers (A). Optic disc of a patient with a 
pituitary adenoma showing atrophy of the nasal and temporal areas (“band” atrophy) and 
relative spare of the superior and inferior areas of the disc (B). 
2.2.15 Other neuro-ophthalmological manifestations 
Apart from the syndromes derivated from the tumour itself, the treatments used in these 
patients can produce neuro-ophthalmological side-effects:  
 Toxic dopaminergic psychosis caused by Bromocriptine. Treatment with this drug can 
also produce a quick tumour regression leading to an empty sella syndrome due to a 
herniation of the chiasm.   
 The surgical treatment most frequently performed today for these patients is the 
endoscopic trans-sphenoidal surgery. This technique can be also responsible for some 
ophthalmological side effects, mainly for damaging the optic nerves or the chiasm; 
nevertheless, the increasingly improvement in the equipment and surgical techniques 
allows treatments with much less complications (Cappabianca, et al, 2002). 
 Post-radiotherapy optic neuropathy. This is a minor problem nowadays because 
radiotherapy is an unusual treatment for these tumours, and also because of the 
improvement in the techniques using fractioned radiotherapy and protecting important 
structures such as the optic discs (Van den Bergh, et al, 2007). 
3. Visual recovery prediction factors  
During the last years different specialists involve in the management of pituitary adenomas 
have tried to establish prognostic factors of visual recovery after the treatment of these 
patients. To date there are several well recognize prognostic factors, such as the age of 
patients (the older the worse prognostic), the duration of the symptoms before the surgery, 
the size of the tumour (better prognostic in microadenomas) and the presence of pituitary 
apoplexy, which is a bad prognostic factor. From the ophthalmology point of view, several 
factors such as visual acuities less than 20/100 or a pale optic disc have been reported to 
determine a worse prognostic (Chhabra & Newman, 2006). 
Although some cases show a severe visual impairment, it is not unusual to observe 
important early recoveries (1st week), intermediate recoveries (1-4 months) or even late 
recoveries in some patients (up to 36 months after surgery) (Kerrison, et al, 2000). This 
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indicates that there must be other factors that determine different degrees of axonal 
affectation in different patients. One of the main current research lines in this field is 
actually seeking the diagnostic tools that allow us to predict the degree of axonal loss, and 
so the possibility of visual function recovery after the treatment.  
During the last years, OCT has been used to establish and quantifying the axonal loss in 
several neurological disorders. OCT is a non-invasive tool that allows the retina to be 
directly approached as an appendix of the central nervous system. We can measure 
peripapillary retinal nerve fiber layer (RNFL) thickness, a parameter which has been  
found to be reproducible and useful for the diagnosis, prognosis and follow-up of optic 
nerve axonal damage in several neurological diseases, including pituitary adenomas (Moura, 
et al, 2007; Parisi, 2003; Sergott, et al, 2007; Kallenbach & Frederiksen, 2007; Toledo, et al, 
2008; Noval, et al, 2006; Vessani, et al, 2009). (figure 6). OCT can be useful predicting  
   
 
Fig. 6. Optical Coherence Tomography. Observe the retinal nerve fiber layer (RNFL) 
measurement in microns. A diagram is included to analyze the different sectors of the optic 
disc and peripapillar area. This example shows thinning of the RNFL affecting the right eye 
(OD) predominantly in the superior and temporal quadrants, the left eye (OS) shows normal 
results. The bottom of the image shows funduscopy of both eyes and demonstrates the optic 
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the visual  function recovery in patients with pituitary adenomas by measuring the axonal 
damage in the retina during the evolution of the disease (Ortiz-Perez, et al, 2009; Jacob, et al, 
2008). 
4. Conclusions 
Pituitary adenomas are a frequent pathology with a wide spectrum of clinical features. 
These tumours should be managed between different specialists including general 
practitioners, endocrinologists, neurologists, neurosurgeons and ophthalmologists. Neuro-
ophthalmological manifestations of pituitary adenomas are frequent and varied. They 
represent sometimes the onset symptoms in these patients. Many of the syndromes 
described above have an important diagnostic value due to their localizing information. 
Physicians must be aware about these syndromes in order to refer patients for 
ophthalmological assessments and establish an early diagnosis.  
OCT is a new device used daily in ophthalmology clinics to study the retina and optic disc. 
This tool gives unique and new information about the axonal loss in patients with 
neurological disorders, including pituitary adenomas. OCT is easily performed, it has no 
side effects or contraindications, so it must be included in the routine examination of 
patients with hypophysis tumours.  
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1. Introduction 
Pituitary (hypophysis), the secreting gland located in the sella turcica, has fascinated the 
scientists since ages. In 1543 the Belgian scientist Andreas Vesalius described the anatomy of 
pituitary gland for the first time. He believed that pituitary produces mucus, which is 
secreted from the brain into the nasal cavity. This is why pituitary was called the mucous 
gland (glandula pituitaria; pituita = mucus). Pituitary gland, also called as „master gland” 
plays the special role in the body. There are plenty of pathological changes with different 
clinical and radiological appearances of lesions located in sellar and parasellar region. The 
knowledge of pituitary anatomy and function, as well as of the characteristic changes in size 
and shape of the pituitary throughout the life and special physiologic conditions, is 
mandatory for the correct diagnosis and therefore these factors have to be taken into account 
before assessing pituitary abnormalities. 
2. Imaging of pituitary gland 
Introduction of imaging modalities, especially magnetic resonance (MR), and of modern 
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(Fig.1a,b). After contrast administration pituitary gland presents the homogenous strong 
enhancement (Fig.2a,b). 
The posterior lobe of the pituitary demonstrates the characteristic high signal intensity on 
T1- and T2-weighted images, seen just in front of the sellar dorsum and clearly 
differentiated from the anterior pituitary lobe. The high signal intensity of the posterior lobe 
is especially clearly visible on the sagittal planes (Fig. 3a,b) and it is called “posterior 
pituitary bright spot”. This high intensity signal observed in the posterior lobe is believed to 
be related to intracellular droplets of lipid or lipidlike material in pituicytes (astrocytic glial 
cells). However, the recent studies using the sequences with fat suppression have not 
confirmed the presence of fat tissue within the neurohypophysis (Arslan et al., 1999).  
Absence of this high intensity signal have been reported in patients with central diabetes 
insipidus (Fig.4a.b). It has to be stressed that some normal subjects lack this hyperintense  
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Fig. 1. MR imaging of normal pituitary gland in coronal planes before contrast 
administration: A. T1-weighted image. B. T2-weighted image. 
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Fig. 2. MR imaging of normal pituitary gland, T1-weighted images after contrast 
administration: A. Coronal plane. B. Sagittal plane. 
 




Fig. 3. MR imaging of normal pituitary gland in sagittal planes before contrast 
administration: A. T1-weighted image. B. T2-weighted image. The high signal intensity of 
the posterior lobe is clearly visible. 
 
A B
Fig. 4. MR imaging in sagittal planes before contrast administration, a 36-y.o. man with 
central diabetes insipidus. A. T1-weighted image. B. T2-weighted image. The high signal 
intensity of the posterior lobe is not visible. 
signal of the posterior lobe, therefore its absence cannot be taken as an absolute sign of 
pituitary disease or dysfunction (Evanson, 2002). 
The normal pituitary gland undergoes the characteristic changes in size and shape throughout 
the life, which have to be taken into account before assessing pituitary abnormalities.  
In neonates, the pituitary gland is typically convex and shows a higher signal intensity 
compared to the brain stem on T1-weighted images (Fig.5). This appearance persists for 
about 2 months, after which the pituitary will present with a flat superior surface and a 
signal intensity similar to the signal of the pons, what is typical for the older children. 
Throughout childhood, the pituitary reveals a slight but definite growth in all dimensions. 
The upper surface is flat or mildly concave and the height of the pituitary in the sagittal 
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Fig. 5. MR imaging in neonate, T1-weighted image in axial plane. The pituitary gland 
demonstrates the characteristic high signal intensity. 
A B
Fig. 6. MR imaging of normal pituitary gland in 5-y.o. boy, T1-weighted images.: A. Sagittal 
plane B. Coronal plane after contrast administration. 
At puberty the pituitary gland demonstrates the huge changes in size and shape, becoming 
larger than at any other time of the whole life. In girls the gland can reach the height of 
10mm, while in boys it may measure 7-8mm. Furthermore, in pubertal girls the gland can 
also project above the sella and present with a marked convexity of its superior surface 
(Elster, 1990, 1993). 
Physiologic hypertrophy of the pituitary can be observed during pregnancy, when the gland 
may increase in weight by 30%-100%. By the third trimester the pituitary usually measures 
even 10mm of height and shows the typical convex superior surface. It has to be stressed 
that during pregnancy and the 1st postpartum week, the pituitary gland demonstrates the 
 
Diagnostic Imaging of the Pituitary and Parasellar Region 
 
17 
high signal intensity on T1-weighted images (Fig.7), like in the neonate period (Bladowska 
et al., 2004; Elster, 1991, 1993).  
 
Fig. 7. MR imaging of the pituitary gland in 24-y.o. woman 5 days after delivery, T1-
weighted image in axial plane. The pituitary gland demonstrated the characteristic high 
signal intensity. 
From young adulthood until middle age, the pituitary glands of both sexes show usually 
stable appearance. Beyond age of 50 years, progressive involution of the gland is observed, 
what is probably related to the decrease in pituitary activity during menopause and 
andropause period. It has to be emphasized that in about 30% of this population the high 
signal intensity of the posterior pituitary lobe is not visible, as well as the empty sella 
syndrome is more commonly noted, but these changes are typical signs of normal aging 
process (Bladowska et al., 2004; Elster, 1993).  
3. Imaging of pituitary adenomas 
Pituitary adenomas constitute approximately 10 to 15% of all primary intracranial 
neoplasms and are the most common causes of pituitary function disorders and field of 
view deficits. Therefore, early diagnosis and therapy of patients with pituitary tumors are of 
high importance in clinical practice (Bladowska et al., 2010a).  
Pituitary adenomas are the most common pathology encountered in the sellar region. They 
are usually benign and slow growing tumors, but up to 50% reveal histological evidence of 
capsule invasion, furthermore less than 0.2% could be malignant, causing local spread into 
the central nervous system. Pituitary carcinoma is exceedingly rare. 
About 70% of pituitary adenomas are diagnosed in patients aged 30-50-y.o., while subjects 
in age below 20-y.o. constitute only 3 to 7% of all patients with pituitary tumors. Besides, 
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Pituitary adenomas can be classified on the basis of their size: microadenomas are less than 
10mm in diameter and macroadenomas are greater than 10mm. It has to be stressed that the 
separate term “picoadenomas” should be used for describing the tumors smaller than 3mm, 
because these lesions are posing special diagnostic problems – it is often impossible to 
visualize the picoadenomas on MR imaging (Bonneville et al., 2000, 2005).  
Furthermore, clinically adenomas are classified depending upon the presence or absence of 
specific hormonal activity. They are divided into two groups: functioning pituitary 
adenomas and non-functioning adenomas. Functioning adenomas usually secrete a single 
hormone causing a well recognised endocrine syndrome like e.g. acromegaly (GH - growth 
hormone-secreting adenomas). 
In MR imaging, on T1-weighted images, about 80-90% of pituitary microadenomas present 
with lower signal intensity compared to the normal anterior pituitary lobe – they are 
hypointense. The other cases of microadenomas could be isointense and therefore they will 
be not visible on T1-weighted images before contrast administration. Pituitary 
microadenomas can also reveal high signal intensity on T1-weighted images, what may be 
caused by hemorrhagic transformation of the adenoma and this is a frequent sign in 
prolactinomas (PRL - prolactine-secreting adenomas). On T2-weighted images, about 1/3 to 
½ of microadenomas demonstrate high signal intensity (Fig.8), what is especially helpful in 
making the correct diagnosis of pituitary pathology. Increased signal intensity on T2- 
weighted images is noted in over 80% of microprolactinomas. The other types of pituitary 
microadenomas can present different signal intensity on T2- weighted images, iso or 
hypointense signal occurs in about 2/3 cases of GH-secreting microadenomas (Bonneville et 
al., 2005).  
 
A B
Fig. 8. MR imaging in coronal planes before contrast administration. A. T2-weighted image. 
B. T1-weighted image. On the right side of the pituitary gland there is a microadenoma, 
which shows the high signal intensity on T2- weighted image, making the correct diagnosis 
easy, while it is almost not visible on T1-weighted image. 
On the contrast-enhanced T1-weighted images microadenomas can show typically low 
signal intensity compared to the intense enhancement of the unaffected pituitary gland 
(Fig.9) (Bladowska et al., 2004).  
 




Fig. 9. T1-weighted image in coronal plane after contrast administration. The hypointense 
microadenoma is visible on the right side of the pituitary gland. 
It has to be emphasized, as mentioned above, the contrast-enhancement images may be 
normal in case of the extremely small tumor (picoadenoma). When the plain MR images are 
not convincing, other techniques can be also used. The delayed images taken about 30-40 
minutes after contrast administration may reveal late enhancement of the microadenoma 
itself (Bonneville et al., 2005). In our own material of pituitary adenomas we have noticed 
microadenomas, which show contrast-enhancement just about 10 minutes after injection of 
contrast (Fig.10a,b). 
A B
Fig. 10. T1-weighted sagittal images, before (A) and about 10 minutes after contrast 
administration. On the delayed image the enhancing microadenoma is clearly visible. 
The ACTH-secreting microadenomas associated with Cushing’s disease tend to be very 
small (typical feature of picoadenomas) and more often occult on MR imaging (Bonneville et 
al., 2005; Evanson, 2002). Dynamic imaging can be recommended in the diagnosis of ACTH- 
secreting microadenomas, when the clinical symptoms are highly suggesting of pituitary 
pathology, but the plain MR imaging is normal. Dynamic imaging can evidence a lack or a 
temporary delay of enhancement in the microadenoma compared to the unaffected pituitary 
gland. However, the delayed images taken at least about 10 minutes after contrast 
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The diagnosis of macroadenoma in MR imaging is usually simple because of the tumor size 
over 10mm, making the adenoma clearly visible, even in the computed tomography (CT). 
However, the other tumors may also be located in the sellar region and they can mimic 
pituitary adenomas. Therefore, the precise knowledge of the MR appearance of the 
macroadenomas is of high importance in the clinical practice. 
Macroadenomas are usually isointense on T1-weighted images, and after contrast 
administration they show different enhancement patterns (Fig.11, 12). On T2-weighted 
images they may be often inhomogenous, with disseminated high intensity areas of cystic 
degeneration or necrotic regions. About 18% of macroadenomas reveal the cystic 
components, while about 20% show features of haemorrhage, usually clinically 
asymptomatic and diagnosed incidentally in MR imaging. Large pituitary adenomas are 
prone to develop infarction or haemorrhage, because of their tenuous blood supply.  
 
A B
Fig. 11. T1-weighted coronal images before (A) and after contrast administration (B). The 
sellar-suprasellar macroadenoma shows strong contrast-enhancement. There is evidence of 
the optic chiasm and the third ventricle compression. 
A B
 
Fig. 12. T1-weighted coronal images before (A) and after contrast administration (B). The 
macroadenoma does not enhance after contrast injection. The compressed pituitary gland, 
showing the high signal intensity, is displaced to the left side of the sella. There is also the 
right cavernous sinus involvement. 
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Intratumoral hemorrhage is very often found in prolactinomas, especially after the 
treatment with bromocriptine. However, the hemorrhage may be revealed on MR images 
within adenomas in patients, who have not been treated (Bonneville et al., 2005). The 
hemorrhage shows the characteristic high intensity signal on T1-weighted images (Fig.13).  
A “fluid-fluid level” can be seen within the hemorrhage, and this feature is typical and more 
common in adenomas compared to other tumors, such as craniopharyngiomas. 
 
 
Fig. 13. T1-weighted coronal unenhanced image. The high intensity area of hemorrhage 
within prolactine-secreting macroadenoma is visible. 
Macroadenomas are intrasellar masses usually with extrasellar extension. They may grow 
upwards causing the optic chiasm compression and indent the floor of the third ventricle. 
These tumors can also extend downward into the sphenoid sinus, back into the dorsum 
sellae or laterally into the cavernous sinus. Involvement of the cavernous sinus can modify 
the prognosis, therefore the correct diagnosis is of high clinical importance, although it may 
remain difficult to differentiate compression and involvement. The complete encasement of 
the intracavernous part of the internal carotid artery (ICA) by the adenoma is the best sign 
of involvement of the cavernous sinus (Fig.14) (Bladowska et al., 2004).     
 
 
Fig. 14. T1-weighted coronal contrast-enhanced image. The complete encasement of the 
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4. Imaging of other pituitary tumors and parasellar lesions 
The most common pituitary tumors are adenomas, the other tumors constitute approximately 
5 to 10% of all sellar and parasellar lesions. The precise knowledge of the MR appearance of 
these lesions is of high importance in clinical practice, because they can mimic pituitary 
adenomas. In this subsection we describe the characteristic imaging features of these tumors. 
4.1 Craniopharyngiomas 
Craniopharyngiomas are the most common suprasellar lesions. They account for 
approximately 3% of all intracranial neoplasms and are slow-growing, benign tumors, 
which arise from squamous epithelial cell rests of Rathke’s pouch. These tumors are 
frequent in children and young adults, but they also can be found in older adults. 
Craniopharyngiomas may be divided into two histological types: adamantinomatous and 
squamous-papillary (Doerfler & Richter, 2008).  
In MR imaging the signal intensity of craniopharyngioma varies with cyst contents. High T1 
signal is the results of high protein content (Fig.15). The classic adamantinomatous type 
usually consists of hyperintense cysts and heterogeneous nodules. The less common 
papillary type is presented with isointense solid component. On T2-weighted images cysts 
are predominantly hyperintense, while the solid components show heterogeneous signal. 
After contrast administration the solid portions enhance heterogeneously, as well as cysts 
walls reveal strong enhancement (Bladowska et al. 2004; Doerfler & Richter, 2008).   
 
A B
Fig. 15. MR imaging in coronal planes before contrast administration. A. T1-weighted image. 
B. T2-weighted image. The sellar-suprasellar craniopharyngioma presents with high signal 
intensity on both T1- and T2-weighted images. 
4.2 Rathke’s Cleft Cyst 
Rathke’s cleft cysts account for approximately 1.5% of all sellar and parasellar lesions. They, 
like craniopharyngiomas, are also derived from the Rathke’s pouch, but are usually smaller 
and almost always located intrasellar, between the anterior and posterior pituitary lobe. 
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Furthermore, they present with different histological structure compared to 
craniopharyngiomas - Rathke’s cysts are lined by a single layer of epithelium, while 
craniopharyngiomas have thick walls composed of squamous or basal cells (Bladowska et 
al. 2004; Doerfler & Richter, 2008). 
Rathke’s cleft cysts are relatively common incidental findings, usually remaining 
asymptomatic. 
In MR imaging Rathke’s cleft cysts display variable signal intensity. Cysts containing serous 
fluid are typically hypointense on T1-weighted images and hyperintense on T2-weighted 
images (Fig.16), while mucoid cyst reveal high signal intensity on T1-weighted images and 
often characteristic very low signal on T2-weighted images (Fig.17). After contrast 
administration they usually do not enhance, although sometimes they can show very thin 




Fig. 16. MR imaging in coronal planes before contrast administration. A. T1-weighted image. 
B. T2-weighted image. Rathke’s cleft cyst containing serous fluid – it is hypointense on T1 
and hyperintense on T2-weighted image.  
A B
 
Fig. 17. MR imaging in sagittal planes before contrast administration. A. T1-weighted image. 
B. T2-weighted image. Rathke’s cleft cyst containing mucoid fluid – it is hyperintense on T1 
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approximately 3% of all intracranial neoplasms and are slow-growing, benign tumors, 
which arise from squamous epithelial cell rests of Rathke’s pouch. These tumors are 
frequent in children and young adults, but they also can be found in older adults. 
Craniopharyngiomas may be divided into two histological types: adamantinomatous and 
squamous-papillary (Doerfler & Richter, 2008).  
In MR imaging the signal intensity of craniopharyngioma varies with cyst contents. High T1 
signal is the results of high protein content (Fig.15). The classic adamantinomatous type 
usually consists of hyperintense cysts and heterogeneous nodules. The less common 
papillary type is presented with isointense solid component. On T2-weighted images cysts 
are predominantly hyperintense, while the solid components show heterogeneous signal. 
After contrast administration the solid portions enhance heterogeneously, as well as cysts 
walls reveal strong enhancement (Bladowska et al. 2004; Doerfler & Richter, 2008).   
 
A B
Fig. 15. MR imaging in coronal planes before contrast administration. A. T1-weighted image. 
B. T2-weighted image. The sellar-suprasellar craniopharyngioma presents with high signal 
intensity on both T1- and T2-weighted images. 
4.2 Rathke’s Cleft Cyst 
Rathke’s cleft cysts account for approximately 1.5% of all sellar and parasellar lesions. They, 
like craniopharyngiomas, are also derived from the Rathke’s pouch, but are usually smaller 
and almost always located intrasellar, between the anterior and posterior pituitary lobe. 
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Furthermore, they present with different histological structure compared to 
craniopharyngiomas - Rathke’s cysts are lined by a single layer of epithelium, while 
craniopharyngiomas have thick walls composed of squamous or basal cells (Bladowska et 
al. 2004; Doerfler & Richter, 2008). 
Rathke’s cleft cysts are relatively common incidental findings, usually remaining 
asymptomatic. 
In MR imaging Rathke’s cleft cysts display variable signal intensity. Cysts containing serous 
fluid are typically hypointense on T1-weighted images and hyperintense on T2-weighted 
images (Fig.16), while mucoid cyst reveal high signal intensity on T1-weighted images and 
often characteristic very low signal on T2-weighted images (Fig.17). After contrast 
administration they usually do not enhance, although sometimes they can show very thin 




Fig. 16. MR imaging in coronal planes before contrast administration. A. T1-weighted image. 
B. T2-weighted image. Rathke’s cleft cyst containing serous fluid – it is hypointense on T1 
and hyperintense on T2-weighted image.  
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Fig. 17. MR imaging in sagittal planes before contrast administration. A. T1-weighted image. 
B. T2-weighted image. Rathke’s cleft cyst containing mucoid fluid – it is hyperintense on T1 





Other cysts located in the sellar and parasellar region include: arachnoid, dermoid, 
epidermoid and colloid cysts (Bladowska et al., 2010c; Doerfler & Richter 2008). 
4.3 Meningiomas 
Meningiomas of the sellar region (cavernous sinus, planum sphenoidale, diaphragm sellae 
and clinoid process) account for about 11% of all sellar and parasellar tumors and for 20-
30% of all intracranial meningiomas (Doerfler & Richter 2008). They are slow-growing, 




Fig. 18. T1-weighted coronal contrast-enhanced image. The meningioma of the left 
cavernous sinus is visible. 
In MR imaging meningiomas are isointense compared to grey matter on T1-weighted 
images and isointense or slightly hyperintense on T2-weighted images. After contrast 
administration they reveal homogeneous enhancement (Fig.18). Often they present with 
characteristic so-called “dural tail sign”, what can help in differential diagnosis, but it has to 
be stressed that the “dural tail sign” is a nonspecific feature and may also be visible in other 
intracranial tumors. 
4.4 Other rare sellar and parasellar lesions 
Rare primary neoplasm of the pituitary and sellar region include: melanoma, intrasellar 
meningioma, germinoma, choristoma, glioma and metastases (Elster 1993; Ruscalleda 2005). 
Inflammatory and infectious lesions of pituitary and sellar region include: abscess (Fig.19) 
(Bladowska et al., 2010d), sarcoidosis, cysticercosis, Langerhans cell histiocytosis, 
blastomycosis, Wegener granulomatosis, Tolosa-Hunt syndrome, lymphocytic 
adenohypophysitis, giant cell granuloma and tuberculosis (Elster 1993; Doerfler & Richter 
2008).   
 





Fig. 19. MR imaging in coronal planes of the pituitary abscess. A. T2-weighted unenhanced 
image. B. T1-weighted contrast-enhanced image. There is characteristic strong rim 
enhancement visible. 
5. Postoperative MR imaging of pituitary and sellar region – own experience 
Post-surgical evaluation of the pituitary gland in MR is difficult because of a change in 
anatomical conditions. Interpretation of MR images taken after surgical therapy of pituitary 
tumors depends also on numerous other factors, including: size and expansion of a tumor 
before operation, type of surgical access, quality and volume of filling material and time of 
its resorption. Proper evaluation of post-surgical MR images is crucial for determination of 
completeness of the resection. Therefore neuro-radiologists face a responsible and difficult 
task of evaluation of structures present in the surgical area, and especially of differentiation 
of residual tumor from the implanted material and from post-surgical changes (fibrous and 
cicatrical), or even from a part of normal gland left at site (Bladowska et al., 2010a,b). 
In general, the residual tumors could be differentiated from postoperative changes by 
means of location, characteristic signal intensity and enhancing pattern, which should be 
similar to those in the preoperative MR imaging of the tumor. The infundibulum tilt could 
be additional factor suggesting the presence of residual adenoma. The endocrine studies are 
very helpful in postoperative diagnosis of hormone-secreting residual pituitary adenomas 
and are regarded as a method of choice in postoperative management of these tumors. It is 
especially difficult to evaluate the effectiveness of the surgical treatment of the 
nonfunctioning pituitary tumors, these tumors require a postsurgical MR follow-up 
examinations.  
The basic therapeutic method of pituitary tumors (apart from microprolactinoma) is 
surgery. Among several operation methods of the sellar region, the most frequently applied 
is the one with transnasal transsphenoidal approach. This method has widely forced  
out craniotomy and is now concerned the method of choice in the treatment of the majority 
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A characteristic feature of transsphenoidal surgery is the necessity of applying different 
filling materials to obtain haemostasis, to fill the resection site within the sella, and to inhibit 
the outflow of the CSF (cerebrospinal fluid).  
Filling materials are foreign or autogenic bodies that do not become vascularised. To sustain 
haemostasis, the following materials are used: oxidized cellulose (Oxycel or Surgicel), 
spongostan (Gelfoam), tissue glue (Tissucol or Beriplast), bone wax (to restrain bleeding 
from bone). Liquorrhoea requires a reconstructive operation of sella, with the use of 
autogenic fascia, lyophilisated dura mater or tissue glue. Next, the sella is sealed with a 
muscle or flakes of oxidized cellulose. To close the bottom of the sella, it is necessary to use a 
fragment of the collected cartilaginous septum from the nose, the vomer, or a silicon plate. 
To protect the postresection site and to reinforce the bottom of the sella, an autogenic fat 
graft is implanted in the sphenoid sinus. The graft is collected from the fatty tissue of the 
lateral part of the thigh or from the patient’s abdomen (Bladowska et al., 2010b). 
Application of the filling materials constitutes a considerable challenge in interpretation of 
the MR imaging results in patients who underwent surgery of the pituitary tumors. This can 
also lead to misdiagnosis. The knowledge of MR characteristics of the implanted materials is 
very important in postoperative diagnosis of pituitary tumors and may help to discriminate 
between tumorous and non-tumorous involvement of the sellar region (Bladowska et al., 
2010b). 
In the MRI examination, on T1-weighted images, Surgicel (Oxycel) is represented by a 
heterogeneous structure with a regular, oval shape, low signal intensity, surrounded by a 
hyperintense rim. Examinations performed in the first days after the procedure, frequently 
reveal the presence of small air bubbles closed in the strips of Surgicel, in the hypointense 
central part of the filling material (Bladowska et al., 2010b; Bonneville et al., 2003). 
Spongostan (gelfoam) is represented in the MRI examination by an intrasellar mass of signal 
intensity similar to that of the grey matter. In rare cases, spongostan may produce a 
heterogeneous high signal caused most probably by the presence of methemoglobin 
(Bladowska et al., 2010b; Bonneville et al., 2003). 
The similarity between signal intensity of the filling material, of the anterior pituitary lobe, 
and of a potential residual tumour often makes it difficult to interpret the image in an 
unequivocal way and to carry out a correct differential diagnosis. However, according to T. 
Kilic et al., spongostan and Surgicel (Oxycel) may be recognised only on an early performed 
MRI, i.e. within 24–48 hours after the procedure, because afterwards, the materials begin to 
undergo a progressive degeneration and their radiological identification becomes harder 
(Kilic et al., 2001). E. Steiner et al reported that these materials are normally recognisable on 
MRI for up to 3–6 months after the procedure (Steiner et al., 1992). Our studies showed that 
haemostatic materials may be identified only in the early postoperative period – in own 
material is was 1 month (Fig.20) (Bladowska et al., 2010b). 
After contrast administration, the central part of the haemostatic material remained 
hypointense, with peripheral rim of enhancement. This peripheral enhancement is caused 
by granulation tissue forming around the implanted material. Filling materials  
undergo changes which surely inhibit their identification. It should be underscored  
that a hypointense mass with peripheral enhancement after contrast administration is not 
characteristic for the filling material only. It may also correspond to the presence of a fluid  
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Fig. 20. T1-weighted contrast-enhanced coronal images. A. Before operation – on the left side 
of the pituitary the microadenoma is visible (arrow). B. Follow-up MRI performed 1 month 
after surgery – there is haemostatic material implanted into the operation site (arrow). 
cistern, regions of necrosis within the tumor or cicatrical fibrous tissue with granulation 
around it (Bladowska et al., 2010b; Bonneville et al., 2003). 
In our own material, as much as 85.61% of the patients had their first postoperative MRI 
examination performed after 3 months following the procedure, and only 14.39% of the 
studied individuals (20 patients) – during the first 3 months. There were no examinations 
carried out within 24–48 hours from the procedure. When we consider the date of MRI 
examinations and the fast degeneration of the filling material, it is then easy to explain the 
fact why the haemostatic material was identified in only two patients of the studied group. 
The analysis of the conducted examinations revealed that the implanted autogenic fat and 
muscle with fascia, located in the lumen of the sphenoid sinus, can be observed on MRI for 
much longer (Bladowska et al., 2010b). 
Fatty tissue is not too difficult to identify, as it provides a characteristic signal of high 
intensity on T1-weighted images (Fig.21). There were reported cases of residual fatty 
material present in the sphenoidal sinus examined at 1–2 years after the procedure or even 
3–4 years afterwards. However, according to our assessments, the implanted fat may remain 
in place for much longer. The volume of the implanted fat influences the duration of its 
presence on MRI. Normally, the adipose tissue implanted in larger amounts (in case of 
macroadenoma resection) retains for much longer than the small amount of that material 
(implanted after microadenoma resection), absorbed within 9–12 months. 
As compared to other filling materials, identification of the fatty tissue in the MRI 
examination is easy thanks to the characteristic high signal intensity produced by the 
material, its longer persistence, but also the absence of adjacent contrast-enhanced areas 
formed by the granulation tissue. 
In the studied material, the implanted fatty tissue was identified in as many as 86 patients after 
pituitary tumour surgery. In the remaining 12 patients, who according to surgical reports were 
implanted fatty filling material, it was impossible to find that material on MRI. No fatty tissue 
found in these patients may result from a small amount of the implanted material, from its fast 
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Fig. 21. T1-weighted unenhanced sagittal images. A. MRI performed 10 months after 
transsphenoidal operation reveals the implanted fatty material inside the sphenoid sinus – it 
presents with high signal intensity. B. Follow-up MRI performed 23 months after surgery – 
there is no implanted material visible. 
The earliest total absorption of the fatty material was observed 11 months after the 
procedure. In most of the cases, residues of the adipose tissue were present for a long time, 
for even up to 112 months (nearly 10 years) after the procedure, while in one patient, there 
was a large amount of the fatty material still present in the lumen of the sphenoidal sinus 
after 348 months (29 years) (Bladowska et al., 2010b). 
In 2 patients, it was possible to visualise the implanted titanium mesh (Fig.22). On MRI, the 
titanium mesh was represented by a linear area producing no signal and located in the 






Fig. 22. MR imaging of implanted titanium mesh. A. T1-weighted coronal image. B. T2-
weighted coronal image. A linear area producing no signal and located in the bottom of the 
sella is visible.  
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In 3 individuals, an implanted muscle with fascia was identified. It was represented by a 
round, isointense structure, filling nearly the whole sphenoidal sinus on T1-weighted MRI 
images. After intravenous contrast administration, the structure was becoming slightly 
enhanced in its peripheral part, with a central round area of lower signal intensity (Fig.23a). 
Such an image of the implanted muscle was found in 2 patients after 4 months following the 
procedure, and in 1 patient after 5 months from surgery. The follow-up MRIs (beginning 
approx. from the 12th postoperative month) were revealing a gradual change in the image of 
that material. After contrast administration, the previously distinct border between the 
enhanced peripheral part and the central hypointense part of the implanted muscle became 
indistinct. In further MRI examinations, performed approx. 25 months after surgery or later, 
the structure present in the lumen of the sphenoidal sinus remained hypointense after 
contrast administration. Without the analysis of previous images and the knowledge of 
patient’s history, the correct diagnosis of that mass on T1-weighted images was impossible 
(especially its differentiation from e.g. fluid cistern). The implanted muscle with fascia 
produced a very characteristic and almost stable image in T2-weighted sequence (Fig.23b), 
for at least 31 months following the procedure. In the T2-weighted sequence, the material is 
represented by a hyperintense mass with a linear structure, of a very low signal intensity, 
corresponding to fascia (Fig.23b). It should also be pointed out that fascia was not identified 
on T1-weighted images (Fig.23a) (Bladowska et al., 2010b, 2011). 
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Fig. 23. MR imaging of muscle with fascia implanted into the sphenoid sinus. A. T1-
weighted enhanced coronal image. B. T2- weighted unenhanced coronal image – the linear 
structure, of a very low signal intensity, corresponding to fascia is very well visible. 
The final diagnosis and evaluation of the surgical completeness on the basis of the 
performed MRI is often equivocal, in spite of the presence of the above mentioned criteria. 
It is especially hard to evaluate the effectiveness of the surgical treatment of the hormonally 
inactive tumors on the basis of the MRI examination results and their interpretation only. 
These tumors require a postsurgical endocrinological and MRI follow-up. 
Follow-up of abnormal structures present in the postsurgical area may allow for their 
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lesion, this excludes the presence of a residual tumor and indicates to the filling material or 
postoperative changes.  
If the size and volume of the pathological structure increases, this points to the presence of a 
residual tumor. On the other hand, it should be remembered that pituitary tumors grow 
slowly, so in a long-term follow-up, the tumor may seem stable, which does not facilitate the 
final diagnosis in unclear cases of hormonally inactive tumors. 
As mentioned above, the transsphenoidal approach is currently the method of choice in 
treatment of most of pituitary tumors. There are characteristic changes inside the sphenoid 
sinus after the surgery (Connor & Deasy, 2002). MRI findings of sphenoid sinus filling 
(opacification) are present in approximately 37% of examinations performed more than 12 
months after transsphenoidal surgery. The contrast enhancement at the margins of the 
sphenoid sinus, called as Rodriguez’s changes (Fig.24), is always apparent in cases of 
hypervascularized and swollen mucosa (Rodriguez et al., 1996) and could persist even 10 




Fig. 24. MR imaging of Rodriguez’s changes, T1-weighted sagittal images: unenhanced (A), 
contrast-enhanced (B). There are hypointense masses inside the sphenoid sinus, which show 
the characteristic rim contrast enhancement.  
The special attention should be also paid to usefulness of T2-weighted images in assessment 
of postoperative sella and sellar region. T2-weighted images may help to discriminate 
between tumorous and non-tumorous involvement of the postoperative sella and the 
sphenoid sinus especially in cases, in which the signal intensity and enhancement pattern of 
pituitary gland and tumor are the same on T1-weighted images. T2-weighted images are 
also very useful in the postoperative evaluation of the implanted muscle with fascia, 
especially during long term follow-up. The best protocol for the postoperative imaging after 
pituitary tumor resections should include both T1- and T2-weighted imaging, because T1- 
and T2-weighted images supplement each other in the postoperative examination of the 
sella and sellar region. However, in some cases T2 could replace post-contrast T1, especially 
in patients with high risk of Nephrogenic Systemic Fibrosis (NSF) (Bladowska et al., 2011). 
 




Pituitary adenomas are common neoplasm, they account for 10-15% of all diagnosed 
intracranial tumors. The proper diagnosis and management of patients with pituitary 
lesions are of high importance in the clinical practice. Currently, MR is the method of choice 
for imaging of the pituitary gland and the parasellar area. MR imaging protocol of pituitary 
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Pituitary adenomas are typically benign, slow-growing tumors that arise from cells in the 
pituitary gland. Those are classified based on secretory products (1). The functioning 
(endocrine-active) tumors include almost 70% of pituitary tumors which produce 1 or 2 
hormones that are measurable in the serum and cause definite clinical syndromes that are 
classified based on their secretory product(s). Non-functioning adenomas are endocrine-
inactive tumors (2). Because of the physiologic effects of excess hormones, functioning 
tumors usually present earlier than non-functioning adenomas (3). On the other hand, mass 
effect from large pituitary adenomas (often due to endocrine-inactive tumors) may lead to 
pressure symptoms such as headaches, visual field defects (typically loss of peripheral 
vision), cranial nerve deficits, hypopituitarism (compression of normal pituitary gland), 
pituitary apoplexy (sudden bleeding or infarction from outgrowing tumor blood supply), or 
stalk dysfunction (4). Compression of pituitary stalk is termed “stalk effect” which can cause 
a mild elevation in prolactin, and must be differentiated from a prolactinoma (5).  
The purpose of this chapter is to review all types of functioning pituitary adenoma 
(prolactin, ACTH, GH, TSH, LH and FSH secreting) from studies indexed in PubMed. We 
describe the symptoms, epidemiology, diagnosis, management, outcome and complications 
of each. 
2. Prolactinoma 
This type of pituitary adenoma arises from neoplastic transformation of anterior pituitary 
lactotrophs and produces an excessive amount of hormone prolactin. A prolactinoma is the 
most common cause of chronic hyperprolactinemia once pregnancy, primary 
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This type of pituitary adenoma arises from neoplastic transformation of anterior pituitary 
lactotrophs and produces an excessive amount of hormone prolactin. A prolactinoma is the 
most common cause of chronic hyperprolactinemia once pregnancy, primary 






In female patients, even small prolactinomas can cause irregular menstrual periods or 
complete loss of menses. Higher prolactin levels lead to galactorrhea in women, whereas 
men may experience gynecomastia. In male patients, altered spermatogenesis with 
oligospermia and infertility may be found; galactorrhea and gynaecomastia are much less 
frequent. Hypogonadism, reduced libido and infertility are the most frequent symptoms in 
both genders. Patients can also present with osteopenia and osteoporosis (due to estrogen 
and testosterone deficiency, not due to the elevated prolactin itself). Large prolactinomas, 
more commonly found in men, may cause mass effect from the tumor (5-9). 
2.2 Epidemiology  
The estimated prevalence of prolactinoma is 100 per million adults (10). Prolactinomas are 
the most common hormone-secreting pituitary tumors, representing approximately 40% of 
all pituitary tumors (8, 11, 12). Recent data show a high prevalence of prolactinoma in the 
general population, 3-5 times more than the previously reported ones (13). The incidence of 
prolactinomas varies with age and sex; these tumors occur with the highest frequency in 
women aged 20–50 years, at which point the ratio between the sexes is estimated to be 10:1. 
In adults aged >60 years, prolactinomas occur with a similar frequency in both sexes (12). 
Men generally have macroadenomas (≥10mm diameter) whereas women generally have 
microadenomas (<10mm) (6, 13, 14). The mean age at diagnosis is 10 years greater in men. 
This delay possibly accounts for their greater incidence of macroprolactinomas with visual 
field defects and hypopituitarism at first presentation (15). 
2.3 Diagnosis 
A serum prolactin level is acquired in response to a specific presentation, including 
symptoms of hyperprolactinemia (such as amenorrhea and galactorrhea) it may also be an 
integral part of an infertility assessment. An initial level above the normal range should be 
followed by a repeat level from a blood sample drawn in the morning with the patient in a 
fasting state. When hyperprolactinemia is confirmed, a cause for the disorder needs to be 
sought. This involves a careful history and examination, followed by laboratory tests and 
diagnostic imaging of the sella turcica. If serum prolactin levels are above 200 µg/L, a 
prolactinoma is almost certainly the underlying cause, but if levels are lower, the differential 
diagnoses include pregnancy, treatment with drugs (such as neuroleptics) that reduce 
dopaminergic effects on the pituitary, compression of the pituitary stalk by other pathology, 
primary hypothyroidism, renal failure, cirrhosis, chest wall lesions, or idiopathic 
hyperprolactinemia. In the absence of such causes, radiologic imaging of the sella turcica is 
necessary to establish whether a prolactinoma or other lesions are present (4, 6, 16). 
2.4 Management 
The main purpose of treating prolactinomas, both micro- and macroprolactinomas, are to 
suppress excess hormone secretion and its clinical effects, to remove the tumor mass, and to 
prevent disease return or progression (16, 17). If there is no indication for therapy (such as 
amenorrhea, infertility or bothersome galactorrhea), microadenomas may be followed 
conservatively, and regular follow-up with serial prolactin measurements and pituitary 
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imaging should be organized (6, 16). Most prolactinomas can be effectively treated with 
dopaminergic drugs as primary management. For most patients,  medical therapy produces 
normalization of prolactin secretion, gonadal function, and considerable tumor shrinkage in 
the majority (16). The most commonly used dopamine agonists are bromocriptine, 
cabergoline (ergot derivatives) as well as quinagolide (a non-ergot derivative) (4, 18). 
Bromocriptine (D2 receptor agonist and D1 receptor antagonist) is the oldest drug for 
medical treatment of prolactinomas, and normalizes prolactin levels in 80-90% of 
microprolactinomas and 70% of macroprolactinomas. Tumor-mass shrinkage and 
improvement of visual-field deficits are commonly achieved in macroprolactinomas. 
Bromocriptine frequently can cause several side effects such as nausea, vomiting, postural 
hypotension, headache and dizziness (12). Cabergoline (a selective D2 receptor agonist) is 
very effective and well tolerated in more than 90% of the patients with either 
microprolactinomas or macroprolactinomas. Cabergoline treatment also induces tumor 
shrinkage in most macroprolactinomas. If patients have not previously been treated with 
other dopamine agonists, tumor shrinkage is more evident (17). When comparing the 
plasma half-life, efficacy and tolerability of these drugs, cabergoline seems to have the most 
favorable profile, followed by quinagolide (16). As a well tolerated and effective therapy 
and a simple dosing regimen, quinagolide (selective D2 receptor agonist) can also be 
considered a first-line therapy in the treatment of hyperprolactinaemia (19). Pergolide (a D1 
and D2 agonist) normalizes prolactin excess and reduces tumor size in recently diagnosed 
patients with macroprolactinomas with a potency of about 100-fold that of bromocriptine 
(20). However pergolide as approved treatment for prolactinomas was withdrawn in 2007 
because of adverse effects on cardiac valves (12).  
If prolactin levels are well controlled with dopamine agonist therapy, gradual tapering of 
the dose to the lowest effective amount is recommended, and in some cases medication can 
be stopped after several years. Evidence to date suggests that cabergoline and quinagolide 
appear to have a good safety profile for women who wish to conceive, but hard evidence 
proving that dopamine agonists do not provoke congenital malformations when taken 
during early pregnancy is currently only available for bromocriptine. Once pregnant, 
dopamine agonist therapy should be immediately stopped, unless the growth of a 
macroprolactinoma or pressure symptoms is likely to occur (4, 16). Hyperprolactinemia may 
recur after dopamine agonist withdrawal in a considerable proportion of patients. The 
probability of successful treatment was highest when cabergoline was used for at least two 
years (21). 
Surgery is generally used as second-line treatment in prolactinomas (22). Transsphenoidal 
surgery is an alternative for patients who are intolerant of or resistant to dopamine agonists 
or when hyperprolactinemia is caused by non-prolactin-secreting tumors compressing the 
pituitary stalk (4). 
Because pituitary adenomas respond well to radiation, radiotherapy has been a part of their 
management for the past three decades (23). Radiotherapy is given if both pharmacologic 
therapy and surgery fail (4, 16). However, Sasaki et al. reported that the local control rate for 
secreting adenomas by radiotherapy is unsatisfactory (23). 
Gamma knife radiosurgery can be offered as a safe and effective treatment option especially 
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tumor control rate after gamma knife radiosurgery for pituitary adenomas is equivalent to 
fractionated radiation therapy (24).  
Some experimental treatments have been attempted, such as somatostatin analogues, hybrid 
molecules (both somatostatin and a dopamine agonist in a single molecule), selective 
estrogen receptor modulators, prolactin-receptor antagonists, and temozolomide are utilized 
in selected case reports or in trial settings. These have not yet been included in standard 
medical practice (12).   
2.5 Outcome 
The ultimate goal of therapy for prolactinomas is restoration or achievement of eugonadism 
through the normalization of hyperprolactinemia and control of tumor mass (11). Medical 
and surgical therapies generally have excellent results, and most prolactinomas are well 
controlled or even cured in some cases (19). Dopamine agonists are the preferred therapy for 
prolactinomas because of the risk of recurrent hyperprolactinemia that accompanies 
transsphenoidal surgery (25, 26). Dopamine agonists are the first line of therapy for 
macroprolactinomas, resulting in normalizing prolactin levels in 85%, inducing tumor 
shrinkage in 57%, and long-term remission rates in 22% of the patients (11, 27).  
Surgery should be reserved for patients with dopamine agonist resistance or intolerance. 
Success rates after surgical treatment of microadenomas range from 73–90% and 30–50% for 
macroadenomas, with little morbidity and near zero mortality (28). However, subsequent 
relapse is possible in up to 20% of the cases (22). Surgical outcomes are highly dependent 
upon the expertise and experience of the neurosurgeon (11, 22).  
Following radiotherapy the prevalence of subsequent hypopituitarism is high; therefore, 
this therapy should be carefully considered, and rather be indicated for mass control than 
for hyperprolactinemia (27). 
Overall, patients with pituitary adenoma treated with surgery and radiotherapy have an 
increased risk of cerebrovascular motrtality compared to the general population, which 
mirrors the increased incidence of stroke (29).  
2.6 Complications 
As mentioned in the symptoms section, prolactinomas left untreated may lead to various 
complications. In both women and men, prolactinoma can cause reduced libido, infertility 
and osteoporosis. Women with prolactinoma may experience complications during 
pregnancy. A woman who has a large prolactinoma and becomes pregnant may experience 
additional pituitary growth and associated mass effect. Prolactinoma may also lead to 
impaired glucose tolerance and diabetes. If tumor grows large enough, prolactinoma may 
cause visual loss, headache and hypopituitarism. Disturbances of the haemostatic system 
and dyslipidemia may lead to excess mortality in patients with prolactinoma (5-9, 30, 31). 
3. ACTH secreting PA 
Approximately 80% of the cases of Cushing’s syndrome are due to the excessive secretion of 
adrenocorticotropic hormone (ACTH). This is usually (60-80%) due to a pituitary 
corticotroph adenoma and is defined as Cushing’s disease (2, 32).  
 




Cushing's syndrome refers to clinical manifestations induced by chronic exposure to excess 
glucocorticoids. The most common symptom of glucocorticoid excess is centripetal fat 
deposition which is frequently the initial symptom of the patient. 
Fat accumulates in the face as well as supraclavicular and dorsocervical fat pads, resulting 
in a typical moon face and buffalo hump, which is most often accompanied by facial 
plethora. Fat also accumulates over the thorax and the abdomen, which becomes 
protuberant (33).  
Other symptoms and signs include obesity; protein-wasting features such as skin thinning, 
large and purple abdominal striae, multiple ecchymotic lesions or purpura generated by 
minimal trauma, lower limb edema, spontaneous ruptures of tendons, slow healing of 
minor wounds, muscle atrophy, particularly in the lower limbs; bone wasting such as 
osteoporosis, pathological fractures, kyphosis and loss of height (34, 35); impaired 
protection mechanism against infections (36);  high blood pressure and cardiovascular 
complications (37, 38); hirsutism; gonadal dysfunction (39); psychic disturbances such as 
anxiety, irritability, sleep disorders, depression, maniac disorders, delusions and/or 
hallucinations (40); and decreased short-term memory and cognition (41). 
3.2 Epidemiology 
The prevalence of Cushing’s disease is approximately 40 per million. ACTH-producing 
adenomas comprise 10-20% of pituitary adenomas (42). Cushing’s disease is nine times 
more common in women than men(2).  
3.3 Diagnosis 
The clinical history is important to assess the general impact of hypercortisolism on organs 
and systems as well as to guide suspicion toward more aggressive entities such as the 
ectopic ACTH syndrome or to detect an iatrogenic etiology of Cushing's syndrome (43). 
Initial diagnosis is performed using tests such as urinary free cortisol, nocturnal salivary 
cortisol and 1 mg dexamethasone suppression that are sensitive but not specific, and still 
require established assessment criteria(44). A dexamethasone- corticotrophin releasing 
hormone (CRH) test can discriminate between Cushing's syndrome and pseudo-Cushing's 
syndrome. If ACTH is elevated, combinations of high-dose dexamethasone tests, 
CRH/desmopressin tests, and pituitary magnetic resonance imaging can indicate a pituitary 
source. Discrimination from an ectopic ACTH tumor often requires inferior petrosal sinus 
sampling to confirm the source of ACTH. If ACTH is low, adrenal computed tomography 
will identify the adrenal lesion(s) implicated. Some cortisol-producing adrenal tumors or, 
more frequently, bilateral macronodular hyperplasia, are under the control of aberrant 
membrane hormone receptors, or the altered activity of ectopic receptors (43-46). 
Sophisticated imaging and isotopic techniques play a significant role in locating the source 
of ACTH in ectopic syndromes but are not always effective. In general, biochemical and 
imaging tests should be combined in order to assess different mechanisms and perspectives 
of the syndrome. Rigorous methodology is essential to obtain accurate results, allowing a 





tumor control rate after gamma knife radiosurgery for pituitary adenomas is equivalent to 
fractionated radiation therapy (24).  
Some experimental treatments have been attempted, such as somatostatin analogues, hybrid 
molecules (both somatostatin and a dopamine agonist in a single molecule), selective 
estrogen receptor modulators, prolactin-receptor antagonists, and temozolomide are utilized 
in selected case reports or in trial settings. These have not yet been included in standard 
medical practice (12).   
2.5 Outcome 
The ultimate goal of therapy for prolactinomas is restoration or achievement of eugonadism 
through the normalization of hyperprolactinemia and control of tumor mass (11). Medical 
and surgical therapies generally have excellent results, and most prolactinomas are well 
controlled or even cured in some cases (19). Dopamine agonists are the preferred therapy for 
prolactinomas because of the risk of recurrent hyperprolactinemia that accompanies 
transsphenoidal surgery (25, 26). Dopamine agonists are the first line of therapy for 
macroprolactinomas, resulting in normalizing prolactin levels in 85%, inducing tumor 
shrinkage in 57%, and long-term remission rates in 22% of the patients (11, 27).  
Surgery should be reserved for patients with dopamine agonist resistance or intolerance. 
Success rates after surgical treatment of microadenomas range from 73–90% and 30–50% for 
macroadenomas, with little morbidity and near zero mortality (28). However, subsequent 
relapse is possible in up to 20% of the cases (22). Surgical outcomes are highly dependent 
upon the expertise and experience of the neurosurgeon (11, 22).  
Following radiotherapy the prevalence of subsequent hypopituitarism is high; therefore, 
this therapy should be carefully considered, and rather be indicated for mass control than 
for hyperprolactinemia (27). 
Overall, patients with pituitary adenoma treated with surgery and radiotherapy have an 
increased risk of cerebrovascular motrtality compared to the general population, which 
mirrors the increased incidence of stroke (29).  
2.6 Complications 
As mentioned in the symptoms section, prolactinomas left untreated may lead to various 
complications. In both women and men, prolactinoma can cause reduced libido, infertility 
and osteoporosis. Women with prolactinoma may experience complications during 
pregnancy. A woman who has a large prolactinoma and becomes pregnant may experience 
additional pituitary growth and associated mass effect. Prolactinoma may also lead to 
impaired glucose tolerance and diabetes. If tumor grows large enough, prolactinoma may 
cause visual loss, headache and hypopituitarism. Disturbances of the haemostatic system 
and dyslipidemia may lead to excess mortality in patients with prolactinoma (5-9, 30, 31). 
3. ACTH secreting PA 
Approximately 80% of the cases of Cushing’s syndrome are due to the excessive secretion of 
adrenocorticotropic hormone (ACTH). This is usually (60-80%) due to a pituitary 
corticotroph adenoma and is defined as Cushing’s disease (2, 32).  
 




Cushing's syndrome refers to clinical manifestations induced by chronic exposure to excess 
glucocorticoids. The most common symptom of glucocorticoid excess is centripetal fat 
deposition which is frequently the initial symptom of the patient. 
Fat accumulates in the face as well as supraclavicular and dorsocervical fat pads, resulting 
in a typical moon face and buffalo hump, which is most often accompanied by facial 
plethora. Fat also accumulates over the thorax and the abdomen, which becomes 
protuberant (33).  
Other symptoms and signs include obesity; protein-wasting features such as skin thinning, 
large and purple abdominal striae, multiple ecchymotic lesions or purpura generated by 
minimal trauma, lower limb edema, spontaneous ruptures of tendons, slow healing of 
minor wounds, muscle atrophy, particularly in the lower limbs; bone wasting such as 
osteoporosis, pathological fractures, kyphosis and loss of height (34, 35); impaired 
protection mechanism against infections (36);  high blood pressure and cardiovascular 
complications (37, 38); hirsutism; gonadal dysfunction (39); psychic disturbances such as 
anxiety, irritability, sleep disorders, depression, maniac disorders, delusions and/or 
hallucinations (40); and decreased short-term memory and cognition (41). 
3.2 Epidemiology 
The prevalence of Cushing’s disease is approximately 40 per million. ACTH-producing 
adenomas comprise 10-20% of pituitary adenomas (42). Cushing’s disease is nine times 
more common in women than men(2).  
3.3 Diagnosis 
The clinical history is important to assess the general impact of hypercortisolism on organs 
and systems as well as to guide suspicion toward more aggressive entities such as the 
ectopic ACTH syndrome or to detect an iatrogenic etiology of Cushing's syndrome (43). 
Initial diagnosis is performed using tests such as urinary free cortisol, nocturnal salivary 
cortisol and 1 mg dexamethasone suppression that are sensitive but not specific, and still 
require established assessment criteria(44). A dexamethasone- corticotrophin releasing 
hormone (CRH) test can discriminate between Cushing's syndrome and pseudo-Cushing's 
syndrome. If ACTH is elevated, combinations of high-dose dexamethasone tests, 
CRH/desmopressin tests, and pituitary magnetic resonance imaging can indicate a pituitary 
source. Discrimination from an ectopic ACTH tumor often requires inferior petrosal sinus 
sampling to confirm the source of ACTH. If ACTH is low, adrenal computed tomography 
will identify the adrenal lesion(s) implicated. Some cortisol-producing adrenal tumors or, 
more frequently, bilateral macronodular hyperplasia, are under the control of aberrant 
membrane hormone receptors, or the altered activity of ectopic receptors (43-46). 
Sophisticated imaging and isotopic techniques play a significant role in locating the source 
of ACTH in ectopic syndromes but are not always effective. In general, biochemical and 
imaging tests should be combined in order to assess different mechanisms and perspectives 
of the syndrome. Rigorous methodology is essential to obtain accurate results, allowing a 






The best treatment option for Cushing's disease is when the responsible corticotroph adenoma 
can be entirely removed surgically by the trans-sphenoidal approach, with sufficient skill to 
preserve normal anterior pituitary function (32, 46). This induces remission in approximately 
80% of the patients, but long-term relapse occurs in up to 30% of these cases (45). The choice of 
second-line therapy remains controversial (46). Repeat surgery can be successful when 
residual tumor is detectable on magnetic resonance imaging; however, it carries a high risk of 
hypopituitarism. The histological pseudocapsule of a pituitary adenoma is a layer of 
compressed normal anterior lobe that surrounds the adenoma and can be used during surgery 
to identify and guide the removal of the tumor. With this approach, the overall remission rate 
is high and the rate of complications is low (47). Radiotherapy combined with ketoconazole or 
radiosurgery was recently found effective, but a longer-term evaluation of hypopituitarism 
and brain function is required. As soon as residual tumor progresses, surgery and 
radiotherapy should be initiated. Various drugs which inhibit steroid synthesis (ketoconazole, 
metyrapone, aminoglutethimide, mitotane) are sometimes temporarily effective for rapidly 
controlling hypercortisolism either in preparation for surgery, after the unsuccessful removal 
of the etiologic tumor, or while awaiting the full effect of radiotherapy or more definitive 
therapy (45). Other modes of radiotherapy (heavy particles, stereotactic radiosurgery with 
gamma knife) are limited to specialized centers. Despite initial enthusiasm for gamma knife 
(48), a relapse rate of up to 20% has been reported following treatment. It may, however, be 
more rapid than conventional radiotherapy in onset of lowering cortisol levels (49).  
3.5 Outcome 
The long-term follow-up of patients treated for Cushing's disease should include the 
adequate replacement of glucocorticoids and other hormones, treatment of osteoporosis, 
and detection of long-term relapse of Cushing's disease (45). Following pituitary surgery, 
careful ongoing expert endocrine assessment is mandatory, as the incidence of relapse 
increases with time and also with the increasing rigor of the endocrine evaluation. (50). 
3.6 Complications 
Today, cardiovascular and psychiatric co-morbidities still remain the major life-threatening 
complication. The final prognostic criterion for Cushing's syndrome lies in the severity of 
the hypercortisolism and the aggressiveness of the responsible tumor (37, 46). Bone wasting 
results in generalized osteoporosis. The prevalence of bone demineralisation assessed by 
bone mineral density using dual energy X-ray absorptiometry is about 40% (51). 
Compression fractures of the spine are evident on plain radiographs in about 20% - 80% of 
the patients, depending on the studies, and almost half the patients complain about 
backache. Kyphosis and loss of height, sometimes dramatic, are frequent. Pathological 
fractures can occur elsewhere, particularly in the ribs, feet and pelvis (36). Transient features 
of brain atrophy can disappear after cure (52). Impaired quality of life may persist years 
after controlling hypercortisolism (53).  
4. GH secreting PA 
Excessive secretion of growth hormone (GH) is responsible for acromegaly (54). This disease 
is almost always due to a GH-secreting pituitary adenoma. It is distinguished by a gradual 
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progressively acquired somatic disfigurement (primarily involving the face and extremities) 
and leads to acromegaly: a disorder of disproportionate tissue, skeletal, and organ growth 
(55, 56). 
4.1 Symptoms 
Because of the insidious onset and slow progression, acromegaly is frequently diagnosed 
from four to more than ten years after its onset (57). Patients usually display coarsened facial 
appearance, acral enlargement, increased skin thickness and soft tissue hyperplasia. Other 
manifestations include increased sweating, goiter, joint involvement, carpal tunnel 
syndrome, visual abnormalities, headache, colon polyps, sleep apnea, reproductive 
disorders, metabolic disturbances (hypertriglyceridemia, reduced insulin sensitivity), and 
cardiovascular disease (cardiac hypertrophy, hypertension, arrhythmias, and 
cardiomyopathy) (57-59). 
4.2 Epidemiology 
The prevalence is estimated to be 40-130 per million inhabitants, with 3-4 new cases per 
million populations per year (55, 58). It is most often diagnosed in middle-aged adults 
(average age 40 years). Men and women are equally affected (57).  
4.3 Diagnosis 
The measurement of fasting or random GH and of Insulin-like Growth Factor 1 (IGF-1) are 
baseline biochemical criteria for the diagnosis of acromegaly. A random GH level lower 
than 0.4 μg/l and an IGF-1 value in the age- and sex-matched normal range exclude the 
diagnosis of acromegaly. When these two parameters are dissonant, a 75 gram oral glucose 
tolerance test (OGTT) should be performed: a fall of serum GH to 1 μg/l or less within two 
hours will exclude acromegaly (60, 61). 
Measurement of circulating GH-releasing hormone (GHRH) is the preferred test for the 
differential diagnosis between GH-secreting pituitary adenoma and ectopic GHRH 
secretion. Stimulatory tests (thyroid releasing hormone (TRH) stimulation test or 
gonadotropin releasing hormone (GnRH) stimulation test) provide no advantage over 
OGTT, and their use is not recommended for diagnosis (58). 
Acromegaly is caused by an adenoma of the pituitary gland in more than 98% of all patients. 
The size of the tumor and its expansion should be documented by MRI.  If the tumor 
expands into the suprasellar space and/or laterally beyond the cavernous sinus, an 
ophthalmological assessment is suggested to determine the possible impairment of the 
visual field and function of oculomotor nerves (58). 
4.4 Management 
The goal of treatment is to relieve symptoms, to obtain control of local tumor mass, and to 
reduce morbidity and mortality. Treatment options include surgery, medical therapy and 
radiotherapy. Transsphenoidal surgery is the first choice of treatment when a definitive cure 
can be achieved, mainly in the cases of microadenomas and when decompression of 
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is the first-line therapy except when the macroadenoma is giant or if surgery is contra-
indicated.  Primary medical therapy should be conducted in patients bearing 
macroadenomas with significant lateral extension. In addition, preoperative primary 
medical therapy may result in tumor shrinkage, facilitating tumor resection, and may 
reduce preoperative complications due to GH excess. Within the spectrum of medical 
therapy, long-acting somatostatin analogues (somatostatins) are considered as primary 
therapy. Treatment with somatostatins results in GH control in about 60% of the cases. 
Somatostatins also induce tumor contraction in 30-50% of the patients, most effectively 
when applied as first-line treatment. Prolonged treatment with somatostatins is safe and 
well tolerated. Octreotide and lanreotide (two currently available somatostatins) appear to 
have equal effectiveness. In patients with suboptimal clinical and biochemical response to 
somatostatins, combination therapy with dopamine receptor agonists or pegvisomant (a 
new GH-receptor antagonist) typically leads to effective disease control. New developments 
in the medical therapy of acromegaly include the universal somatostatin receptor agonist 
pasireotide, and chimerical compounds that interact with both somatostatin and dopamine 
receptors with synergizing effects on GH secretion (54, 58, 62, 63). 
If surgery fails, medical therapy should be started or reinstated. Dopaminergic drugs might 
be considered for a small group of patients with mildly elevated GH/IGF-1 levels or 
harboring GH-prolactin co-secreting adenomas (64, 65). The use of radiotherapy 
(fractionated, or by gamma-knife) appears to be justified as a treatment of last resort in 
patients with tumors progressively growing and unresponsive to somatostatins, and in a 
small group of patients who bear aggressive pituitary adenomas invasive of local structures 
including the cavernous sinus and even the temporal lobes. These tumors occur more 
frequently in younger patients, for whom the concerns about radiation-dependent 
hypopituitarism and second tumor formation are higher. Therefore several considerations 
must be taken into account when choosing an individualized treatment program for each 
patient (63, 66). 
4.5 Outcome 
Rheumatologic, cardiovascular, respiratory and metabolic consequences are major factors 
that determine the prognosis (55). The control of GH and IGF-1 secretion is the main goal of 
treatment, since normalization of these two parameters is the most significant determinant 
of reversing the increased mortality rate of the patients. The outcome of transsphenoidal 
surgery is far better for microadenomas (80-90%) than for macroadenomas (less than 50%), 
which unfortunately represent more than 70% of all GH-secreting pituitary tumors. 
Therefore, pituitary surgery is the first line treatment for microadenomas (58). Indeed, 
survival in acromegaly is restored to that observed in the general population after correction 
of GH/IGF-1 hypersecretion, while morbidity (obstructive sleep apnea, carpal tunnel 
syndrome, cardiac dysfunction, and diabetes mellitus) is markedly improved by lowering 
IGF-1 levels(67). 
4.6 Complications 
Acromegaly is a slowly progressive disease characterized by a 30% increase of mortality rate 
for cardiovascular disease (atherosclerosis, cardiomyopathy), respiratory complications, 
arthrosis and malignancies. Patients with acromegaly display an enhanced mortality rate, 
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cardiovascular disease represents the cause of death in 60%, respiratory disease in 25% and 
malignancies in 15% of the cases. High GH levels, high blood pressure and heart disease 
represent the major negative survival determinants in acromegaly, whereas symptom 
duration, diabetes mellitus and cancer play a minor role in determining mortality (54, 58). If 
the condition is untreated, enhanced mortality due to cardiovascular, cerebrovascular, and 
pulmonary dysfunction is associated with a 30% decrease in life span (56). 
5. TSH secreting PA 
Thyroid stimulating hormone (TSH) secreting pituitary adenomas are a rare cause of 
secondary or central hyperthyroidism (68, 69). The pathogenesis of TSH-secreting-adenomas 
is indefinite and no definite role for various oncogenes has been demonstrated (70). Based 
on the Clarke et al. study, these tumors are often delayed in diagnosis, are frequently 
macroadenomas and plurihormonal in terms of their pathological characteristics, have a 
heterogeneous clinical picture, and are difficult to treat (71). Sometimes mixed pituitary 
tumors co-secrete TSH, growth hormone and prolactin (70). 
5.1 Symptoms 
Because of the long standing duration of the disease, patients present mild or moderate 
signs of hyperthyroidism and can rarely be asymptomatic (68, 72, 73). In addition, mass 
effects of the pituitary tumor such as loss of vision and visual field defects may be occurred 
(70, 73). Moreover, hyperthyroid features can be eclipsed by those of acromegaly in patients 
with mixed TSH/GH adenomas, thus emphasizing the importance of systematic 
measurement of TSH and free thyroxin (FT4) in patients with pituitary tumor (74). 
5.2 Epidemiology  
TSH secreting tumors account for 0.9 to 2.8% percent of all pituitary adenomas. The 
diagnosis of these tumors has been increasing in the past 20 years (69). Most patients have 
macroadenomas, and microadenomas are exceptional (75).  
5.3 Diagnosis 
Hormonal evaluation shows increased free thyroid hormone concentration with detectable, 
normal or increased serum TSH level, raising the differential diagnosis of pituitary 
resistance to thyroid hormone (72). Ultrasensitive TSH assays allow a clear distinction 
between patients with suppressed and those with non-suppressed circulating TSH 
concentrations, i.e. between patients with primary hyperthyroidism (Graves' disease or toxic 
nodular goiter) and those with central hyperthyroidism (TSH-secreting adenomas or 
pituitary resistance to thyroid hormone action) (73). The MRI discloses the pituitary 
adenoma (72). A (99 m) Tc-octreotide scan can be a useful tool for confirming diagnosis of 
TSH-secreting adenoma (76).  
5.4 Management  
Therapy of TSH-secreting adenomas can be accomplished by surgery, radiation therapy, 
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arthrosis and malignancies. Patients with acromegaly display an enhanced mortality rate, 
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cardiovascular disease represents the cause of death in 60%, respiratory disease in 25% and 
malignancies in 15% of the cases. High GH levels, high blood pressure and heart disease 
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duration, diabetes mellitus and cancer play a minor role in determining mortality (54, 58). If 
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signs of hyperthyroidism and can rarely be asymptomatic (68, 72, 73). In addition, mass 
effects of the pituitary tumor such as loss of vision and visual field defects may be occurred 
(70, 73). Moreover, hyperthyroid features can be eclipsed by those of acromegaly in patients 
with mixed TSH/GH adenomas, thus emphasizing the importance of systematic 
measurement of TSH and free thyroxin (FT4) in patients with pituitary tumor (74). 
5.2 Epidemiology  
TSH secreting tumors account for 0.9 to 2.8% percent of all pituitary adenomas. The 
diagnosis of these tumors has been increasing in the past 20 years (69). Most patients have 
macroadenomas, and microadenomas are exceptional (75).  
5.3 Diagnosis 
Hormonal evaluation shows increased free thyroid hormone concentration with detectable, 
normal or increased serum TSH level, raising the differential diagnosis of pituitary 
resistance to thyroid hormone (72). Ultrasensitive TSH assays allow a clear distinction 
between patients with suppressed and those with non-suppressed circulating TSH 
concentrations, i.e. between patients with primary hyperthyroidism (Graves' disease or toxic 
nodular goiter) and those with central hyperthyroidism (TSH-secreting adenomas or 
pituitary resistance to thyroid hormone action) (73). The MRI discloses the pituitary 
adenoma (72). A (99 m) Tc-octreotide scan can be a useful tool for confirming diagnosis of 
TSH-secreting adenoma (76).  
5.4 Management  
Therapy of TSH-secreting adenomas can be accomplished by surgery, radiation therapy, 





The major aim is to remove the pituitary tumor and restore euthyroidism. Thus, the first 
therapeutic approach to TSH-secreting pituitary microadenomas should be the 
transsphenoidal or subfrontal adenomectomy, the choice of the route depending on the tumor 
volume and its suprasellar extension. This may be complex because of the occasional marked 
fibrosis of these tumors, possibly related to high expression of basic fibroblast growth factor 
(68, 77). In patients with macroadenomas or invasive pituitary tumors, long-acting 
somatostatin analogs may be an effective therapeutic measure to decrease TSH and thyroid 
hormone secretion (72, 78). Octreotide can control central hyperthyroidism, induce tumor 
shrinkage, and it can be a satisfactory method of preoperative preparation for TSH-secreting 
adenoma (73, 76). Aberrant expression of TRβ4 (a novel thyroid hormone receptor β isoform) 
could possibly contribute to the aberrant secretion of TSH in a TSH-secreting adenoma (79). 
5.5 Outcome 
In the past, about one third of the patients were diagnosed as having a primary 
hyperthyroidism (Graves’ disease) and thus mistakenly were treated with thyroid ablation 
(thyroidectomy and/or radioiodine) (73).  
The increasing frequency and early diagnosis of TSH secreting pituitary adenoma may be 
explained by ultrasensitive methods now used for TSH measurement and progress in 
pituitary imaging, mainly with MRI. This change in the presentation and the state of disease 
at diagnosis and the excellent response to somatostatins has improved the prognosis for this 
uncommon disease (70, 80). 
5.6 Complications 
Failure to recognize the presence of a TSH-secreting adenoma may result in dramatic 
consequences, such as improper thyroid ablation that may cause the pituitary tumor volume 
to further expand (73). 
6. LH and FSH secreting PA 
Recent studies have found that a high proportion of clinically non-functioning pituitary 
adenomas are largely gonadotrope-derived, i.e. produce and secrete low levels of intact 
follicle-stimulating hormone (FSH), luteinizing hormone (LH) or only biologically inert 
alpha- or beta-subunits of these hormones (81, 82). 
6.1 Symptoms 
Gonadotroph adenomas are not typically associated with a clinical syndrome (2). They are 
almost always discovered in patients presenting with  mass effect, including visual field loss 
and headache, hypogonadism, and hypopituitarism (81). Anterior pituitary insufficiency is 
much more frequent than gonadal hyperstimulation such as ovarian hyperstimulation (83), 
testicular enlargement (82), and precocious puberty (81, 84). 
6.2 Epidemiology  
Advances in immunocytochemistry, electron microscopy, cell culture, and molecular 
techniques have demonstrated that 80 to 90% of the clinically nonfunctioning pituitary 
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adenomas are gonadotrope-derived and recently recognized as gonadotropinomas, which 
account for as many as 40 to 50% of all pituitary macroadenomas (81, 84). 
Gonadotropinomas have been reported with increasing frequency in middle-aged men, but 
they are less frequently recognized in women. This could be the result of greater difficulty in 
diagnosis due to the normal increase in serum gonadotropins in postmenopausal women 
(85). 
6.3 Diagnosis 
Both clinical and hormonal characteristics of gonadotropinomas usually make them readily 
distinguishable from pituitary enlargement due to long-standing primary hypogonadism 
(86). A careful analysis of hormone assay results show that baseline concentrations of 
gonadotrophin or their free sub-units are elevated in 30 to 50% of the cases. The GnRH test 
is positive in 75 to 100% of the cases (84). The majority of the cases can be recognized, even 
in postmenopausal women, by the serum LH beta responses to TRH, and some can be 
recognized by the responses of serum FSH and LH (87, 88). 
6.4 Management 
Most gonadotropinomas are now first treated by transsphenoidal surgery, to make an 
attempt to restore vision as quickly as possible, and then by radiation therapy to prevent the 
regrowth of any remaining adenomatous tissue. Radiosurgery using gamma knife, the 
linear accelerator, or proton beam therapy showed promising results, especially for 
controlling residual or recurrent tumors (63, 81). Medical therapy for a gonadotrope 
adenoma with a somatostatin analogs, dopamine agonists, or GnRH agonists and 
antagonists has limited utility but is employed in patients who are unable to undergo 
surgery. They may delay or prevent additional tumor growth (64, 84, 89, 90). Experimental 
therapy with intraoperative local chemotherapy or potential gene therapy requires further 
investigation (81). 
6.5 Outcome & Complications 
Long-term outcomes and complications of gonadotropinomas are similar to those of non-
functioning pituitary adenomas.    
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1. Introduction  
Pituitary adenomas (PA) constitute about 10% of intracranial neoplasm. Most of them have 
its origin in adenohypophysis (Cury et al., 2009; Rosai, 1989). They occur most often in 
adults between the ages of 30 and 60 years, and may have slightly higher incidence in 
females in early life (20-45 years) and in males in later life (35-60 years) (Davis et al., 2001; 
McDowell et al., 2011). The majority of pituitary adenomas have a sporadic origin; familial 
cases represent 5% of all pituitary tumors (Vandeva et al., 2010; Tichomirowa et al., 2009). 
Couldwell and Cannon (2010) report strong evidence of genetic contribution for 
predisposition to symptomatic pituitary tumors.  
Pituitary adenomas clinically manifest by signs of hypopituitarism, this is caused by the 
compression of the gland by the tumor which may affect fertility, the compression of other 
adjacent structures may cause headache and if the optic chiasm is affected visual alterations; 
secretion of one or more specific hormones can take place (Galland & Chanson, 2009; 
Melmed, 2010). However, up to 30% of adenomas do not secrete hormones (Cury et al., 
2009; Martinez, 1986; Moreno, 2005). 
Pituitary adenomas have been classified as: microadenomas (<10mm diameter) and 
macroadenomas (> 10 mm diameter), according to its size assessed by tomography and 
magnetic resonance; staining affinity (acidophilic, chromophobic or basophilic); hormonal 
activity or secretion of growth hormone (GH), prolactin (PRL), thyroid stimulating 
hormone(TSH), adrenocorticotrophin hormone (ACTH), follicle stimulating hormone (FSH), 
and luteinizing hormone (LH); and ultrastructural characteristics (Galland & Chanson, 2009; 
Nosé, 2011). Hardy (1973) classified pituitary adenomas in four grades according to its size 
and local invasion degree: 
Grade I: Microadenomas, measuring less than 10mm in diameter, they minimally alter the 
radiographic appearance of the sella. 
Grade II: Macroadenomas are bigger than 10mm in diameter, they enlarge the sella or 
exhibit suprasellar expansion, but not cause destruction. 
Grade III: Invasive adenomas, locally eroded the sella, and show suprasellar outgrowth. 
Grade IV: Strongly invasive adenomas, that destroys adjacent bony structures and with 
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secretion of one or more specific hormones can take place (Galland & Chanson, 2009; 
Melmed, 2010). However, up to 30% of adenomas do not secrete hormones (Cury et al., 
2009; Martinez, 1986; Moreno, 2005). 
Pituitary adenomas have been classified as: microadenomas (<10mm diameter) and 
macroadenomas (> 10 mm diameter), according to its size assessed by tomography and 
magnetic resonance; staining affinity (acidophilic, chromophobic or basophilic); hormonal 
activity or secretion of growth hormone (GH), prolactin (PRL), thyroid stimulating 
hormone(TSH), adrenocorticotrophin hormone (ACTH), follicle stimulating hormone (FSH), 
and luteinizing hormone (LH); and ultrastructural characteristics (Galland & Chanson, 2009; 
Nosé, 2011). Hardy (1973) classified pituitary adenomas in four grades according to its size 
and local invasion degree: 
Grade I: Microadenomas, measuring less than 10mm in diameter, they minimally alter the 
radiographic appearance of the sella. 
Grade II: Macroadenomas are bigger than 10mm in diameter, they enlarge the sella or 
exhibit suprasellar expansion, but not cause destruction. 
Grade III: Invasive adenomas, locally eroded the sella, and show suprasellar outgrowth. 
Grade IV: Strongly invasive adenomas, that destroys adjacent bony structures and with 





This classification remains valid using computed tomography scanning and magnetic 
resonance imaging. 
Histologically pituitary adenomas are dense cellular tumors, composed by cells with solid 
nuclei, rounded and uniform. These cells can be arranged in big groups (diffused pattern), 
around sinusoidal vessels (sinusoidal pattern), or covering connective-vascular axes 
(papillary pattern). In all PA types, atypia and mitotic cells are rare. Despite the 
histologically benign aspect, pituitary adenomas may have an invasive behavior (Chang, 
2010; Lau, et al., 2010; Li-Ng, 2008; Melmed, 2010; Scheithauer, 1986; Zada et al., 2011;). This 
factor is not necessarily indicative of malignancy, because tumor growth is slow and 
metastases are rare. The histological aspect is not different from the rare carcinoma cases 
(Colao et al., 2010; Crocker, 1978; Kaltsas et al., 2005; Schteithauer et al., 2005; Tena-Suck et 
al., 2006;). 
In most patients the pathologist cannot provide information about the PA behavior, if will 
be aggressive based on the histological appearance of adenomas, this is because tumors with 
variations in the size, shape and nuclear density and the presence of bi-or multinucleated 
cells do not necessarily had a poor prognosis.  
The functional classification of pituitary adenomas based on its hormonal activity, assessed 
by immunohistochemistry technique, and associated with the transmission electron 
microscopy analysis, has allowed the characterization of neoplastic cells in detail and 
proposes the classification of the adenomas in 14 different types, this allows a better 
correlation with the clinical manifestations that the old classification of chromophobe, 
acidophilic and basophilic pituitary adenomas (Horvath & Kovacs, 1992; Horvath, 1994; 
Kovacs & Horvath, 1986). 
The aim of this investigation is to present a review of different cases of pituitary adenomas 
studied in the Laboratory of Experimental Neuropathology of National Institute of 
Neurology and Neurosurgery, correlating the local invasion degree, clinical manifestations, 
histological aspects, immunohistochemical and ultrastructural features, with  the biological 
behavior, especially with the invasive potential. 
2. Methods  
One hundred and twenty two cases of pituitary adenomas were studied. They were 
classified by their local invasion degree according with Hardy classification (Hardy, 1973), 
endocrine symptoms (clinically functioning and clinically non functioning pituitary 
adenomas) and by their hormonal secretion, assessed by immunohistochemistry. The 
evolution of the disease at the time of diagnosis, tumor regrowth, bromocriptine treatment, 
and time of outcome of the patients, were evaluated to analyze the PA biological behavior. 
2.1 Histopathological analysis  
The biopsies were divided in two parts; the first one was fixed in phosphate-buffer saline 
(PBS)-formalin solution, alcohol dehydrated and paraffin-embedded. Five µm sections were 
stained with hematoxilyn-eosin and Masson’s trichrome (Prophet & Arrington, 1992) for PA 
treated with bomocriptine. In each hematoxylin-eosin stained section was analyzed nuclear 
pleomorphism and mitosis figures. 
 




In other sections, immunohistochemistry (Bratthauer et al., 1994) was performed. Slides of 
each case were deparaffinized, rehydrated, and rinsed in PBS. Later on, endogenous 
peroxidase was blocked with 0.25 % H2O2/distilled water for 15 min., and blocking with 3% 
BSA in PBS (Albumin, Bovine, Sigma-AldrichCo. St. Louis USA). The slides were incubated 
for 1 h in ready to use monoclonal antibodies of pituitary hormones: prolactin, growth 
hormone (GH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid 
stimulating hormone (TSH) (BioGenex, San Ramón, CA) and adrenocorticotropic hormone 
(ACTH, DAKO, Carpinteria, Ca, at a 1;100 dilution). Normal postmortem pituitaries were 
used as positive controls for pituitary hormones. To assess the proliferative index of 
pituitary adenomas Ki-67 antibody was used (Santa Cruz Biotechnology, inc. Santa Cruz 
CA. USA at 1:100 dilution). After that the sections were washed, and incubated for 30 min. 
with the secondary antibody (biotinylated anti-Ig, BioGenex, San Ramón, CA). After 
washing in PBS the sections were incubated for 30 min with peroxidase-conjugated 
streptavidina complex (BioGenex, San Ramón, CA).  The reaction was developed with 
diaminobenzidine (DAB) using a Dako kit detection system (Dako enVision System 
Peroxidase. Dako Carpinteria, CA) according to manufacturer’s instructions and the sections 
were hematoxylin counterstained. The immunodetection was analyzed under a wide-field 
microscope Olympus H2 (Tokyo, Japan). The immunoreactivity to different hormones in 
tumor cells were estimated as positive or negative, and the Ki-67 labeled index (LI) was 
assessed by counting the percentage of number of positive / nuclear cells in five 40x fields. 
Statistics analysis were done to associate Ki-67 labeling index (LI), disease evolution time, 
and outcome, in functional PA and in non-functional PA, hormone secretion, invasion 
degree, and tumor regrowth.  
2.3 Ultrastructural analysis 
The second part of biopsy was processed for its use in electron microscopy to assess the fine 
structure of PA. The tissues were fixed in 2.5% glutaraldehyde in 0.1 M phosphate-buffer-
saline (PBS pH 7.4) and postfixed in 1% tetroxide osmium in the same buffer, dehydrated in 
alcohol, and embedded in Epon. One-micron thick sections were stained with toluidine blue 
and examined by light microscopy. Ultrathin sections at the silver/grey area of the 
spectrum of interference colors were stained with uranyl acetate and lead citrate and 
examined under Zeiss EM 10 transmission electron microscopy. 
2.4 Statistical analysis 
Statistical analysis was performed by using the SPSS 13.0 software. ANOVA test and X2, 
Kurskal-Wallis were used to evaluate differences and association respectively, among 
evolution time and follow up with grades of invasion. Bivariate analysis was accomplished 
by means of Fisher’s exact test for association among functional and non-functional PA, or 
hormonal immunodetection with recurrences. U Mann-Whitney’s test was used to assess 
evolution time and follow up differences among functioning and non-functioning PA. To 
evaluate differences in Ki-67-LI detection among invasion grades, X2 Kurskal-Wallis test was 
done; among functioning and non-functioning PA with recurrences U Mann-Whitney’s test 
was used; and the association of Ki-67-LI detection with hormonal immunodetection, U 
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One hundred and twenty two pituitary adenomas were studied between 1988 and 1992. 
They were organized according to their characteristics, by means of transsphenoidal or 
transcranial-frontal technique, and the tumors were removed in 60 to 100%. Tumors mainly 
affected young adult population with a mean age of 41.4 yr. Sixty five (53.3%) were male, 
mean age of 43.6±14.8 yr (range, 17-71 yr) and 57 (46.7%) were female, mean age of 39.3±14.4 
yr (range, 13-75 yr). Twelve patients were under 20 yr (9.8%). Six males with mean age of 
18.8 ± 2.4 yr, and 6 females with mean age of 16.1 ± 2.5 yr. Clinically they were 11 
functioning PA and 1 non-functioning PA (Table 1). 
 
Grade Gender Age (yr) Evolution Time (yr) F NF Symptoms IHQ 
II M 17 1 X  Hypogonadism Prl 
II M 20 2 X  VA Ha Ac GH 
II F 23 4 X  VA Ha Am-Gal Prl-TSH 
II M 24 6 X  Cush Neg 
II M 18 4  X VA Ha Prl 
III F 14 2 X  VA Am Prl 
III M 20 8 X  Gal-Am Gig Prl-GH 
III F 23 8 X  VA Ha Am-Gal Prl-ACTH 
IV F 18 4 X  VA Ha Am Prl 
IV F 18 4 X  VA Ha Am-Gal Neg 
IV F 13 2 X  VA Am Prl 
IV M 20 2 X  VA Ac Prl-GH 
F= functioning pituitary adenoma; NF= non-functioning pituitary adenoma; VA= visual alterations; 
Ha= headache; Am= amenorrhea; Gal= Galactorrhea; Gig= gigantism; Ac= acromegaly; IHQ= 
immunohistochemical detection. 
Table 1. Pituitary adenomas in young cases under 20 years old at the onset of symptoms.  
The age column is the age at diagnosis.  
Twenty two cases (18%) were classified as I and II invasion grades tumors, and 66 cases 
(54.1%) were in extensive invasion phase (IV grade). The disease evolution time before the 
first surgery was 2.9±2.3 yr (range, 2 months to 10 years). Of the 122 patients thirty eight 
patients continued to attend their review appointments (31%). The average follow up time 
of the patients was 11±7.4 yr (range, 1-27 yr); from 1 to 5 yr, and from 15 to 20 yr, were the 
most frequent. Only one patient (0.8%) was considered healthy; four deaths have been 
reported. The remaining patients stopped coming to the Institute to control appointments. 
Thirty nine (31.9%) cases out of the 122 had recurrence; 23 (58.9%) belong to grade IV PA. In 
grade III and IV, two patients with recurrences were observed (Table 2). 
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(%) 1 2 
I 2 1 (50) 33/31 1.5 1 0   
II 20 4 (20%) 39/45 2.1 10.6 (1m-20yr) 6 (15.3%) 6  
III 34 23 (67%) 40/34 3.4 12.1 (2-20) 10 (25.6%) 7 3 
IV 66 29 (44%) 39/44 3 10.3 (1-27) 23 (58.9%) 21 2 
Table 2. Pituitary adenomas classification by grades of invasion according to Hardy (1973). 
Disease evolution time, follow up time, and recurrences in each grade are shown. 
F= females; M= males; m= month. 
3.1 Immunohistochemistry 
Prolactin was the most frequent hormone detected by immunohistochemistry (54 cases, 
44.2%) (Table 3). Prolactin hormone expression was found in combination with others 
hormones: 10 were in combination with GH (8.1%), 4 (3.2%) with TSH; 3 (2.4%) with ACTH, 
and 1 (0.81%) with LH. Fifteen (12.3%) cases were positive for gonadotroph hormones, 5 
(4%) for growth hormone, 2 (1.6%) for ACTH, 1 (0.82%) for TSH, 1 (0.82%) multihormonal 
(HC-FSH-TSH), and 26 (21.3%) cases were negative for all hormones (Fig. 1). 
  
Fig. 1. Pituitary adenoma classification according to their hormonal content assessed by 
immunohistochemistry. 
Prolactin hormone expression was the most frequent detected. Prl= prolactin hormone; GH= 
Growth hormone; TSH= Thyroid stimulating hormone; ACTH= adrenocorticotropin 
hormone; LH= luteinizing hormone; FSH= follicle stimulating hormone; MH= 
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Fig. 2. Classification of non-functioning pituitary adenomas. 
Immunohistochemical detection of hormonal expression in non-functioning pituitary 
adenomas. Prl= prolactin hormone; GH= Growth hormone; TSH= Thyroid stimulating 
hormone; ACTH= adrenocorticotropin hormone; LH= luteinizing hormone; FSH= follicle 
stimulating hormone; Neg= negative. 
There were 51 (41.8%) non-functioning PA, 17 (33%) were Prl positive by 
immunohistochemistry, 15 (29%) were negative, and 10 (19.6%) were positive for 
gonadotrophic hormones (Fig. 2).  
Non-functioning PA presented visual alterations and headache as clinical manifestations. 
There was 58.2% of clinically functioning pituitary adenomas. The most frequent clinical 
manifestations were:  amenorrhea, galactorrhea, and libido diminished. Acromegaly was 
found in GH positive pituitary adenomas and one patient with gigantism was found (Table 
1). Ki-67-LI was high in IV grade tumors (Table 3, Fig. 3).  
 
Grade Cases # F NF Prl # (%) 
Ki-67-LI 
Median (range) 
I 2 2 - 2 (100) ND 
II 20 10 10 11 (55) 10.7 (10-16) 
III 34 21 13 22 (64.7) 6.8 (1-20) 
IV 66 38 28 37 (56) 25.4 (2-35) 
Table 3. Pituitary adenomas classification according to their endocrine symptoms: Clinically 
functioning pituitary adenomas (F) and clinically non-functioning pituitary adenomas (NF). 
Prolactin hormone expression detected by immunohistochemistry (Prl). Number and 
percentage of positive cases, in each grade. Ki-67 Labeled Index (Ki-67-LI) in each grade. 
ND= No determined. 
 




Fig. 3. Immunohistochemical detection 
Photomicrograph of pituitary adenomas stained with immunohistochemical technique. 
Antibodies against prolactin hormone (A), and Ki-67 (B). Prolactin detection is present in the 
cytoplasm and Ki-67 can be seen in nucleus. Arrows show the immunodetection. (original 
magnification X 400). 
3.2 Statistical analysis 
There was no significative statistic difference in disease evolution time (F=1.0, p=0.351) and 
follow up (F=0.1, p=0.885), compared between invasion degrees. Neither the evolution time 
(p=0.146) nor the follow-up time (p=0.678) differed between functioning PA and non-
functioning PA, however disease evolution time was lightly higher in III and IV invasion 
degrees. Evolution time (X2=2.4, p=0.287) and follow up time (X2=0.1, p=0.939) did not have 
association with the invasion grade.  
No association was found among recurrence and functioning PA (p=0.526), and with 
hormone immunodetection (Prl p=0.595; GH p=0.377; FSH p=0.635). 
Ki-67-LI was higher in IV grade (median value: 24.5%; range 2-35) in comparison with grade 
II (median value 6.8%; range 1-20; X2=6.4, p=0.029); Grade III PA has an intermediate value 
(median value 10.7%; range 10-16). There was no statistic difference of Ki-67-LI between 
functioning PA and non-functioning PA (p=0.893) or between PA with recurrence and PA 
without recurrence (p=0.253). There was no association of Ki-67-LI with hormone secretion 
type (Prl p=0.121; GH p=0.100; FSH p=0.5). 
3.3 Histopathological analysis  
Histologically 98.4% show high cellular density, discrete nuclear pleomorphism, and dense 
nuclei, between 7 and 10 µ of diameter (Fig. 4A). Neither necrosis areas nor mitotic figures 
were observed. Only two cases of IV grade invasion degree, which were prolactin secretor 
PA, show nuclear pleomorphism, pseudoinclusions, bi- or multinucleated cells, and mitotic 
figures (Fig. 4B and 4C). 
There were 11 prolactinomas (15.2%) treated with bromocriptine before surgery for a period 
of 2 months to 3 years. The drug decreased tumor size and serum prolactin levels, the 
menstruation was restored, galactorrhea stopped and fertility returned. Histologically 
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smaller endoplasmic reticulum and Golgi complex; lysosomes were more frequent observed 
and there were scarce secretory granules. 
 
 
Fig. 4. Photomicrograph of pituitary adenomas with hematoxilyn-eosin stain (A-C), and 
with Masson’s trichrome stain for collagen fibers (D).  (A) PA showing solid pattern with 
homogeneous size cells. (B-C) PA showing nuclear pleomorphism (asterisk) and 
pseudoinclusions (arrow). (D) Bromocriptine treated PA which shows interstitial fibrosis 
(arrow). (Original magnification: X400). 
3.4 Ultrastructure 
3.4.1 Prolactin adenomas 
The most frequent type of pituitary adenomas was the prolactinoma (59%). All 
prolactinomas were sparsely granulated. The tumor show polyhedral cells with irregular 
nucleus, and prominent nucleolus. In the cytoplasm abundant, lamellar, rough endoplasmic 
reticulum and well development Golgi complex, was observed. There were scarce secretory 
granules, with size between 100-300 nm in diameter; some of them were localized between 
lateral cell surfaces which are known as misplaced exocytosis, the morphologic mark of 
prolactin secretor PA (Fig. 5). 
3.4.2 Growth hormone adenomas 
Adenoma secreting only growth hormone had an incidence of 4%. Ultrastructuraly this 
tumor was sparsely granulated. The cells showed pleomorphic and eccentric nucleus, with 
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observed, some of them with secretory granules inside it, whose size was between 221 nm 















Fig. 5. Electronmicrographs of sparsely granulated prolactin adenoma grade II. (A) Lamellar 
endoplasmic reticulum (arrow). X 6,076; (B) fused secretory granules (black arrow) and 
misplaced exocytosis (white curved arrow). X9,750. Uranyl acetate-lead citrate. 
3.4.3 GH secreting adenoma and prolactin hormone adenoma 
Ten cases (8%) of pituitary adenomas with prolactin hormone and growth hormone 
secretion were found. Ultrastructuraly it was observed a monomorphous tumor, formed by 
only one cell type. All cells were scarcely granulated with secretory granules with 178 nm of 
















Fig. 6. Electronmicrograph of grade IV, GH PA, with their hall-mark fibrous body (arrow) 
X10,350. (A); grade III PA, prolactin and GH secreting, with lamellar endoplasmic reticulum 
(black arrow), crescent moon nuclei (curved arrow), and fibrous body of type II filaments 







smaller endoplasmic reticulum and Golgi complex; lysosomes were more frequent observed 
and there were scarce secretory granules. 
 
 
Fig. 4. Photomicrograph of pituitary adenomas with hematoxilyn-eosin stain (A-C), and 
with Masson’s trichrome stain for collagen fibers (D).  (A) PA showing solid pattern with 
homogeneous size cells. (B-C) PA showing nuclear pleomorphism (asterisk) and 
pseudoinclusions (arrow). (D) Bromocriptine treated PA which shows interstitial fibrosis 
(arrow). (Original magnification: X400). 
3.4 Ultrastructure 
3.4.1 Prolactin adenomas 
The most frequent type of pituitary adenomas was the prolactinoma (59%). All 
prolactinomas were sparsely granulated. The tumor show polyhedral cells with irregular 
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reticulum and well development Golgi complex, was observed. There were scarce secretory 
granules, with size between 100-300 nm in diameter; some of them were localized between 
lateral cell surfaces which are known as misplaced exocytosis, the morphologic mark of 
prolactin secretor PA (Fig. 5). 
3.4.2 Growth hormone adenomas 
Adenoma secreting only growth hormone had an incidence of 4%. Ultrastructuraly this 
tumor was sparsely granulated. The cells showed pleomorphic and eccentric nucleus, with 
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observed, some of them with secretory granules inside it, whose size was between 221 nm 















Fig. 5. Electronmicrographs of sparsely granulated prolactin adenoma grade II. (A) Lamellar 
endoplasmic reticulum (arrow). X 6,076; (B) fused secretory granules (black arrow) and 
misplaced exocytosis (white curved arrow). X9,750. Uranyl acetate-lead citrate. 
3.4.3 GH secreting adenoma and prolactin hormone adenoma 
Ten cases (8%) of pituitary adenomas with prolactin hormone and growth hormone 
secretion were found. Ultrastructuraly it was observed a monomorphous tumor, formed by 
only one cell type. All cells were scarcely granulated with secretory granules with 178 nm of 
















Fig. 6. Electronmicrograph of grade IV, GH PA, with their hall-mark fibrous body (arrow) 
X10,350. (A); grade III PA, prolactin and GH secreting, with lamellar endoplasmic reticulum 
(black arrow), crescent moon nuclei (curved arrow), and fibrous body of type II filaments 







nucleus show rounded or crescent moon shape in which concave area fibrous bodies were 
observed (Fig. 6B). 
3.4.4 Gonadotroph adenomas 
These adenomas were the most abundant (12%) after prolactinomas (44%) and the negative 
types for immunohistochemistry (21%).  This tumor was formed by polyhedral cells, with 
poorly developed cytoplasm. Nuclei had rounded contours, some of them with irregular 
shapes and eccentric nucleoli attached to the electron-dense perinuclear chromatin. Rough 
endoplasmic reticulum was scarce and dilated, and secretory granules were few and small 
(153 nm in diameter). Big Golgi complex was observed with dilated cisterns (Fig. 7A). In two 
IV grade cases, smooth endoplasmic reticulum, mixed with mitochondria and pleomorphic 
secretory granules were detected; there was a vacuolated Golgi complex which was 
















Fig. 7. Electronmicrograph of grade III gonadotroph PA. (A) This tumor showed big Golgi 
complex with dilated cisterns (arrow), small secretory granules located along the cell 
membrane (thin arrow). X 6,370; (B) Golgi shows a honey comb complex (arrow). X15,600. 
Uranyl acetate-lead citrate. 
3.4.5 Negative pituitary adenomas  
This type of tumors was negative for all hormones with the immunohistochemistry 
technique. Under transmission electron microscopy, poorly developed cells were observed 
with scarce rough endoplasmic reticulum, few secretory granules with 100-200 nm of 
diameter and small Golgi complex. In some cases it was observed numerous mitochondria, 
which is known as oncocytic transformation (Fig. 8A). 
3.4.6 Corticotroph adenoma 
There were 2 cases (1.6%) of ACTH secreting pituitary adenomas. This tumor showed 
polyhedral or elongated cells with poorly developed cytoplasm. The cell boundaries were 
clearly marked, elongated nuclei with irregular contours, and prominent nucleoli (8B); 
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secretory granules were scarce and small (104 nm). In one case proliferation of type I 



















Fig. 8. (A) Electronmicrography of grade IV immunonegative PA.  This tumor showed 
sparsely granulated cells with abundant mitochondria (arrow). X9,900 ;  (B) Corticotroph 
cell adenoma grade III which consist of closely-apposed, angular cells, with marked cell 
boundaries (arrow), and nucleus with irregular shape (N). X6,370 ; (C) Cytoplasm with 
abundant type I filaments were observed (arrow). X8760. Uranyl acetate and lead citrate. 
4. Discussion 
Pituitary adenomas are heterogeneous tumors, this is because their different types of cells. 
The analysis of them had take into account several characteristic, the aim of these is to 
explain its behavior, although until now, has not been understood.  
Pituitary adenomas comprise nearly 15% of intracranial neoplasms and are the most common 
lesions in the sellar region (Valassi et al., 2010). There is a report of 84.6% PA in a study of 4,122 
tumors of sellar region (Saeger et al., 2007). In a 10-year study conducted at the National 
Institute of Neurology and Neurosurgery, in Mexico City, from 2,041 central nervous system 
tumors and covers, 26.2% were PA (personal communication). Here we present a study of 122 
case of PA which occurred between 13 and 75 yr old, with peak of incidence from 20 and 60 
years (100 cases; 81.9%), 10 yr earlier than other series (Davis et al., 2001). There was a slightly 
higher incidence in men; however women had earlier age at diagnosis (since 13 yr) than men 
(since 17), with higher frequency between 20 and 48 yr (men between 30 and 60 yr; 68%). 
Pituitary adenomas incidence are rare in young people under 20 yr and mostly are 
prolactinomas (86%) or corticotropinomas (10%) (Mindermann & Wilson, 1994). In this study  
was found 12 patients under 20 yr (9.8%); Nine (75%) were prolactinomas, one of which was 
Prl-ACTH positive, two Prl-GH, one Prl-TSH. From these 12 cases, one (8.3%) was GH 
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secretory granules were scarce and small (104 nm). In one case proliferation of type I 
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observed, that in some patients the age at diagnosis (age column) is over 20 yr, although the 
patients reported that the beginning of the symptoms was some years before (evolution time). 
In general, tumor size correlates with functional activity (clinically functioning and clinically 
non-functioning pituitary adenomas), and in women has been observed that, prolactinomas 
and also in ACTH clinically functioning pituitary adenomas, the diagnosis is carry out at 
early stages. (Kontogeorgos, 2006). In our work we found 71 (58.1%) functioning PA; 44 
(61.9%) were in female of which only 5 (11%) were grade I and II PA and 39 (88.6%) were 
classified in III and IV grades. Out of this 39 PA, 29 (74%; 13 in grade III and 16 in grade IV) 
were prolactin immunopositive. In this case, women functioning adenomas, which 
produced prolactin hormone, were detected at an advance stage of invasion. 
In this study must of the PA were in a invasive phase (grade III and IV), and the disease 
evolution time in these patients was higher than in I and II grades, even though there was 
no statistical association with clinical manifestation (functioning or non-functioning PA) or 
hormonal activity assessed by immunohistochemistry. Similar long evolution time (from 10 
days to 20 years), has been reported in a Brazilian serie which was greater than the Italian 
and US series (Drange et al, 2000; Ferrante et al., 2006).   This may be due to the class of 
population that assist to this Institute, which are used to endure the symptoms of the disease 
for a long time before seeking medical treatment, or do not have the right information to 
perceive them at an early stage, also before turning to adequate health service they look for 
alternative therapies. As it has been suggested by other authors, the clinical signs might be 
underestimated or not correctly diagnosed (Drange et al., 2000; Ferrate et al., 2006). In our 
experience, patients as first choice went to the ophthalmologist, because of the visual 
alterations, and by the computed tomography or magnetic resonance imaging scans, sellar 
alterations were observed. Nowadays incidental detection of PA tumors has been increased 
due to radiological evaluations performed for unrelated reasons (Saeger et al., 2007). In this 
analysis we can observed that the functionality was not related to tumor size, but with time 
the patient will assit to the health center. 
Non-functioning pituitary adenomas are a diverse and heterogeneous group, where 
glycoprotein hormones, null cell adenoma and oncocytoma are included (Laws et al., 1982; 
Moreno et al., 2005). They are usually diagnosed as macroadenomas due to absence of 
clinical manifestations, which cause tumor growth in long time. Non-functioning PA 
account between 15% and 45% of pituitary tumors (Asa & Kovacs, 1992; Milker-Zabel et al., 
2005). It has been reported that 95-100% of non-functioning pituitary adenomas are 
macroadenomas, and the frequency of recurrence varies between 19% and 34.8% in different 
studies (Aurer & Clarici, 1985; Reddy et al., 2011); up to 79% has hormone expression, 
evaluated by immunohistochemistry (Moreno et al., 2005), being gonadotroph hormones 
and/or their α- β- subunits the most common (Cury et al., 2009, Hanson et al., 2005). In our 
study 51 (42%) tumors were non-functioning PA, of which 38 (74.5%) were men, this is 
consistent with other studies (Asa & Kovacs, 1992; Cury et al., 2009; Ferrante et al., 2006; 
Milker-Zabel et al., 2005). Out of 51 non-functioning pituitary adenomas, 15 (29.4%) showed 
recurrence and 41 (80%) were macroadenomas. In 71% of non-functioning PA hormone 
expression was found, being prolactin the most frequent hormone detected by 
immunohistochemistry (33%), followed by gonadotroph hormones (20%); there were 29% of 
immunonegative PA in accordance with Turner report (Turner et al., 1999). It is important to 
point out that 13 cases of non-functionig PA were female, 7 of grade III and 6 of grade IV. 
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There were no adenomas classified in grades I and II. In our case, in women non-
functioming pituitary adenomas could be related with the size.  
In pituitary adenomas recurrences are common problems. The large size and the invasive 
behavior of these tumors cause difficulties in their removal (Paek et al., 2005). It has been 
reported that about 50% of patients have tumor remnants, and tumor re-growth can be 
presented at 10 years after neurosurgery (Reddy, 2011; Sassolas et al., 1993). Generally larger 
tumors recurred more frequently than smaller adenomas after surgery (Gopalan et al., 2011; 
Saeger et al., 2007). In our work the tumors were removed between 60% and 100%, by means 
of transcranial-frontal or transsphenoidal technique, and in III and IV grades the recurrences 
were higher, with secondary recurrences in 5 patients (three in III grade and 2 in IV grade). 
The time of interval between surgery and recurrence ranged from 1 to 11 years in both 
clinically functioning PA and non-functioning PA. In non-functioning pituitary adenomas 
Reddy et al. (2011) showed relapse/re-growth in 10 or more years after the initial surgery, 
and found significant increase in re-growth rates when remnant pituitary tumors are 
observed on the first post-operative scan or if the patient is younger age at initial surgery.  
The follow up time of the patients is an important factor for their outcome (Dekkers et al., 
2008). In our work 38 (31%) patients were found  with  a mean of 11 yr of follow up (range 1-27 
yr),  12 of them were non-functioning PA with 10.3 yr of follow up (range, 1-27 yr). Reddy 
et.al. (Reddy, 2011) reports an average of 6.1 yr (range, 1-25.8) of follow up in 29 patients with  
non-functioning PA out of 155, of which 54 (34.8%) had recurrence, with 20% of relapse after 
10 years of surgery; they suggest that it is necessary to track patients beyond this time.  
In this study, few patients continued to attend for monitoring appointments. This could be 
because the patients who come to this health institution live outside of Mexico city, and 
sometimes it is difficult for them to travel to the city. Other patients are sent to other hospitals 
for continue their treatment, or they have no financial means for the follow up. Patients, who 
maintain their treatment and attendance to appointments for periodic reviews, have good 
outcome, with a improve of their visual impairments and hormonal levels, treated by 
hormonal substitution. It has been observed that patients with pre-operative anterior dysfunction 
recover function after surgery and the cases who presented with visual disturbance improve 
their vision with a second surgery (Chang et al., 2010; Müslüman et al., 2011). 
An important factor in the biological behavior of pituitary adenomas is their proliferative 
capacity, which could be assessed by counting mitoses and the immunostaining of nuclei for 
proliferation markers as Ki-67. Mitoses figures are rare in non-invasive pituitary adenomas 
(3.9% of cases), they are more frequent in invasive PA (21.4%) and are greater in carcinomas 
(66.7%) (Pernicope et al., 2001). In our study there were found 2 cases (1.6%) with mitoses, 
which is not different from that reported in other studies, including the recently established 
rare subtype spindle cell oncocytoma of the pituitary gland (Matyja et al., 2010; Saeger et al., 
2007). 
Ki-67 is the most important proliferation marker; it is expressed in early G1, S, G2, and M 
phases of the cell cycle. This marker is associated with tumor proliferation, invasiveness, 
and prognosis (Cattoretti et al., 1992; Petrowsky et al., 2001). In pituitary adenomas the 
value of Ki-67 is controversial, in relation to the aggressive behavior (de Aguiar et al., 2010; 
Zhao et al., 1999), and in pituitary carcinoma appear to predict rapid disease progression 
(Dudziak et al., 2011). In a study performed in 44 pituitary macroadenomas, visual field 
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observed in Ki-67 LI in relation to the Hardy´s classification (Paek et al., 2005). In other 
study in a series of 20 radically resected pituitary macroadenomas (11 functioning, 9 
nonfunctioning) MIB-1(antibody of Ki-67 antigen) did not show a significant difference of 
expression between recurrent and non-recurrent adenomas (Ruggeri et al., 2011). Yarman 
(2010) assessed Ki-67 expression in growth hormone-secreting pituitary adenomas and 
showed no correlation with the invasive character. In other study it has been observed that 
Ki-67 LI was marginally higher in clinically functioning adenomas than clinically non-
functioning adenomas. They also found significant difference in the MIB-1 LI in tumors with 
a maximum diameter of more than 4cm at a MIB-1 LI of ≥2%, however this difference was 
not statistically significant at a higher MIB-1 LI cut off value of >3% (Chacko et al., 2010). On 
the other hand, there is other report in which no significant difference in MIB-1 LI was 
found between functioning and non-functioning PA  (Scheithauer et al., 2006). In our results, 
Ki-67 LI was significantly higher in IV grade PA than those of II grade which is different to 
that reported by Paek (2005); however there was no statistic difference of Ki-67 LI between 
pituitary adenomas with recurrence or without recurrence. About functionality we did not 
found differences between functioning and non-functioning pituitary adenomas which 
differs with Scheithauer report (2006).  
Ultrastructural analysis of pituitary adenomas is an important tool for the detailed 
characterization of this type of tumors, particularly in problematic cases, because it is the 
initial basis of adenoma classification. With transmission electron microscopy it can be 
confirmed the endocrine nature of PA and their functional differentiation, which can be 
identified based on their ultrastructural markers of each hormonal type.  Despite the utility 
of electron microscopy analysis in the evaluation of these tumors, diagnostic cannot be 
made on ultrastructural grounds alone, it should be done taking into consideration 
histology, immunohistochemistry and electron microscopical morphologic features, as well 
as findings from imaging studies and the symptoms (Kontogeorgos, 2006). Both clinical and 
histopathological factors are important for the diagnostic and outcome of patients. 
In our study we observed the ultrastructural features of the different types of PA according 
to their hormonal expression, and in relation to clinical manifestations. Ultrastructural 
analysis was very useful in mixed secretory adenomas, as growth hormone and prolactin 
secreting PA where cells with fibrous bodies, hall-mark of GH pituitary adenoma. In this 
way, ultrastructural findings of most PA are consistent with the immunophenotype, 
however there are occasional cases with ultrastructural features less well differentiated like 
the rare carcinomas (Scheithauer et. al., 2001). 
5. Conclusion 
Pituitary adenomas are a heterogeneous group whose behavior has not been understood 
yet. In our study must of the tumors were in a extensive invasive phase, they affected young 
adult population and in this series of cases people under 20 years were founded. The disease 
evolution time and recurrence frequency was high in the advanced grades. The diagnosis of 
these tumors was not related with the clinical manifestations, according to the time taken by 
the patients to consult a doctor. The good outcome of patients depends on the follow-up, 
which has a very low rate for different reasons. 
Pituitary adenomas have benign histological aspect, however can be aggressive, and may 
have one or more recurrences, as has been shown in this analysis.  These neoplasms seem to 
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have, a natural evolution, a potential to invasion, sparing the nervous tissue and without 
seeding to distant organs. 
Although there are no parameters or experimental tests that serve as clear markers of disease 
progression, the data that have been obtained as a result of the evaluation of hormone 
expression and clinical evaluation, have important information that can be associated with 
pathogenicity of PA. Currently, there are new molecular techniques, as proteomic technique 
that allows us to investigate the proteins involved in the disease process. 
The setup of registry on pituitary tumours constitutes a useful tool to analyze clinical 
experience, improve therapeutic strategies and patient's care. It also contributes for teaching 
medical students and develops clinical research. 
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observed in Ki-67 LI in relation to the Hardy´s classification (Paek et al., 2005). In other 
study in a series of 20 radically resected pituitary macroadenomas (11 functioning, 9 
nonfunctioning) MIB-1(antibody of Ki-67 antigen) did not show a significant difference of 
expression between recurrent and non-recurrent adenomas (Ruggeri et al., 2011). Yarman 
(2010) assessed Ki-67 expression in growth hormone-secreting pituitary adenomas and 
showed no correlation with the invasive character. In other study it has been observed that 
Ki-67 LI was marginally higher in clinically functioning adenomas than clinically non-
functioning adenomas. They also found significant difference in the MIB-1 LI in tumors with 
a maximum diameter of more than 4cm at a MIB-1 LI of ≥2%, however this difference was 
not statistically significant at a higher MIB-1 LI cut off value of >3% (Chacko et al., 2010). On 
the other hand, there is other report in which no significant difference in MIB-1 LI was 
found between functioning and non-functioning PA  (Scheithauer et al., 2006). In our results, 
Ki-67 LI was significantly higher in IV grade PA than those of II grade which is different to 
that reported by Paek (2005); however there was no statistic difference of Ki-67 LI between 
pituitary adenomas with recurrence or without recurrence. About functionality we did not 
found differences between functioning and non-functioning pituitary adenomas which 
differs with Scheithauer report (2006).  
Ultrastructural analysis of pituitary adenomas is an important tool for the detailed 
characterization of this type of tumors, particularly in problematic cases, because it is the 
initial basis of adenoma classification. With transmission electron microscopy it can be 
confirmed the endocrine nature of PA and their functional differentiation, which can be 
identified based on their ultrastructural markers of each hormonal type.  Despite the utility 
of electron microscopy analysis in the evaluation of these tumors, diagnostic cannot be 
made on ultrastructural grounds alone, it should be done taking into consideration 
histology, immunohistochemistry and electron microscopical morphologic features, as well 
as findings from imaging studies and the symptoms (Kontogeorgos, 2006). Both clinical and 
histopathological factors are important for the diagnostic and outcome of patients. 
In our study we observed the ultrastructural features of the different types of PA according 
to their hormonal expression, and in relation to clinical manifestations. Ultrastructural 
analysis was very useful in mixed secretory adenomas, as growth hormone and prolactin 
secreting PA where cells with fibrous bodies, hall-mark of GH pituitary adenoma. In this 
way, ultrastructural findings of most PA are consistent with the immunophenotype, 
however there are occasional cases with ultrastructural features less well differentiated like 
the rare carcinomas (Scheithauer et. al., 2001). 
5. Conclusion 
Pituitary adenomas are a heterogeneous group whose behavior has not been understood 
yet. In our study must of the tumors were in a extensive invasive phase, they affected young 
adult population and in this series of cases people under 20 years were founded. The disease 
evolution time and recurrence frequency was high in the advanced grades. The diagnosis of 
these tumors was not related with the clinical manifestations, according to the time taken by 
the patients to consult a doctor. The good outcome of patients depends on the follow-up, 
which has a very low rate for different reasons. 
Pituitary adenomas have benign histological aspect, however can be aggressive, and may 
have one or more recurrences, as has been shown in this analysis.  These neoplasms seem to 
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have, a natural evolution, a potential to invasion, sparing the nervous tissue and without 
seeding to distant organs. 
Although there are no parameters or experimental tests that serve as clear markers of disease 
progression, the data that have been obtained as a result of the evaluation of hormone 
expression and clinical evaluation, have important information that can be associated with 
pathogenicity of PA. Currently, there are new molecular techniques, as proteomic technique 
that allows us to investigate the proteins involved in the disease process. 
The setup of registry on pituitary tumours constitutes a useful tool to analyze clinical 
experience, improve therapeutic strategies and patient's care. It also contributes for teaching 
medical students and develops clinical research. 
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multisource Cobalt 60 units. In order to enhance precision, various devices may incorporate 
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the Gamma Knife® System (GKS). Its clinical efficacy has been well documented, with more 
than 550,312 cases treated worldwide by December 2009 providing the data for over 2,500 
publications in peer-reviewed medical literature. The GKS is ideal for tumors less than 3.5 
cm, and functional disorders of the brain.  
The modified linear accelerator (m-LINAC) based radiosurgery machines are prevalent 
throughout the world. The modified linear accelerator systems use similar principles as the 
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radiation beams that are redirected in many "arcs" centered over an isocenter to lessen the 
adverse effects on healthy tissue. These machines can perform radiosurgery on tumors 
smaller than 3.5cm in diameter with the same range of precision of the GKS. Most of the 
GKS and m-LINAC systems employ a stereotactic head frame (ring). The head frame allows 
a precise localization of the lesion to be treated. The head frame, which is attached to the 
skull with four small screws, ensures that the radiation beams are precisely targeted. The 
frame also prevents head motion during the treatment procedure, which ensures that only 
the target area receives the prescribed radiation. However, modern localization techniques 
using bony landmarks identified by diagnostic X-Rays system has allowed some systems of 
m-LINAC to avoid the use of the stereotactic head frame. One of the advantages of these 
systems is that patients can be treated over more than one day without the need of wearing 
a head frame over extended periods of time, and in a few special situations can treat tumors 
slightly larger than 3.5 cm in diameter with this hypofractionating technique. Another 
advantage of the m-LINAC system is that they can use Intensity-Modulated Radiation 
Therapy (IMRT) and Image Guided Radiotherapy (IGRT) dosimetries algorithms to treat 
critically located lesions. In IMRT, the intensity of the radiation beam is non-uniform (i.e., 
modulated) across the treatment field, rather than producing a single, uniform, intensity 
beam. When combining this technique with the imaging done in the pre-plan, it further 
improves the delivery of radiation. These systems can provide treatment to lesions outside 
the brain. 
A special type of m-LINAC is the CyberKnife® Robotic Radiosurgery System. It utilizes a 6 
MV compact linear accelerator mounted on a computer-controlled six-axis robotic 
manipulator that permits a wide range of beam orientations and takes advantage of 
intelligent robotics to enable the effective treatment of tumors in the brain and anywhere in 
the body. To date, an estimated over 80,000 patients have been treated with the 
CyberKnife® System and currently more than 50 percent of all CyberKnife® procedures in 
the United States are extra cranial.  
The proton beam radiosurgery systems employ a stream of protons to treat lesions. As of 
June 2011, there were a total of 37 proton therapy centers in Canada, China, England, 
France, Germany, Italy, Japan, Korea, Poland, Russia, South Africa, Sweden, Switzerland, 
and USA and more than 73,800 patients had been treated (Particle Therapy Co-Operative 
Group, 2011). One hindrance to universal use of the proton in cancer treatment is the size 
and cost of the cyclotron or synchrotron equipment necessary to produce the protons. 
The authors have used a modified linear accelerator-based system to provide radiosurgery 
treatment to pituitary adenomas. The initial radiosurgery system installed in 1999 was 
manufactured by Radionics®. In 2003 this system was upgraded to a Brain Lab System® 
that incorporated a multileaf collimator. 
2. The radiobiology of radiosurgery  
The basic principle of ionizing radiation is the creation of ions or free radicals in the 
irradiated tissues. This ions or free radicals interact with the cell’s molecules producing 
damage to them. The radiation dose is usually measured in grays, where one gray (Gy) is 
the absorption of one joule per kilogram of mass. These ions and radicals, which may be 
formed from the water and oxygen in the cell or from the tissue substance, can produce 
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irreparable damage to DNA, proteins, membranes, and lipids that can evolve into the cell's 
death. The radiation effects can be seen in the order of minutes to years (Figure 1).  
 
Fig. 1. Effects of Ionizing radiation over time. 
Radiation damages the cell’s structures of tumor cells as well of normal cells in the radiation 
beam path. Normal tissue, however, is generally more proficient repairing sublethal damage 
than tumors cells. In general terms, tumors cells have altered repair mechanisms tolerating 
less irradiation damage than normal cells. Cells require time to repair DNA damage and one 
of the normal responses of the cell is delaying the cell cycle, delaying G2 phase. In 
radiotherapy where daily treatments with sublethal doses of radiation are given for several 
days, the difference in proficiency to repair the damage between normal and tumoral tissues 
is essential. Therefore, the radiobiology of the cell cycle and differences in cell repair are of 
great importance for fractionated radiotherapy. In radiosurgery, were a lethal dose of 
radiation is given in a single treatment, the repairing capacity of different tissues play a less 
critical role. Radiosurgery in many instances activates the apoptosis cascade resulting in cell 
death. The rate of proliferation of cells can determine the response to radiation, resulting in 
increased sensitivity of endothelial, glial and subependymal cells. Vascular endothelial cell 
damage tends to produce vessels obliteration that could play a role in the death of tumor 
cells as well.  
The radiation doses prescribed for radiotherapy have been developed from decades of 
clinical experience. However, the radiobiological principles of multifraction treatments do 
not necessarily apply to high dose ionizing beams as used in radiosurgery. Radiosurgery 
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target volume. Normal tissue is excluded from the target as much as possible and a steep 
dose gradient at the margin of the target volume assures that the surrounding tissue 
receives a minimal dosage. Therefore, repair capacity of normal tissue during treatment is 
less critical in radiosurgery. 
3. Pituitary adenomas 
Pituitary adenomas represent nearly 10-20% of all intracranial tumors. Multimodal 
treatment includes microsurgery, medical management, radiotherapy and radiosurgery. 
Pituitary adenomas are broadly classified into two groups—functioning (secretory) and 
nonfunctioning. Microsurgery is the primary recommendation for nonfunctioning and most 
of functioning adenomas, except for prolactinomas that are usually managed with 
dopamine agonist drugs. Long-term tumor control rates after microsurgery alone range 
from 50 to 80%. For both functioning and nonfunctioning pituitary adenomas, incomplete 
tumor resection or recurrence because of tumor invasion into surrounding structures (for 
example, the dura mater or cavernous sinus) is common. Postsurgical residual secretory 
adenoma results in the persistence of a hypersecretory state and the associated deleterious 
clinical features. Moreover, about 30% of patients require additional treatment after 
microsurgery for recurrent or residual tumors. In patients with recurrent or residual 
pituitary adenomas, treatment options include repeat resection, radiation therapy, medical 
management, and radiosurgery. More recently, radiosurgery has been established as a 
treatment option. Radiosurgery allows the delivery of prescribed dose with high precision 
strictly to the target and spares the surrounding tissues. Therefore, the risks of 
hypopituitarism, visual damage and vasculopathy are significantly lower. Furthermore, the 
latency of the radiation response after radiosurgery is substantially shorter than that of 
fractionated radiotherapy. 
4. Planning and technique 
All patients suspected of harboring a pituitary tumor should undergo a complete 
neurologic, ophthalmologic, endocrinologic, and radiologic work-up (Laws & Sheehan, 
2006; Laws & Thapar 1996). This includes formal visual fields, an acuity testing and a 
detailed fundoscopic examination. Each facet of the hypothalamic-pituitary-end organ axis 
should be assessed by an endocrinologist and re-assessed by the neurosurgeon. (Table 1) 
Evaluation of the sellar region is best accomplished by using a thin slice pre- and post-
contrast magnetic resonance (MR) imaging. When there is a contraindication to MR or is not 
available, a computed tomography (CT) imaging can be useful (Jagannathan et al., 2005; 
Kanter et al., 2005).  
If a patient has a neurological deficit attributable to an adenoma, surgery is the initial 
treatment of choice for all tumors except prolactinomas. Transsphenoidal microsurgery 
(endoscopic or microscopic) affords the best chance of rapid relief of mass effect and 
reduction in excessive hormone levels in patients with Cushing’s disease and acromegaly 
(Laws & Sheehan, 2006; Laws & Thapar 1996; Laws et al., 1985a, 1985b, 2000). This approach 
is associated with a low rate of complications in the hands of experienced neurosurgeons 
(Ciric, 1997). For this reason, tumors located in areas such as the sellar floor or sphenoid that 
can be safely accessed surgically should undergo surgical removal, with radiosurgery being 
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reserved for tumor residuals or recurrences. For tumors that cannot be removed completely 
depending on the size, location, and invasiveness of surrounding tissues by the tumor, one 
surgical goal could be to create a safe distance of 2 to 5 mm between the lesion and optic 
apparatus so that an adequate radiosurgery dose can be delivered to the adenoma with 
minimal risk of radiation injury to the optic pathways. 
 
Hormone Test Results and Additional Evaluations 
Prolactin 
function Serum Levels 
Elevated prolactin, usually with serum 
levels > 75 ng/ml 
Thyroid 
function 
Free thyroxine and thyroid 
stimulating hormone  
Adrenal 
function 
Morning fasting and afternoon 
serum cortisol and ACTH level. 
Salivary cortisol levels. 
In Cushing’s syndrome, a 24 h urine 





Growth hormone and insulin-like 
growth factor (IGF)-1. 
Oral glucose tolerance test with growth 
hormone measurements for GH 
secreting tumors. 
Table 1. Minimal basic endocrine workup for pituitary adenomas. 
Patients harboring secretory pituitary tumors warrant a special consideration regarding 
radiosurgery pre-planning. Since 2000, several studies have documented that cessation of 
suppressive medication before radiosurgery is recommended to offer the best normalization 
of hormone values after the treatment (Landolt 2000a, 2000b; Pouratian et al., 2006; Pollock 
et al., 2007). The optimal time period to temporarily halt anti-secretory medications is 
unclear and class I evidence is sill unavailable to support temporary cessation of 
antisecretory medications as a standard of care.  
5. Radiosurgery procedure 
When medical and surgical treatments are not curative or cannot control the tumor growth 
or symptoms, radiosurgery needs to be considered. Prior to considering radiosurgery, the 
neurosurgeon and the radiation oncologist of the radiosurgery team evaluate the patient, 
both need to agree that radiosurgery is an optimal option. Then, the patient is scheduled for 
the procedure. On the day of the treatment or the day before, a MR study is obtained, with 3 
mm thick slices of the brain including the sella and skull base. On the day of treatment a 
stereotactic head frame is applied under local anesthesia and/or IV sedation. Subsequently, 
stereotactic CT scanning is performed with the CT scan localizer on. Three-millimeter thick 
slices are obtained throughout the entire head. The stereotactic CT scan and MR images are 
transferred to the treatment-planning computer. The CT scan and MR images are fused 
electronically. The tumor, optic apparatus and critical surrounding structures are delineated 
in the planning computer. (Figure 2) The plan is carefully examined and adjusted to 
generate the actual treatment plan, maximizing the dose delivery to the tumor and 
minimizing irradiation of the optic apparatus and the surrounding tissues.  
The radiation oncologist and the neurosurgeon review and approve the plan. Four or more 





target volume. Normal tissue is excluded from the target as much as possible and a steep 
dose gradient at the margin of the target volume assures that the surrounding tissue 
receives a minimal dosage. Therefore, repair capacity of normal tissue during treatment is 
less critical in radiosurgery. 
3. Pituitary adenomas 
Pituitary adenomas represent nearly 10-20% of all intracranial tumors. Multimodal 
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from 50 to 80%. For both functioning and nonfunctioning pituitary adenomas, incomplete 
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If a patient has a neurological deficit attributable to an adenoma, surgery is the initial 
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(Laws & Sheehan, 2006; Laws & Thapar 1996; Laws et al., 1985a, 1985b, 2000). This approach 
is associated with a low rate of complications in the hands of experienced neurosurgeons 
(Ciric, 1997). For this reason, tumors located in areas such as the sellar floor or sphenoid that 
can be safely accessed surgically should undergo surgical removal, with radiosurgery being 
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reserved for tumor residuals or recurrences. For tumors that cannot be removed completely 
depending on the size, location, and invasiveness of surrounding tissues by the tumor, one 
surgical goal could be to create a safe distance of 2 to 5 mm between the lesion and optic 
apparatus so that an adequate radiosurgery dose can be delivered to the adenoma with 
minimal risk of radiation injury to the optic pathways. 
 
Hormone Test Results and Additional Evaluations 
Prolactin 
function Serum Levels 
Elevated prolactin, usually with serum 
levels > 75 ng/ml 
Thyroid 
function 
Free thyroxine and thyroid 
stimulating hormone  
Adrenal 
function 
Morning fasting and afternoon 
serum cortisol and ACTH level. 
Salivary cortisol levels. 
In Cushing’s syndrome, a 24 h urine 





Growth hormone and insulin-like 
growth factor (IGF)-1. 
Oral glucose tolerance test with growth 
hormone measurements for GH 
secreting tumors. 
Table 1. Minimal basic endocrine workup for pituitary adenomas. 
Patients harboring secretory pituitary tumors warrant a special consideration regarding 
radiosurgery pre-planning. Since 2000, several studies have documented that cessation of 
suppressive medication before radiosurgery is recommended to offer the best normalization 
of hormone values after the treatment (Landolt 2000a, 2000b; Pouratian et al., 2006; Pollock 
et al., 2007). The optimal time period to temporarily halt anti-secretory medications is 
unclear and class I evidence is sill unavailable to support temporary cessation of 
antisecretory medications as a standard of care.  
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When medical and surgical treatments are not curative or cannot control the tumor growth 
or symptoms, radiosurgery needs to be considered. Prior to considering radiosurgery, the 
neurosurgeon and the radiation oncologist of the radiosurgery team evaluate the patient, 
both need to agree that radiosurgery is an optimal option. Then, the patient is scheduled for 
the procedure. On the day of the treatment or the day before, a MR study is obtained, with 3 
mm thick slices of the brain including the sella and skull base. On the day of treatment a 
stereotactic head frame is applied under local anesthesia and/or IV sedation. Subsequently, 
stereotactic CT scanning is performed with the CT scan localizer on. Three-millimeter thick 
slices are obtained throughout the entire head. The stereotactic CT scan and MR images are 
transferred to the treatment-planning computer. The CT scan and MR images are fused 
electronically. The tumor, optic apparatus and critical surrounding structures are delineated 
in the planning computer. (Figure 2) The plan is carefully examined and adjusted to 
generate the actual treatment plan, maximizing the dose delivery to the tumor and 
minimizing irradiation of the optic apparatus and the surrounding tissues.  
The radiation oncologist and the neurosurgeon review and approve the plan. Four or more 





multileaf collimator is adjusted every 15 degrees to achieve a conformal treatment to the 
lesion. The head ring is removed on the same day of treatment. After a short observation 
period, the patient is discharged. Close clinical and radiological neuroimaging follow-up 
examination is arranged at appropriate intervals depending on the entity treated and the 
condition of the patient. 
 
Fig. 2. Radiosurgical planning which includes protection of important structures and 
inclusion of treatment area.  
6. Toxicity and side effects 
Like any other medical intervention radiosurgery has side effects. The main concern is 
radionecrosis of structures adjacent to the pituitary gland; optic apparatus, cranial nerves 
within the cavernous sinus, hypothalamus, brainstem and medial temporal lobes. The 
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toxicity of fractionated external beam radiotherapy is low; with 1.5% risk of radiation optic 
neuropathy (Brada et al., 1993; Tsang et al., 1994) and 0.2% risk of necrosis of normal brain 
structures (Becker et al., 2002). The most frequent late consequence of radiation is 
hypopituitarism likely to be primarily due to hypothalamic injury or primary pituitary 
gland injury. In patients with normal pituitary function around the time of radiotherapy, 
hormone replacement therapy is required in 20–40% of patients at 10 years. A rare late effect 
of radiation for pituitary adenoma is the development of second radiation-induced brain 
tumor. The reported frequency is in the region of 2% at 10–20 years (Brada et al., 
1992; Tsang et al., 1993; Erfurth et al., 2001). Although there is an increased incidence of 
cerebrovascular accidents and excess cerebrovascular mortality in patients with pituitary 
adenoma treated with radiation, the influence of radiation on its frequency is not well 
defined (Brada et al., 1999, 2002; Tomlinson et al., 2001; Erfurth et al., 2002). 
The radiation effects on the optic apparatus, other cranial nerves and brainstem are of 
critical importance. Most of the damage is thought to be a result of secondary damage of the 
endothelium of small vessels and protective Schwann cells or oligodendroglia. There is a 
difference in the tolerance of different cranial nerves; with sensory nerves (optic and 
acoustic) tolerating the least radiation. The nerves in the parasellar region, the facial nerves 
and the lower cranial nerves usually tolerate higher doses. Clinical experience suggests that 
these specialized sensory nerves do not show a great capacity to recover from injury. 
Although the precise dose tolerance of the cranial nerves is unclear, the anterior visual 
pathways seem to be the least radio-resistant, and single doses above 8 Gy should be 
avoided (Jagannathan et al., 2007; Leber et al., 1995, 1998). To minimize the risk of 
irradiation injuries to the optic apparatus, the distance between optic nerves and chiasm and 
the lesion being treated should be carefully assessed. A distance of 5 mm between the tumor 
and the optic apparatus is ideal, but a distance of as little as 2 mm may be acceptable. It 
appears that the risk may be related to the volume of the optic apparatus receiving the dose 
(Chen et al., 2001; Lim et al., 1998; Sheehan et al., 2000; Witt et al., 1998). However, a specific 
critical volume has not been agreed. This distance is critical to design a dose plan that 
delivers a lethal radiation dose to the tumor yet spare the optic apparatus. When all these 
precautions and considerations are taken care the patient is treated accordingly.  
7. Radiosurgery for pituitary adenomas 
The goals of radiosurgery for pituitary tumors are control of tumor growth, and in secretory 
adenomas to normalize hormonal hypersecretion. In addition to the above mention, these 
goals need to be carried out avoiding acute and delay radiation injury to neural structures 
and preventing secondary tumor formation.  
7.1 Non-secreting tumors 
In our experience of twelve patients treated for nonfunctioning pituitary tumors (with mean 
follow-up of 47 months), tumor volume decreased in three patients (25%), remained 
unchanged in eight (66%), and there was no increased in size. One patient was lost to 
follow-up. Regarding tumor control, eleven patients achieved tumor control (91%) except 
for the patient who was lost to follow-up. All of our patients were treated with LINAC 
Radiosurgery as secondary therapy. The average prescription peripheral dose (Gy) was 
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toxicity of fractionated external beam radiotherapy is low; with 1.5% risk of radiation optic 
neuropathy (Brada et al., 1993; Tsang et al., 1994) and 0.2% risk of necrosis of normal brain 
structures (Becker et al., 2002). The most frequent late consequence of radiation is 
hypopituitarism likely to be primarily due to hypothalamic injury or primary pituitary 
gland injury. In patients with normal pituitary function around the time of radiotherapy, 
hormone replacement therapy is required in 20–40% of patients at 10 years. A rare late effect 
of radiation for pituitary adenoma is the development of second radiation-induced brain 
tumor. The reported frequency is in the region of 2% at 10–20 years (Brada et al., 
1992; Tsang et al., 1993; Erfurth et al., 2001). Although there is an increased incidence of 
cerebrovascular accidents and excess cerebrovascular mortality in patients with pituitary 
adenoma treated with radiation, the influence of radiation on its frequency is not well 
defined (Brada et al., 1999, 2002; Tomlinson et al., 2001; Erfurth et al., 2002). 
The radiation effects on the optic apparatus, other cranial nerves and brainstem are of 
critical importance. Most of the damage is thought to be a result of secondary damage of the 
endothelium of small vessels and protective Schwann cells or oligodendroglia. There is a 
difference in the tolerance of different cranial nerves; with sensory nerves (optic and 
acoustic) tolerating the least radiation. The nerves in the parasellar region, the facial nerves 
and the lower cranial nerves usually tolerate higher doses. Clinical experience suggests that 
these specialized sensory nerves do not show a great capacity to recover from injury. 
Although the precise dose tolerance of the cranial nerves is unclear, the anterior visual 
pathways seem to be the least radio-resistant, and single doses above 8 Gy should be 
avoided (Jagannathan et al., 2007; Leber et al., 1995, 1998). To minimize the risk of 
irradiation injuries to the optic apparatus, the distance between optic nerves and chiasm and 
the lesion being treated should be carefully assessed. A distance of 5 mm between the tumor 
and the optic apparatus is ideal, but a distance of as little as 2 mm may be acceptable. It 
appears that the risk may be related to the volume of the optic apparatus receiving the dose 
(Chen et al., 2001; Lim et al., 1998; Sheehan et al., 2000; Witt et al., 1998). However, a specific 
critical volume has not been agreed. This distance is critical to design a dose plan that 
delivers a lethal radiation dose to the tumor yet spare the optic apparatus. When all these 
precautions and considerations are taken care the patient is treated accordingly.  
7. Radiosurgery for pituitary adenomas 
The goals of radiosurgery for pituitary tumors are control of tumor growth, and in secretory 
adenomas to normalize hormonal hypersecretion. In addition to the above mention, these 
goals need to be carried out avoiding acute and delay radiation injury to neural structures 
and preventing secondary tumor formation.  
7.1 Non-secreting tumors 
In our experience of twelve patients treated for nonfunctioning pituitary tumors (with mean 
follow-up of 47 months), tumor volume decreased in three patients (25%), remained 
unchanged in eight (66%), and there was no increased in size. One patient was lost to 
follow-up. Regarding tumor control, eleven patients achieved tumor control (91%) except 
for the patient who was lost to follow-up. All of our patients were treated with LINAC 
Radiosurgery as secondary therapy. The average prescription peripheral dose (Gy) was 





median time of tumor shrinkage on MR-imaging was 12 months (range, 8-68 months) 
following radiosurgery. This is consistent with a recently published series that 
demonstrated pituitary adenomas were 90%, 80%, and 70% of their initial volume at 1, 2, 
and 3 years post-GK radiosurgery (Sheehan et al., 2002). Tumors involving the parasellar 
space require special consideration, as they would be otherwise untreatable.  
Most other contemporary series involving stereotactic radiosurgery for non-functioning 
tumors (Table 2) have demonstrated excellent control of tumor growth, with a mean tumor 
control rate of 95.6% (range, 87%–100%) (Hayashi et al., 1999; Losa et al., 2004; Mitsumori et 
al., 1998; Morky et al., 1999; Muramatsu et al., 2003; Pollock & Carpenter, 2003; Pollock et al., 
2008; Sheehan et al., 2002; Witt et al., 1998;).  
In patients with four or more years of follow-up, the reported mean control rate is 95% 
(range, 83–100%) (Yoon et al., 1998; Morky et al., 1999; Feigl et al., 2002; Hoybye et al., 2001; 
Ikeda et al., 2001; Kobayashi et al., 2002; Shin et al., 2000; Wowra et al., 2002). Some series 
have even demonstrated improvement in visual function following radiosurgery after 
shrinkage of the tumor (Abe et al., 2002; Chen et al., 2001; Hayashi et al., 2005; Yoon et al., 
1998). Nevertheless, prevention of tumor growth, without volume reduction, is still 
considered a radiosurgical goal. 
The CyberKnife (Accuray, Calif., USA), is a newer radiosurgical device that is mounted on a 
maneuverable robotic manipulator and tracks the target with the aid of real-time guidance 
(Adler et al., 1997; Chang et al., 1998). Early experience with the Cyberknife has been 
promising for nonfunctioning adenomas, with a growth control rate of 95%, and lower 
prescription doses (14–16 Gy) than described for the Gamma Knife, although long-term 
clinical follow-up is still lacking (Kajiwara et al., 2005). 
 














Mitsumori, et al., 1998 LINAC 7 47 19 15 100 
Witt, et al., 1998 GK 24 32 38 19 94 
Yoon, et al., 1998 LINAC 8 49 21 17 96 
Hayashi, et al., 1999 GK 18 16 NR 20 92 
Mokry, et al., 1999 GK 31 21 28 14 98 
Sheehan, et al., 2002 GK 42 31 32 16 98 
Muramatsu, et al., 
2003 LINAC 8 30 26.9 15 100 
Pollock & Carpenter, 
2003 GK 33 43 36 16 97 
Losa, et al., 2004 GK 54 41 33 17 96 
Iwai 2004 GK 34 60  14 87 
Mingione 2006 GK 90 45  18.5 92 
Pollock 2008 GK 62 45  16 97 
Brau 2011* LINAC 12 47 21.7 15.8 91 
Table 2. Summary of cases treated with Radiosurgery on Non-functioning pituitary 
adenomas. (*Unpublished manuscript in writing) 
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7.2 Secretory tumors 
Most published results on radiosurgery for secretory adenomas have differed based on 
methodology, endocrine criteria for remission, the study population and length of follow-
up. Most series typically report a higher prescription (margin) dose to patients with 
functioning adenomas, with a range between 20 Gy and 25 Gy in most reports (Jagannathan 
et al., 2007; Kim et al., 1999a, 1999b; Pouratian et al., 2006). Because hormone normalization 
has been followed in some cases by relapse, we prefer the term ‘‘remission’’ to ‘‘cure.’’ 
7.2.1 Acromegaly 
In our experience of fifteen patients treated for acromegaly (with mean follow-up of 37.2 
months), tumor volume decreased in five patients (33.3%), remained unchanged in nine 
(60%), and there was one (6.6%) patient that showed an increase in tumor size. Tumor 
control was achieved in fourteen (93.3%) patients. All of our patients were treated with 
LINAC Radiosurgery as secondary therapy. The average prescription peripheral dose (Gy) 
was 19.4Gy with a range from 12 to 25Gy. In our experience, the rate of hormone 
normalization after radiosurgery for Acromegaly was seen in six (41.6%) patients. Hormone 
normalization in these five patients was observed at mean follow-up of 28 months. Tumor 
control was achieved in most patients correlating with hormone remission, except for one 
patient, which despite hormone remission there was a slight increase in tumor size. 
The most widely accepted guidelines for endocrine remission in acromegaly consist of a GH 
level less than 1 ng/ml in response to an oral glucose challenge and a normal serum IGF-1 
when matched for age [Giustina et al., 2000; Vance, 1998).  
Published remission rates following radiosurgery for acromegaly vary widely from 0% to 
100%, with the majority of patients achieving tumor growth control (Table 3) (Buchfelder et 
al., 1991; Cozzi et al., 2001; Freda, 2003; Fukuoka et al., 2001; Horvath et al., 1983; Landolt et 
al., 1998, 2000; Pouratian et al., 2006; Witt et al., 1998). Jezkova et al. reported a remission 
rate of 50% at 42 months follow-up in 96 patients with acromegaly who received  
 










2003 LINAC 4 30 15 50 100 
Attanasio 2003 GK 30 46 20 23 100 
Castinetti 2005 GK 82 49.5 12-40 40 NR 
Voges 2006 LINAC 64 54.3 15.3 49.8 97 
Jezkova 2007 GK 96 53.7 32 50 100 
Pollock 2007 GK 46 63 20 50 100 
Vik-Mo 2007 GK 53 66 26.5 58 89 
Losa 2008 GK 83 69 21.5 60.2 98 
Jagannathan 
2008 GK 95 57 22 53 98 
Brau 2011* LINAC 15 37.2 19.4 41.6 93.3 
Table 3. Summary of cases treated with Radiosurgery for Acromegaly. (*Unpublished 





median time of tumor shrinkage on MR-imaging was 12 months (range, 8-68 months) 
following radiosurgery. This is consistent with a recently published series that 
demonstrated pituitary adenomas were 90%, 80%, and 70% of their initial volume at 1, 2, 
and 3 years post-GK radiosurgery (Sheehan et al., 2002). Tumors involving the parasellar 
space require special consideration, as they would be otherwise untreatable.  
Most other contemporary series involving stereotactic radiosurgery for non-functioning 
tumors (Table 2) have demonstrated excellent control of tumor growth, with a mean tumor 
control rate of 95.6% (range, 87%–100%) (Hayashi et al., 1999; Losa et al., 2004; Mitsumori et 
al., 1998; Morky et al., 1999; Muramatsu et al., 2003; Pollock & Carpenter, 2003; Pollock et al., 
2008; Sheehan et al., 2002; Witt et al., 1998;).  
In patients with four or more years of follow-up, the reported mean control rate is 95% 
(range, 83–100%) (Yoon et al., 1998; Morky et al., 1999; Feigl et al., 2002; Hoybye et al., 2001; 
Ikeda et al., 2001; Kobayashi et al., 2002; Shin et al., 2000; Wowra et al., 2002). Some series 
have even demonstrated improvement in visual function following radiosurgery after 
shrinkage of the tumor (Abe et al., 2002; Chen et al., 2001; Hayashi et al., 2005; Yoon et al., 
1998). Nevertheless, prevention of tumor growth, without volume reduction, is still 
considered a radiosurgical goal. 
The CyberKnife (Accuray, Calif., USA), is a newer radiosurgical device that is mounted on a 
maneuverable robotic manipulator and tracks the target with the aid of real-time guidance 
(Adler et al., 1997; Chang et al., 1998). Early experience with the Cyberknife has been 
promising for nonfunctioning adenomas, with a growth control rate of 95%, and lower 
prescription doses (14–16 Gy) than described for the Gamma Knife, although long-term 
clinical follow-up is still lacking (Kajiwara et al., 2005). 
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7.2 Secretory tumors 
Most published results on radiosurgery for secretory adenomas have differed based on 
methodology, endocrine criteria for remission, the study population and length of follow-
up. Most series typically report a higher prescription (margin) dose to patients with 
functioning adenomas, with a range between 20 Gy and 25 Gy in most reports (Jagannathan 
et al., 2007; Kim et al., 1999a, 1999b; Pouratian et al., 2006). Because hormone normalization 
has been followed in some cases by relapse, we prefer the term ‘‘remission’’ to ‘‘cure.’’ 
7.2.1 Acromegaly 
In our experience of fifteen patients treated for acromegaly (with mean follow-up of 37.2 
months), tumor volume decreased in five patients (33.3%), remained unchanged in nine 
(60%), and there was one (6.6%) patient that showed an increase in tumor size. Tumor 
control was achieved in fourteen (93.3%) patients. All of our patients were treated with 
LINAC Radiosurgery as secondary therapy. The average prescription peripheral dose (Gy) 
was 19.4Gy with a range from 12 to 25Gy. In our experience, the rate of hormone 
normalization after radiosurgery for Acromegaly was seen in six (41.6%) patients. Hormone 
normalization in these five patients was observed at mean follow-up of 28 months. Tumor 
control was achieved in most patients correlating with hormone remission, except for one 
patient, which despite hormone remission there was a slight increase in tumor size. 
The most widely accepted guidelines for endocrine remission in acromegaly consist of a GH 
level less than 1 ng/ml in response to an oral glucose challenge and a normal serum IGF-1 
when matched for age [Giustina et al., 2000; Vance, 1998).  
Published remission rates following radiosurgery for acromegaly vary widely from 0% to 
100%, with the majority of patients achieving tumor growth control (Table 3) (Buchfelder et 
al., 1991; Cozzi et al., 2001; Freda, 2003; Fukuoka et al., 2001; Horvath et al., 1983; Landolt et 
al., 1998, 2000; Pouratian et al., 2006; Witt et al., 1998). Jezkova et al. reported a remission 
rate of 50% at 42 months follow-up in 96 patients with acromegaly who received  
 










2003 LINAC 4 30 15 50 100 
Attanasio 2003 GK 30 46 20 23 100 
Castinetti 2005 GK 82 49.5 12-40 40 NR 
Voges 2006 LINAC 64 54.3 15.3 49.8 97 
Jezkova 2007 GK 96 53.7 32 50 100 
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Vik-Mo 2007 GK 53 66 26.5 58 89 
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radiosurgery (Jezkova et al., 2006). Nearly one-third of these patients, however, had 
radiosurgery as primary treatment, without surgical extirpation of the adenoma. Pollock et 
al., (2007) demonstrated a remission rate of 50% in 46 patients with a higher remission rate 
in patients who were off suppressive medications at the time of radiosurgery. Pollock’s 
group also stated that maximal radiosurgery effects may be delayed up to 5 years after 
treatment, therefore no other surgical treatment or additional radiosurgery should be 
considered within that period unless there is unequivocal evidence of tumor enlargement 
and progressive elevation of HGH and ILGF-1. 
7.2.2 Cushing’s disease 
Cushing’s disease is one of the most devastating pituitary disorders, and is associated with 
significant morbidity and premature death. Even after transsphenoidal surgery, up to 30% 
of patients may have persistent o recurrent disease (Ciric et al., 1997; Laws & Thapar, 1996; 
Mampalam et al., 1988). Most centers define an endocrine remission as a urine free-cortisol 
(UFC) level in the normal range associated with the resolution of clinical stigmata or a series 
of normal post-operative serum cortisol levels obtained throughout the day (Nieman, 2002; 
Sheehan et al., 2000). We have treated ten patients with Cushing’s disease, with 40% of 
patients achieving normalization of hormones levels with a mean margin dose of 20.7Gy. 
The rate of remission statistically correlated with tumor volume, but not with tumor 
invasion into the cavernous sinus or the suprasellar region. 
In our experience, the rate of hormone normalization after radiosurgery for Cushing’s 
disease is difficult to predict, with remission occurring as early as 17months and as late as 
five years after LINAC Radiosurgery. Most patients who have remission, however, will do 
so within the first 2-3 years following radiosurgery. Patients with persistent disease should 
thus consider alternative treatments such as repeat TSS, or repeat radiosurgery (although 
this may be associated with a higher rate of cranial nerve damage) (Jagannathan et al., 2007). 
Published endocrine remission rates following radiosurgery (Table 4) vary considerably, 
from 10% to 100%, with higher remission rates when radiosurgery follows surgical 
debulking (Arnaldi et al., 2003; Chu et al., 2001; Izawa et al., 2000; Jackson & Noren, 1999;  
 









Laws 1999 LINAC 50 --- 22 58 --- 
Izawa 2000 GK 12 28 22 17 94 
Sheehan 2000 GK 43 44 20 63 100 
Hoybye 2001 LINAC 18 204 --- 83 83 
Kobayashi 2003 --- 20 64 29 35 100 
Devin 2004 GK 35 42 15 49 91 
Castinetti 2007 GK 40 55 29.5 42 100 
Jagannathan 
2007 GK 90 45 25 42 100 
Brau 2011* LINAC 10 50 20.7 40 90 
Table 4. Summary of cases involving Radiosurgery in patients with Cushing’s disease. 
(*Unpublished manuscript in writing) 
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Jagannathan et al., 2007; Kobayashi et al., 2002; Morange-Ramos et al., 1998; Petrovich et al., 
2003; Witt et al., 1998). In series with at least ten patients and a median follow-up of 2 years, 
endocrine remission rates range from 17% to 83% (Kobayashi et al., 2002; Mahmoud-Ahmed 
& Suh, 2002; Morange-Ramos et al., 1998, Petrovich et al., 2003). Rähn and associates 
(Flickenger et al., 1992) reported their experience at the Karolinska Institute involving 59 
patients with Cushing’s disease who were treated using the Gamma Knife and followed for 
2–15 years. The efficacy rate of the initial treatment was 50%, with retreatment eventually 
providing normalization of cortisol production in 76% of patients (Rahn et al, 1980). 
7.2.3 Prolactin-secreting adenomas 
We use radiosurgery as a treatment for prolactinomas after failure of medical and/or 
surgical treatment. Ideally most of the prolactinomas should be treated with medication. 
Prolactinomas tumor control with medications has been reported around 80-90% (Ferone et 
al., 2007). Despite having good control, some patients do not tolerate the medications due to 
side effects and other turnout to be allergic to it.  
In our series two patients were treated as primary therapy for medical reasons. Most of the 
patients were treated following microsurgery. Of the seven patients treated at our 
institution, complete normalization of prolactin levels occurred in only 14.2%, at an average 
time of 22 months, with a mean prescription dose of 18.7Gy. Tumor control was achieved in 
100% of the cases, but did not correlate with hormone remission. 
In published studies of radiosurgery for prolactinomas, the mean prescription dose has 
varied from 13.3 Gy to 33 Gy, and remission rates varied from 0% to 84% (Table 5) (Kim et 
al., 1999, 2007; Landolt & Lomax, 2000; Laws & Vance, 1999; Post & Habas, 1990; Pouratian 
et al., 2006; Yildiz et al., 1999). Variations in success rate are likely related to the dose 
delivered to the tumor as well as other factors. Witt et al. noted no remissions with a 
prescription dose of 19 Gy (Witt et al., 1998; Witt, 2003). Pan et al. (Pan et al., 2000) reported 
a 52% endocrine ‘‘cure’’ rate in a retrospective study of 128 patients in whom GKRS was 
used as first-line treatment for prolactinomas with a prescription dose of 30 Gy. This study 
is on a large sample size, and is interesting in that GKRS was used as a first-line treatment 














Mitsumori 1998 LINAC 4 47 15 0 100 
Yoon 1998 LINAC 11 49 17 84 96 
Mokry 1999 GK 21 31 14 21 NR 
Pan 2000 GK 128 33 31.5 52 98.4 
Choi 2003 GK 21 42.5 28.5 24 100 
Muramatsu 
2003 LINAC 1 30 15 0 100 
Pouratian 2006 GK 23 58 18.6 24 89 
Brau 2011* LINAC 7 35.7 18.7 14.2 100 
Table 5. Summary of cases involving Radiosurgery in patients with prolactinomas. 
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Table 4. Summary of cases involving Radiosurgery in patients with Cushing’s disease. 
(*Unpublished manuscript in writing) 
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Jagannathan et al., 2007; Kobayashi et al., 2002; Morange-Ramos et al., 1998; Petrovich et al., 
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7.2.4 Nelson’s syndrome 
Compared with nonfunctioning and other functioning pituitary adenomas, much less 
information is available about the efficacy of stereotactic radiosurgery for the treatment of 
Nelson syndrome. A subset of Cushing’s patients do not achieve hormone normalization 
following microsurgery and radiosurgery, and undergo adrenalectomy as a ‘‘salvage’’ 
treatment for their disease. Although adrenalectomy is the definitive treatment for cortisol 
overproduction, a subset of patients may develop Nelson’s syndrome, characterized by 
rapid adenoma growth, hyper-pigmentation and tumor invasion into the parasellar 
structures (Nagesser et al., 2000). This is thought to be related to the lack of feedback on the 












Tumor   
Control (%) 
Ganz 1993 GKS 3 18 NR 0 100 
Wolffenbuttel 
1998 GKS 1 33 12 0 100 
Kobayashi 2002 GKS 6 63 28.7 33 100 
Pollock 2002 GKS 11 37 20 24 82 
Vogues 2006 LINAC 9 63/47a 15.3 16.7 89 
Mauerman 2007 GKS 23 20/50a 25 17/60b 91 
Table 6. Endocrine and radiographic outcomes of GKRS for Nelson’s syndrome. (a) Mean 
imaging follow-up/mean endocrine follow-up (b)ACTH levels decreased/ACTH reduced 
to normal values (50 pg/ml)  
Pollock and Young reported on 11 patients who underwent GKRS for Nelson’s syndrome. 
They reported control of tumor growth in 9 of 11 patients, with ACTH normalization in four 
patients (36%) (Pollock & Young, 2002).  
There are relatively few studies detailing the results of radiosurgery for Nelson’s syndrome 
(Table 6) ( Ganz, 2000; Ganz et al., 1993; Kobayashi et al., 2002; Laws & Vance, 1999; Levy et 
al., 1991; Mauermann et al., 2007; Pollock & Wolffenbuttel et al., 1998; Young, 2002). These 
studies report a mean tumor dose from between 12 Gy to 28.7 Gy, and an endocrine 
remission rate ranging from 0% to 36%, although only a minority of these studies defined 
what was meant by endocrine remission. Even cases where endocrine remission was not 
achieved, tumor growth control rates were favorable, ranging from 82% to 100%. 
8. Complications following radiosurgery for pituitary adenomas 
As previously stated, the most common problem after radiosurgery is development of 
hypopituitarism. Several groups have reported a low incidence (0–36%) of pituitary 
dysfunction following radiosurgery (Jagannathan et al., 2007; Jane et al., 2003; Sheehan et al., 
2006; Pollock et al., 1994). This incidence is likely higher when patients are followed long-
term, with the Karolinska Institute reporting a 72% incidence of hypopituitarism when 
patients were followed over 10 years (Hoybye et al., 2001). We have observed an overall risk 
of 20–30% for development of new hormone deficiency following radiosurgery without a 
significant difference across tumor pathologies. Recent studies using the Cyberknife for 
secretory adenomas, points to a significantly lower (9.5%) rate of endocrinopathy, although 
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these studies are limited by follow-up of 12 months and less in some cases (Adler et al., 
2006; Kajiwara et al., 2005; Pham et al., 2004).  
Ultimately, total dose prescribed and the prescription (margin) doses are likely the major 
factors determining the risk and onset of radiation induced hypopituitarism. The sequence 
of hormone loss following pituitary radiosurgery is unknown. The difficulty with 
determining the exact incidence of radiosurgery-induced hypopituitarism stems in part 
from the fact that many of the patients have previously undergone resection and some 
fractionated radiotherapy. In addition, pituitary deficiencies may results in part from aging. 
Thus, it is likely that hypopituitarism in the post-radiosurgical population is multifactorial 
in cause and related to radiosurgery as well as age-related changes and previous treatments 
(for example, microsurgery and radiotherapy). In spite of this, however, some have argued 
that the GH axis is the most sensitive to the late effects of radiation, with the radiation 
induced defect likely occurring at the hypothalamic level (Blacklay et al., 1986; Shalet, 1993). 
The gonadotropin and corticotrophin axes are also thought to be sensitive to radiation 
damage. Diabetes insipidus appears to be uncommon after radiosurgery with only sporadic 
case reports (Piedra et al., 2004). A well-controlled, long-term study focusing on this issue is 
needed to determine definitively the incidence of radiosurgery-induced hypopituitarism. 
Cranial neuropathies following radiosurgery are exceedingly rare following the first 
procedure, although the incidence may increase on re-treatment (Jagannathan et al., 2007). 
Visual injury in general can be avoided if the dose to the optic apparatus is restricted to less 
than 8 Gy (see previous discussion). 
Injury to the cavernous segment of the carotid artery or brain parenchyma is uncommon 
following radiosurgery. Pollock and associates have recommended that the prescription 
dose should be limited to less than 50% of the intracavernous CA vessel diameter (Pollock & 
Carpenter, 2003). Shin recommended restricting the dose to the internal CA to less than 30 
Gy (Shin et al., 2000).  
Parenchymal brain injury can be present especially in the hypothalamic and temporal 
regions. Patients with injuries to medial temporal lobes can present with complex partial 
seizures or if the injury is bilateral with recent memory impairment. Induction of cavernous 
malformations following radiosurgery to the sellar region is also theoretically possible but 
thus far has not been reported. 
The exact incidence of radiosurgical-induced neoplasm is unknown at present, although we 
have not seen one in our series of pituitary patients treated with m-LINAC system. Loeffler 
and colleagues recently reported on 6 patients, including 2 patients with pituitary adenomas 
who developed new tumors following radiosurgery (Loeffler et al., 2003). They concluded 
that although the risk of new tumor formation after radiosurgery appears to be significantly 
less than that seen following fractionated radiotherapy, new tumors can develop in the full 
dose region as well as in the low-dose periphery of the radiosurgical field. The latency to 
new tumor formation in this small series (between 6 years and 20 years) was similar to that 
seen after conventional radiation therapy. 
9. Prognosis and follow-up 
Prognosis for pituitary adenoma patients is largely dependent upon the adenoma size and 
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pituitary adenomas must be followed long-term with serial clinical, ophthalmological, 
endocrine and radiological evaluations.  
Serial visual field examinations and hormonal screening should be performed. In the 
majority of cases serial testing of adrenal, thyroid function and GH reserves may be 
required as well. Patients receiving hormone replacement should have their replacement 
therapy adjusted as necessary. 
Finally, serial MR imaging should be performed to assess for tumor recurrence. It is our 
practice to perform an initial post-radiosurgical MRI at 6 months after treatment with 
follow-up MRI’s yearly thereafter, unless otherwise indicated. Endocrine and 
ophthalmologic follow-up should typically occur at the same time to provide adequate 
correlation with the treatment. There should be a good communication with every discipline 
involved in the treatment of these patients. 
10. Conclusions 
Multimodality treatment is often used to manage pituitary adenomas. Therapeutic options 
include medical management, microsurgery, radiosurgery, and radiotherapy. Except for 
prolactinomas, microsurgery remains the primary treatment for sellar lesions in surgically 
fit patients, particularly when the lesion is exerting a mass effect on the optic apparatus or 
producing hormone overproduction. Nevertheless, 20 to 50% of patients experience 
recurrence of their adenomas, and adjuvant treatment is recommended for these patients. 
Stereotactic radiosurgery has been demonstrated to be a safe and highly effective treatment 
for patients with recurrent or residual pituitary adenomas. Radiosurgery affords effective 
growth control and hormone normalization for patients and has a generally shorter latency 
period than that of fractionated radiotherapy. This shorter latency period with radiosurgery 
can typically be managed with hormone-suppressive medications. Furthermore, the 
complications (for example, radiation-induced neoplasia and cerebral vasculopathy) 
associated with radiosurgery appear to occur less frequently than those associated with 
radiotherapy. Radiosurgery may even serve as a primary treatment for those patients 
deemed unfit for microsurgical tumor removal because they have other co morbidities or 
demonstrable tumors in a surgically inaccessible location. Radiosurgery can frequently 
preserve and, at times, even restore neurological and hormone function. 
Radiosurgery is a useful tool in the treatment of both secretory and non-secretory pituitary 
adenomas. In most patients, radiosurgery controls adenoma growth. However, 
normalization of hormone overproduction can vary considerably depending on the patients’ 
presenting condition. Challenges for the future include delineating the optimal timing for 
the administration of antisecretory medications and identifying factors that can improve the 
response of pituitary adenomas to radiosurgery. Finally, physicians caring for patients with 
pituitary disorders should establish uniform endocrinological criteria and diagnostic testing 
for pre- and post-radiosurgical evaluations. 
11. References 
Abe T, Yamamoto M, Taniyama M, Tanioka D, Izumiyama H, Matsumoto K (2002) Early 
palliation of oculomotor nerve palsy following gamma knife radiosurgery for 
pituitary adenoma. Eur Neurol 47:61–63. 
 
Stereotactic Radiosurgery for Pituitary Adenomas 
 
81 
Adler JR Jr, Chang SD, Murphy MJ, Doty J, Geis P, Hancock SL (1997) The Cyberknife: a 
frameless robotic system for radiosurgery. Funct Neurosurg 69: 124–128. 
Adler JR Jr, Gibbs IC, Puataweepong P, Chang SD (2006) Visual field preservation after 
multisession cyberknife radiosurgery for perioptic lesions. Neurosurgery 59:244–254 
discussion 244–254 
Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, 
Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, 
Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) 
Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin 
Endocrinol Metab 88:5593–5602.  
Becker, G., Kocher, M., Kortmann, R.D., Paulsen, F., Jeremic, B., Muller, R.P. & Bamberg, M. 
(2002) Radiation therapy in the multimodal treatment approach of pituitary 
adenoma. Strahlentherapie und Onkologie, 178, 173–186. 
Blacklay A, Grossman A, Ross RJ, Savage MO, Davies PS, Plowman PN, Coy DH, Besser 
GM (1986) Cranial irradiation for cerebral and nasopharyngeal tumors in children: 
evidence for the production of a hypothalamic defect in growth hormone release. J 
Endocrinol 108:25–29 
Brada, M., Burchell, L., Ashley, S. & Traish, D. (1999) The incidence of cerebrovascular 
accidents in patients with pituitary adenoma. International Journal of Radiation 
Oncology, Biology, Physics, 45, 693–698. 
Brada, M., Ford, D., Ashley, S., Bliss, J.M., Crowley, S., Mason, M., Rajan, B. & Traish, D. 
(1992) Risk of second brain tumor after conservative surgery and radiotherapy for 
pituitary adenoma. British Medical Journal, 304, 1343–1346. 
Brada, M., Rajan, B., Traish, D., Ashley, S., Holmes-Sellors, P.J., Nussey, S. & Uttley, D. 
(1993) The long-term efficacy of conservative surgery and radiotherapy in the 
control of pituitary adenomas. Clinical Endocrinology, 38, 571–578.  
Brada, M., Ashley, S., Ford, D., Traish, D., Burchell, L. & Rajan, B. (2002) Cerebrovascular 
mortality in patients with pituitary adenoma. Clinical Endocrinology, 57, 713–717. 
Buchfelder M, Fahlbusch R, Schott W, Honegger J (1991) Long term follow-up results in 
hormonally active pituitary adenomas after primary successful transsphenoidal 
surgery. Acta Neurochir Suppl (Wien) 53:72–76 
Chang SD, Murphy M, Geis P, Martin DP, Hancock SL, Doty JR, Adler JR Jr (1998) Clinical 
experience with image-guided robotic radiosurgery (the Cyberknife) in the 
treatment of brain and spinal cord tumors. Neurol Med Chir 38:780–783. 
Chen JC, Giannotta SL, Yu C, Petrovich Z, Levy ML, Apuzzo ML (2001) Radiosurgical 
management of benign cavernous sinus tumors: dose profiles and acute 
complications. Neurosurgery 48:1022–1030 discussion 1030–1022 
Chen JC, Giannotta SL, Yu C, Petrovich Z, Levy ML, Apuzzo ML (2001) Radiosurgical 
management of benign cavernous sinus tumors: dose profiles and acute 
complications. Neurosurgery 48:1022–1030 discussion 1030–1022  
Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D (2001) Successful 
long-term treatment of refractory Cushing’s disease with high-dose mifepristone 
(RU 486). J Clin Endocrinol Metab 86:3568–3573. 
Ciric I, Ragin A, Baumgartner C, Pierce D (1997) Complications of transsphenoidal surgery: 
results of a national survey, review of the literature, and personal experience. 





pituitary adenomas must be followed long-term with serial clinical, ophthalmological, 
endocrine and radiological evaluations.  
Serial visual field examinations and hormonal screening should be performed. In the 
majority of cases serial testing of adrenal, thyroid function and GH reserves may be 
required as well. Patients receiving hormone replacement should have their replacement 
therapy adjusted as necessary. 
Finally, serial MR imaging should be performed to assess for tumor recurrence. It is our 
practice to perform an initial post-radiosurgical MRI at 6 months after treatment with 
follow-up MRI’s yearly thereafter, unless otherwise indicated. Endocrine and 
ophthalmologic follow-up should typically occur at the same time to provide adequate 
correlation with the treatment. There should be a good communication with every discipline 
involved in the treatment of these patients. 
10. Conclusions 
Multimodality treatment is often used to manage pituitary adenomas. Therapeutic options 
include medical management, microsurgery, radiosurgery, and radiotherapy. Except for 
prolactinomas, microsurgery remains the primary treatment for sellar lesions in surgically 
fit patients, particularly when the lesion is exerting a mass effect on the optic apparatus or 
producing hormone overproduction. Nevertheless, 20 to 50% of patients experience 
recurrence of their adenomas, and adjuvant treatment is recommended for these patients. 
Stereotactic radiosurgery has been demonstrated to be a safe and highly effective treatment 
for patients with recurrent or residual pituitary adenomas. Radiosurgery affords effective 
growth control and hormone normalization for patients and has a generally shorter latency 
period than that of fractionated radiotherapy. This shorter latency period with radiosurgery 
can typically be managed with hormone-suppressive medications. Furthermore, the 
complications (for example, radiation-induced neoplasia and cerebral vasculopathy) 
associated with radiosurgery appear to occur less frequently than those associated with 
radiotherapy. Radiosurgery may even serve as a primary treatment for those patients 
deemed unfit for microsurgical tumor removal because they have other co morbidities or 
demonstrable tumors in a surgically inaccessible location. Radiosurgery can frequently 
preserve and, at times, even restore neurological and hormone function. 
Radiosurgery is a useful tool in the treatment of both secretory and non-secretory pituitary 
adenomas. In most patients, radiosurgery controls adenoma growth. However, 
normalization of hormone overproduction can vary considerably depending on the patients’ 
presenting condition. Challenges for the future include delineating the optimal timing for 
the administration of antisecretory medications and identifying factors that can improve the 
response of pituitary adenomas to radiosurgery. Finally, physicians caring for patients with 
pituitary disorders should establish uniform endocrinological criteria and diagnostic testing 
for pre- and post-radiosurgical evaluations. 
11. References 
Abe T, Yamamoto M, Taniyama M, Tanioka D, Izumiyama H, Matsumoto K (2002) Early 
palliation of oculomotor nerve palsy following gamma knife radiosurgery for 
pituitary adenoma. Eur Neurol 47:61–63. 
 
Stereotactic Radiosurgery for Pituitary Adenomas 
 
81 
Adler JR Jr, Chang SD, Murphy MJ, Doty J, Geis P, Hancock SL (1997) The Cyberknife: a 
frameless robotic system for radiosurgery. Funct Neurosurg 69: 124–128. 
Adler JR Jr, Gibbs IC, Puataweepong P, Chang SD (2006) Visual field preservation after 
multisession cyberknife radiosurgery for perioptic lesions. Neurosurgery 59:244–254 
discussion 244–254 
Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, 
Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, 
Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) 
Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin 
Endocrinol Metab 88:5593–5602.  
Becker, G., Kocher, M., Kortmann, R.D., Paulsen, F., Jeremic, B., Muller, R.P. & Bamberg, M. 
(2002) Radiation therapy in the multimodal treatment approach of pituitary 
adenoma. Strahlentherapie und Onkologie, 178, 173–186. 
Blacklay A, Grossman A, Ross RJ, Savage MO, Davies PS, Plowman PN, Coy DH, Besser 
GM (1986) Cranial irradiation for cerebral and nasopharyngeal tumors in children: 
evidence for the production of a hypothalamic defect in growth hormone release. J 
Endocrinol 108:25–29 
Brada, M., Burchell, L., Ashley, S. & Traish, D. (1999) The incidence of cerebrovascular 
accidents in patients with pituitary adenoma. International Journal of Radiation 
Oncology, Biology, Physics, 45, 693–698. 
Brada, M., Ford, D., Ashley, S., Bliss, J.M., Crowley, S., Mason, M., Rajan, B. & Traish, D. 
(1992) Risk of second brain tumor after conservative surgery and radiotherapy for 
pituitary adenoma. British Medical Journal, 304, 1343–1346. 
Brada, M., Rajan, B., Traish, D., Ashley, S., Holmes-Sellors, P.J., Nussey, S. & Uttley, D. 
(1993) The long-term efficacy of conservative surgery and radiotherapy in the 
control of pituitary adenomas. Clinical Endocrinology, 38, 571–578.  
Brada, M., Ashley, S., Ford, D., Traish, D., Burchell, L. & Rajan, B. (2002) Cerebrovascular 
mortality in patients with pituitary adenoma. Clinical Endocrinology, 57, 713–717. 
Buchfelder M, Fahlbusch R, Schott W, Honegger J (1991) Long term follow-up results in 
hormonally active pituitary adenomas after primary successful transsphenoidal 
surgery. Acta Neurochir Suppl (Wien) 53:72–76 
Chang SD, Murphy M, Geis P, Martin DP, Hancock SL, Doty JR, Adler JR Jr (1998) Clinical 
experience with image-guided robotic radiosurgery (the Cyberknife) in the 
treatment of brain and spinal cord tumors. Neurol Med Chir 38:780–783. 
Chen JC, Giannotta SL, Yu C, Petrovich Z, Levy ML, Apuzzo ML (2001) Radiosurgical 
management of benign cavernous sinus tumors: dose profiles and acute 
complications. Neurosurgery 48:1022–1030 discussion 1030–1022 
Chen JC, Giannotta SL, Yu C, Petrovich Z, Levy ML, Apuzzo ML (2001) Radiosurgical 
management of benign cavernous sinus tumors: dose profiles and acute 
complications. Neurosurgery 48:1022–1030 discussion 1030–1022  
Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D (2001) Successful 
long-term treatment of refractory Cushing’s disease with high-dose mifepristone 
(RU 486). J Clin Endocrinol Metab 86:3568–3573. 
Ciric I, Ragin A, Baumgartner C, Pierce D (1997) Complications of transsphenoidal surgery: 
results of a national survey, review of the literature, and personal experience. 





Cozzi R, Barausse M, Asnaghi D, Dallabonzana D, Lodrini S, Attanasio R (2001) Failure of 
radiotherapy in acromegaly. Eur J Endocrinol 145:717–726. 
Erfurth, E.M., Bulow, B., Mikoczy, Z., Svahn-Tapper, G. & Hagmar, L. (2001) Is there an 
increase in second brain tumours after surgery and irradiation for a pituitary 
tumour? Clinical Endocrinology, 55, 613–616.  
Erfurth, E.M., Bulow, B., Svahn-Tapper, G., Norrving, B., Odh, K., Mikoczy, Z., Bjork, J. & 
Hagmar, L. (2002) Risk factors for cerebrovascular deaths in patients operated and 
irradiated for pituitary tumors. Journal of Clinical Endocrinology and Metabolism, 87, 
4892–4899. 
Feigl GC, Bonelli CM, Berghold A, Mokry M (2002) Effects of gamma knife radiosurgery of 
pituitary adenomas on pituitary function. J Neurosurg 97:415–421 
Ferone D, Pivonello R, Resmini E, Boschetti M, Rebora A, Albertelli M, Albanese V, Colao A, 
Culler MD, Minuto F. Preclinical and clinical experiences with the role of dopamine 
receptors in the treatment of pituitary adenomas. Eur J Endocrinol. 2007 Apr; 156 
Suppl 1:S37-43.  
Flickinger JC, Lunsford LD, Kondziolka D (1992) Dose prescription and dose-volume effects 
in radiosurgery. Neurosurg Clin N Am 3:51–59 
Freda PU (2003) How effective are current therapies for acromegaly? Growth Horm IGF Res 
13(Suppl A): S144–S151  
Fukuoka S, Ito T, Takanashi M, Hojo A, Nakamura H (2001) Gamma knife radiosurgery for 
growth hormone-secreting pituitary adenomas invading the cavernous sinus. 
Stereotact Funct Neurosurg 76:213–217.  
Ganz JC (2002) Gamma knife radiosurgery and its possible relationship to malignancy: a 
review. J Neurosurg 97:644–652 
Ganz JC, Backlund EO, Thorsen FA (1993) The effects of Gamma Knife surgery of pituitary 
adenomas on tumor growth and endocrinopathies. Stereotact Funct Neurosurg 
61(Suppl 1):30–37. 
Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, 
Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus 
statement. J Clin Endocrinol Metab 85:526–529 
Hayashi M, Izawa M, Hiyama H, Nakamura S, Atsuchi S, Sato H, et al: Gamma knife 
radiosurgery for pituitary adenomas. Stereotact Funct Neurosurg 72 (Suppl 1):111–
118, 1999 
Hayashi M, Taira T, Ochiai T, Chernov M, Takasu Y, Izawa M, Kouyama N, Tomida M, 
Tokumaru O, Katayama Y, Kawakami Y, Hori T, Takakura K (2005) Gamma knife 
surgery of the pituitary: new treatment for thalamic pain syndrome. J Neurosurg 
102:38–41 Suppl 
Horvath E, Kovacs K, Scheithauer BW, Randall RV, Laws ER Jr, Thorner MO, Tindall GT, 
Barrow DL (1983) Pituitary adenomas producing growth hormone, prolactin, and 
one or more glycoprotein hormones: a histologic, immunohistochemical, and 
ultrastructural study of four surgically removed tumors. Ultrastruct Pathol 5:171–
183. 
Hoybye C, Grenback E, Rahn T, Degerblad M, Thoren M, Hulting AL (2001) 
Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up 
after treatment with stereotactic radiosurgery. Neurosurgery 49:284–291 discussion 
291–282 
 
Stereotactic Radiosurgery for Pituitary Adenomas 
 
83 
Ikeda H, Jokura H, Yoshimoto T (2001) Transsphenoidal surgery and adjuvant gamma knife 
treatment for growth hormone-secreting pituitary adenoma. J Neurosurg 95:285–291 
Izawa M, Hayashi M, Nakaya K, Satoh H, Ochiai T, Hori T, Takakura K (2000) Gamma knife 
radiosurgery for pituitary adenomas. J Neurosurg 93(Suppl 3):19–22 
Jackson IM, Noren G (1999) Gamma knife radiosurgery for pituitary tumors. Best Pract Res 
Clin Endocrinol Metab 13:461–469. 
Jagannathan J, Dumont AS, Jane JA Jr, Laws ER Jr (2005) Pediatric sellar tumors: diagnostic 
procedures and management. Neurosurg Focus 18:6. 
Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML (2007)  Gamma knife 
surgery for Cushing’s disease. J Neurosurg 106:980–987. 
Jane JA Jr, Vance ML, Woodburn CJ, Laws ER Jr (2003) Stereotactic radiosurgery for 
hypersecreting pituitary tumors: part of a multimodality approach. Neurosurg Focus 
14:e12. 
Jezkova J, Marek J, Hana V, Krsek M, Weiss V, Vladyka V, Lisak R, Vymazal J, Pecen L 
(2006) Gamma knife Radiosurgery for acromegaly – long-term experience. Clin 
Endocrinol 64:588–595. 
Kajiwara K, Saito K, Yoshikawa K, Kato S, Akimura T, Nomura S, Ishihara H, Suzuki M 
(2005) Image-guided stereotactic radiosurgery with the CyberKnife for pituitary 
adenomas. Minim Invasive Neurosurg 48:91–96. 
Kajiwara K, Saito K, Yoshikawa K, Kato S, Akimura T, Nomura S, Ishihara H, Suzuki M 
(2005) Image-guided stereotactic radiosurgery with the CyberKnife for pituitary 
adenomas. Minim Invasive Neurosurg 48:91–96. 
Kanter AS, Diallo AO, Jane JA Jr, Sheehan JP, Asthagiri AR, Oskouian RJ, Okonkwo DO, 
Sansur CA, Vance ML, Rogol AD, Laws ER Jr (2005) Single-center experience with 
pediatric Cushing’s disease. J Neurosurg 103:413–420 
Kim MS, Lee SI, Sim JH (1999) Gamma Knife radiosurgery for functioning pituitary 
microadenoma. Stereotact Funct Neurosurg 72(Suppl 1):119–124. 
Kim SH, Huh R, Chang JW, Park YG, Chung SS (1999) Gamma Knife radiosurgery for 
functioning pituitary adenomas. Stereotact Funct Neurosurg 72(Suppl 1):101–110. 
Kobayashi T, Kida Y, Mori Y (2002) Gamma knife Radiosurgery in the treatment of Cushing 
disease: long-term results. J Neurosurg 97:422–428  
Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, Wellis G (2000) 
Octreotide may act as a radio protective agent in acromegaly. J Clin Endocrinol 
Metab 85:1287–1289.  
Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, Wellis G (1998) 
Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison 
with fractionated radiotherapy. J Neurosurg 88:1002–1008 
Landolt AM, Lomax N (2000) Gamma knife radiosurgery for prolactinomas. J Neurosurg 
93(Suppl 3):14–18. 
Laws ER Jr, Ebersold MJ, Piepgras DG, Randall RV, Salassa RM (1985) The results of 
transsphenoidal surgery in specific clinical entities. In: Management of pituitary 
adenomas and related lesions with emphasis on Transsphenoidal microsurgery. Laws ER 
Jr, Randall RV, Kern EB et al (eds) Appleton-Century-Crofts, New York, pp 277–305 
Laws ER Jr, Fode NC, Redmond MJ (1985) Transsphenoidalsurgery following unsuccessful 






Cozzi R, Barausse M, Asnaghi D, Dallabonzana D, Lodrini S, Attanasio R (2001) Failure of 
radiotherapy in acromegaly. Eur J Endocrinol 145:717–726. 
Erfurth, E.M., Bulow, B., Mikoczy, Z., Svahn-Tapper, G. & Hagmar, L. (2001) Is there an 
increase in second brain tumours after surgery and irradiation for a pituitary 
tumour? Clinical Endocrinology, 55, 613–616.  
Erfurth, E.M., Bulow, B., Svahn-Tapper, G., Norrving, B., Odh, K., Mikoczy, Z., Bjork, J. & 
Hagmar, L. (2002) Risk factors for cerebrovascular deaths in patients operated and 
irradiated for pituitary tumors. Journal of Clinical Endocrinology and Metabolism, 87, 
4892–4899. 
Feigl GC, Bonelli CM, Berghold A, Mokry M (2002) Effects of gamma knife radiosurgery of 
pituitary adenomas on pituitary function. J Neurosurg 97:415–421 
Ferone D, Pivonello R, Resmini E, Boschetti M, Rebora A, Albertelli M, Albanese V, Colao A, 
Culler MD, Minuto F. Preclinical and clinical experiences with the role of dopamine 
receptors in the treatment of pituitary adenomas. Eur J Endocrinol. 2007 Apr; 156 
Suppl 1:S37-43.  
Flickinger JC, Lunsford LD, Kondziolka D (1992) Dose prescription and dose-volume effects 
in radiosurgery. Neurosurg Clin N Am 3:51–59 
Freda PU (2003) How effective are current therapies for acromegaly? Growth Horm IGF Res 
13(Suppl A): S144–S151  
Fukuoka S, Ito T, Takanashi M, Hojo A, Nakamura H (2001) Gamma knife radiosurgery for 
growth hormone-secreting pituitary adenomas invading the cavernous sinus. 
Stereotact Funct Neurosurg 76:213–217.  
Ganz JC (2002) Gamma knife radiosurgery and its possible relationship to malignancy: a 
review. J Neurosurg 97:644–652 
Ganz JC, Backlund EO, Thorsen FA (1993) The effects of Gamma Knife surgery of pituitary 
adenomas on tumor growth and endocrinopathies. Stereotact Funct Neurosurg 
61(Suppl 1):30–37. 
Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, 
Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus 
statement. J Clin Endocrinol Metab 85:526–529 
Hayashi M, Izawa M, Hiyama H, Nakamura S, Atsuchi S, Sato H, et al: Gamma knife 
radiosurgery for pituitary adenomas. Stereotact Funct Neurosurg 72 (Suppl 1):111–
118, 1999 
Hayashi M, Taira T, Ochiai T, Chernov M, Takasu Y, Izawa M, Kouyama N, Tomida M, 
Tokumaru O, Katayama Y, Kawakami Y, Hori T, Takakura K (2005) Gamma knife 
surgery of the pituitary: new treatment for thalamic pain syndrome. J Neurosurg 
102:38–41 Suppl 
Horvath E, Kovacs K, Scheithauer BW, Randall RV, Laws ER Jr, Thorner MO, Tindall GT, 
Barrow DL (1983) Pituitary adenomas producing growth hormone, prolactin, and 
one or more glycoprotein hormones: a histologic, immunohistochemical, and 
ultrastructural study of four surgically removed tumors. Ultrastruct Pathol 5:171–
183. 
Hoybye C, Grenback E, Rahn T, Degerblad M, Thoren M, Hulting AL (2001) 
Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up 
after treatment with stereotactic radiosurgery. Neurosurgery 49:284–291 discussion 
291–282 
 
Stereotactic Radiosurgery for Pituitary Adenomas 
 
83 
Ikeda H, Jokura H, Yoshimoto T (2001) Transsphenoidal surgery and adjuvant gamma knife 
treatment for growth hormone-secreting pituitary adenoma. J Neurosurg 95:285–291 
Izawa M, Hayashi M, Nakaya K, Satoh H, Ochiai T, Hori T, Takakura K (2000) Gamma knife 
radiosurgery for pituitary adenomas. J Neurosurg 93(Suppl 3):19–22 
Jackson IM, Noren G (1999) Gamma knife radiosurgery for pituitary tumors. Best Pract Res 
Clin Endocrinol Metab 13:461–469. 
Jagannathan J, Dumont AS, Jane JA Jr, Laws ER Jr (2005) Pediatric sellar tumors: diagnostic 
procedures and management. Neurosurg Focus 18:6. 
Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML (2007)  Gamma knife 
surgery for Cushing’s disease. J Neurosurg 106:980–987. 
Jane JA Jr, Vance ML, Woodburn CJ, Laws ER Jr (2003) Stereotactic radiosurgery for 
hypersecreting pituitary tumors: part of a multimodality approach. Neurosurg Focus 
14:e12. 
Jezkova J, Marek J, Hana V, Krsek M, Weiss V, Vladyka V, Lisak R, Vymazal J, Pecen L 
(2006) Gamma knife Radiosurgery for acromegaly – long-term experience. Clin 
Endocrinol 64:588–595. 
Kajiwara K, Saito K, Yoshikawa K, Kato S, Akimura T, Nomura S, Ishihara H, Suzuki M 
(2005) Image-guided stereotactic radiosurgery with the CyberKnife for pituitary 
adenomas. Minim Invasive Neurosurg 48:91–96. 
Kajiwara K, Saito K, Yoshikawa K, Kato S, Akimura T, Nomura S, Ishihara H, Suzuki M 
(2005) Image-guided stereotactic radiosurgery with the CyberKnife for pituitary 
adenomas. Minim Invasive Neurosurg 48:91–96. 
Kanter AS, Diallo AO, Jane JA Jr, Sheehan JP, Asthagiri AR, Oskouian RJ, Okonkwo DO, 
Sansur CA, Vance ML, Rogol AD, Laws ER Jr (2005) Single-center experience with 
pediatric Cushing’s disease. J Neurosurg 103:413–420 
Kim MS, Lee SI, Sim JH (1999) Gamma Knife radiosurgery for functioning pituitary 
microadenoma. Stereotact Funct Neurosurg 72(Suppl 1):119–124. 
Kim SH, Huh R, Chang JW, Park YG, Chung SS (1999) Gamma Knife radiosurgery for 
functioning pituitary adenomas. Stereotact Funct Neurosurg 72(Suppl 1):101–110. 
Kobayashi T, Kida Y, Mori Y (2002) Gamma knife Radiosurgery in the treatment of Cushing 
disease: long-term results. J Neurosurg 97:422–428  
Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, Wellis G (2000) 
Octreotide may act as a radio protective agent in acromegaly. J Clin Endocrinol 
Metab 85:1287–1289.  
Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, Wellis G (1998) 
Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison 
with fractionated radiotherapy. J Neurosurg 88:1002–1008 
Landolt AM, Lomax N (2000) Gamma knife radiosurgery for prolactinomas. J Neurosurg 
93(Suppl 3):14–18. 
Laws ER Jr, Ebersold MJ, Piepgras DG, Randall RV, Salassa RM (1985) The results of 
transsphenoidal surgery in specific clinical entities. In: Management of pituitary 
adenomas and related lesions with emphasis on Transsphenoidal microsurgery. Laws ER 
Jr, Randall RV, Kern EB et al (eds) Appleton-Century-Crofts, New York, pp 277–305 
Laws ER Jr, Fode NC, Redmond MJ (1985) Transsphenoidalsurgery following unsuccessful 






Laws ER Jr, Thapar K (1996) Recurrent pituitary adenomas. In: Pituitary adenomas. Landolt 
AM, Vance ML, Reilly PL (eds) Churchill-Livingtone, Edinburgh, pp 385–394 
Laws ER Jr, Vance ML (1999) Radiosurgery for pituitary tumors and craniopharyngiomas. 
Neurosurg Clin N Am 10:327–336 
Laws ER, Sheehan JP (2006) Pituitary surgery: a modern approach. Front Horm Res. Basel, 
Karger vol 34, pp I-X 
Laws ER, Vance ML, Thapar K (2000) Pituitary surgery for the management of acromegaly. 
Horm Res 53(Suppl 3):71–75. 
Leber KA, Bergloff J, Langmann G, Mokry M, Schrottner O, Pendl G (1995) Radiation 
sensitivity of visual and oculomotor pathways. Stereotact Funct Neurosurg 64(Suppl 
1):233–238 
Leber KA, Bergloff J, Pendl G (1998) Dose-response tolerance of the visual pathways and 
cranial nerves of the cavernous sinus to stereotactic radiosurgery. J Neurosurg 
88:43–50. 
Levy RP, Fabrikant JI, Frankel KA, Phillips MH, Lyman JT, Lawrence JH, Tobias CA (1991) 
Heavy-charged-particle Radiosurgery of the pituitary gland: clinical results of 840 
patients. Stereotact Funct Neurosurg 57:22–35.  
Lim YL, Leem W, Kim TS, Rhee BA, Kim GK (1998) Four years’ experiences in the treatment 
of pituitary adenomas with gamma knife radiosurgery. Stereotact Funct Neurosurg 
70(Suppl1):95–109.  
Loeffler JS, Niemierko A, Chapman PH (2003) Second tumors after radiosurgery: tip of the 
iceberg or a bump in the road? Neurosurgery 52:1436–1440 discussion 1440–1432 
Losa M, Valle M, Mortini P, Franzin A, Da Passano CF, Cenzato M, et al. (2004) Gamma 
Knife surgery for treatment of residual nonfunctioning pituitary adenomas after 
surgical debulking. J Neurosurg 100:438–444 
Mahmoud-Ahmed AS, Suh JH (2002) Radiation therapy for Cushing’s disease: a review. 
Pituitary 5:175–180. 
Mampalam TJ, Tyrrell JB, Wilson CB (1988) Transsphenoidal microsurgery for Cushing 
disease. A report of 216 cases. Ann Intern Med 109:487–493 
Mauermann WJ, Sheehan JP, Chernavvsky DR, Laws ER, Steiner L, Vance ML (2007) 
Gamma Knife surgery for adrenocorticotropic hormone-producing pituitary 
adenomas after bilateral adrenalectomy. J Neurosurg 106:988–993.  
Mitsumori M, Shrieve DC, Alexander E III, Kaiser UB, Richardson GE, Black PM, et al. 
(1998): Initial clinical results of LINAC-based stereotactic radiosurgery and 
stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 42:573–
580 
Mokry M, Ramschak-Schwarzer S, Simbrunner J, Ganz JC, Pendl G (1999): A six year 
experience with the postoperative radiosurgical management of pituitary 
adenomas. Stereotact Funct Neurosurg 72 (Suppl 1):88–100 
Morange-Ramos I, Regis J, Dufour H, Andrieu JM, Grisoli F, Jaquet P, Peragut JC (1998) 
Gamma-knife surgery for secreting pituitary adenomas. Acta Neurochir (Wien) 
140:437–443.  
Muramatsu J, Yoshida M, Shioura H, Kawamura Y, Ito H, Takeuchi H, et al. (2003): [Clinical 
results of LINAC-based stereotactic Radiosurgery for pituitary adenoma.] Nippon 
Igaku Hoshasen Gakkai Zasshi 63:225–230 
 
Stereotactic Radiosurgery for Pituitary Adenomas 
 
85 
Nagesser SK, van Seters AP, Kievit J, Hermans J, Krans HM, van de Velde CJ (2000) Long-
term results of total adrenalectomy for Cushing’s disease. World J Surg 24:108–113.  
Nieman LK (2002) Medical therapy of Cushing’s disease. Pituitary 5:77–82. 
Pan L, Zhang N, Wang EM, Wang BJ, Dai JZ, Cai PW (2000) Gamma knife radiosurgery as a 
primary treatment for prolactinomas. J Neurosurg 93(Suppl 3):10–13 
Petrovich Z, Yu C, Giannotta SL, Zee CS, Apuzzo ML (2003) Gamma knife radiosurgery for 
pituitary adenoma: early results. Neurosurgery 53:51–59 discussion 59–61 
Pham CJ, Chang SD, Gibbs IC, Jones P, Heilbrun MP, Adler JR Jr (2004) Preliminary visual 
field preservation after staged CyberKnife radiosurgery for perioptic lesions. 
Neurosurgery 54:799–810 discussion 810–812 
Piedra MP, Brown PD, Carpenter PC, Link MJ (2004) Resolution of diabetes insipidus 
following gamma knife surgery for a solitary metastasis to the pituitary stalk. Case 
report. J Neurosurg 101:1053–1056 
Pollock BE, Carpenter PC: Stereotactic radiosurgery as an alternative to fractionated 
radiotherapy for patients with recurrent or residual nonfunctioning pituitary 
adenomas. Neurosurgery 53: 1086–1094, 2003 
Pollock BE, Cochran J, Nat N, Brown PD, Erickson D, Link MJ, Garces YI, Foote RL, Stafford 
SL, Shomberg PJ. (2008) Gamma knife Radiosurgery for patients with 
nonfunctioning pituitary adenomas: results from a 15 year experience. Int J Radiat 
Oncol Biol Phys. 70(5): 1325-9. 
Pollock BE, Jacob JT, Brown PD, Nippoldt TB (2007) Radiosurgery of growth hormone-
producing pituitary adenomas: factors associated with biochemical remission. J 
Neurosurg 106:833–838. 
 Pollock BE, Kondziolka D, Lunsford LD, Flickinger JC (1994) Stereotactic radiosurgery for 
pituitary adenomas: imaging, visual and endocrine results. Acta Neurochir Suppl 
(Wien) 62:33–38 
Pollock BE, Young WF Jr (2002) Stereotactic radiosurgery for patients with ACTH-
producing pituitary adenomas after prior adrenalectomy. Int J Radiat Oncol Biol 
Phys 54:839–841. 
Post KD, Habas JE (1990) Comparison of long term results between prolactin secreting 
adenomas and ACTH secreting adenomas. Can J Neurol Sci 17:74–77 
Pouratian N, Sheehan J, Jagannathan J, Laws ER Jr, Steiner L, Vance ML (2006) Gamma knife 
radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 
59:255–266 discussion 255–266.  
Rahn T, Thoren M, Hall K, Backlund EO (1980) Stereotactic radiosurgery in Cushing’s 
syndrome: acute radiation effects. Surg Neurol 14:85–92 
Shalet SM (1993) Radiation and pituitary dysfunction. N Engl J Med 328:131–133. 
Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws ER Jr (2000) Radiosurgery for 
Cushing’s disease after failed transsphenoidal surgery. J Neurosurg 93:738–742 
Sheehan JP, Jagannathan J, Pouratian N, Steiner L (2006) Stereotactic radiosurgery for 
pituitary adenomas: a review of the literature and our experience. Front Horm Res 
34:185–205 
Sheehan JP, Kondziolka D, Flickinger J, Lunsford LD (2002) Radiosurgery for residual or 
recurrent nonfunctioning pituitary adenoma. J Neurosurg 97:408–414 
Sheehan JP, Kondziolka D, Flickinger J, Lunsford LD (2002): Radiosurgery for residual or 





Laws ER Jr, Thapar K (1996) Recurrent pituitary adenomas. In: Pituitary adenomas. Landolt 
AM, Vance ML, Reilly PL (eds) Churchill-Livingtone, Edinburgh, pp 385–394 
Laws ER Jr, Vance ML (1999) Radiosurgery for pituitary tumors and craniopharyngiomas. 
Neurosurg Clin N Am 10:327–336 
Laws ER, Sheehan JP (2006) Pituitary surgery: a modern approach. Front Horm Res. Basel, 
Karger vol 34, pp I-X 
Laws ER, Vance ML, Thapar K (2000) Pituitary surgery for the management of acromegaly. 
Horm Res 53(Suppl 3):71–75. 
Leber KA, Bergloff J, Langmann G, Mokry M, Schrottner O, Pendl G (1995) Radiation 
sensitivity of visual and oculomotor pathways. Stereotact Funct Neurosurg 64(Suppl 
1):233–238 
Leber KA, Bergloff J, Pendl G (1998) Dose-response tolerance of the visual pathways and 
cranial nerves of the cavernous sinus to stereotactic radiosurgery. J Neurosurg 
88:43–50. 
Levy RP, Fabrikant JI, Frankel KA, Phillips MH, Lyman JT, Lawrence JH, Tobias CA (1991) 
Heavy-charged-particle Radiosurgery of the pituitary gland: clinical results of 840 
patients. Stereotact Funct Neurosurg 57:22–35.  
Lim YL, Leem W, Kim TS, Rhee BA, Kim GK (1998) Four years’ experiences in the treatment 
of pituitary adenomas with gamma knife radiosurgery. Stereotact Funct Neurosurg 
70(Suppl1):95–109.  
Loeffler JS, Niemierko A, Chapman PH (2003) Second tumors after radiosurgery: tip of the 
iceberg or a bump in the road? Neurosurgery 52:1436–1440 discussion 1440–1432 
Losa M, Valle M, Mortini P, Franzin A, Da Passano CF, Cenzato M, et al. (2004) Gamma 
Knife surgery for treatment of residual nonfunctioning pituitary adenomas after 
surgical debulking. J Neurosurg 100:438–444 
Mahmoud-Ahmed AS, Suh JH (2002) Radiation therapy for Cushing’s disease: a review. 
Pituitary 5:175–180. 
Mampalam TJ, Tyrrell JB, Wilson CB (1988) Transsphenoidal microsurgery for Cushing 
disease. A report of 216 cases. Ann Intern Med 109:487–493 
Mauermann WJ, Sheehan JP, Chernavvsky DR, Laws ER, Steiner L, Vance ML (2007) 
Gamma Knife surgery for adrenocorticotropic hormone-producing pituitary 
adenomas after bilateral adrenalectomy. J Neurosurg 106:988–993.  
Mitsumori M, Shrieve DC, Alexander E III, Kaiser UB, Richardson GE, Black PM, et al. 
(1998): Initial clinical results of LINAC-based stereotactic radiosurgery and 
stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 42:573–
580 
Mokry M, Ramschak-Schwarzer S, Simbrunner J, Ganz JC, Pendl G (1999): A six year 
experience with the postoperative radiosurgical management of pituitary 
adenomas. Stereotact Funct Neurosurg 72 (Suppl 1):88–100 
Morange-Ramos I, Regis J, Dufour H, Andrieu JM, Grisoli F, Jaquet P, Peragut JC (1998) 
Gamma-knife surgery for secreting pituitary adenomas. Acta Neurochir (Wien) 
140:437–443.  
Muramatsu J, Yoshida M, Shioura H, Kawamura Y, Ito H, Takeuchi H, et al. (2003): [Clinical 
results of LINAC-based stereotactic Radiosurgery for pituitary adenoma.] Nippon 
Igaku Hoshasen Gakkai Zasshi 63:225–230 
 
Stereotactic Radiosurgery for Pituitary Adenomas 
 
85 
Nagesser SK, van Seters AP, Kievit J, Hermans J, Krans HM, van de Velde CJ (2000) Long-
term results of total adrenalectomy for Cushing’s disease. World J Surg 24:108–113.  
Nieman LK (2002) Medical therapy of Cushing’s disease. Pituitary 5:77–82. 
Pan L, Zhang N, Wang EM, Wang BJ, Dai JZ, Cai PW (2000) Gamma knife radiosurgery as a 
primary treatment for prolactinomas. J Neurosurg 93(Suppl 3):10–13 
Petrovich Z, Yu C, Giannotta SL, Zee CS, Apuzzo ML (2003) Gamma knife radiosurgery for 
pituitary adenoma: early results. Neurosurgery 53:51–59 discussion 59–61 
Pham CJ, Chang SD, Gibbs IC, Jones P, Heilbrun MP, Adler JR Jr (2004) Preliminary visual 
field preservation after staged CyberKnife radiosurgery for perioptic lesions. 
Neurosurgery 54:799–810 discussion 810–812 
Piedra MP, Brown PD, Carpenter PC, Link MJ (2004) Resolution of diabetes insipidus 
following gamma knife surgery for a solitary metastasis to the pituitary stalk. Case 
report. J Neurosurg 101:1053–1056 
Pollock BE, Carpenter PC: Stereotactic radiosurgery as an alternative to fractionated 
radiotherapy for patients with recurrent or residual nonfunctioning pituitary 
adenomas. Neurosurgery 53: 1086–1094, 2003 
Pollock BE, Cochran J, Nat N, Brown PD, Erickson D, Link MJ, Garces YI, Foote RL, Stafford 
SL, Shomberg PJ. (2008) Gamma knife Radiosurgery for patients with 
nonfunctioning pituitary adenomas: results from a 15 year experience. Int J Radiat 
Oncol Biol Phys. 70(5): 1325-9. 
Pollock BE, Jacob JT, Brown PD, Nippoldt TB (2007) Radiosurgery of growth hormone-
producing pituitary adenomas: factors associated with biochemical remission. J 
Neurosurg 106:833–838. 
 Pollock BE, Kondziolka D, Lunsford LD, Flickinger JC (1994) Stereotactic radiosurgery for 
pituitary adenomas: imaging, visual and endocrine results. Acta Neurochir Suppl 
(Wien) 62:33–38 
Pollock BE, Young WF Jr (2002) Stereotactic radiosurgery for patients with ACTH-
producing pituitary adenomas after prior adrenalectomy. Int J Radiat Oncol Biol 
Phys 54:839–841. 
Post KD, Habas JE (1990) Comparison of long term results between prolactin secreting 
adenomas and ACTH secreting adenomas. Can J Neurol Sci 17:74–77 
Pouratian N, Sheehan J, Jagannathan J, Laws ER Jr, Steiner L, Vance ML (2006) Gamma knife 
radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 
59:255–266 discussion 255–266.  
Rahn T, Thoren M, Hall K, Backlund EO (1980) Stereotactic radiosurgery in Cushing’s 
syndrome: acute radiation effects. Surg Neurol 14:85–92 
Shalet SM (1993) Radiation and pituitary dysfunction. N Engl J Med 328:131–133. 
Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws ER Jr (2000) Radiosurgery for 
Cushing’s disease after failed transsphenoidal surgery. J Neurosurg 93:738–742 
Sheehan JP, Jagannathan J, Pouratian N, Steiner L (2006) Stereotactic radiosurgery for 
pituitary adenomas: a review of the literature and our experience. Front Horm Res 
34:185–205 
Sheehan JP, Kondziolka D, Flickinger J, Lunsford LD (2002) Radiosurgery for residual or 
recurrent nonfunctioning pituitary adenoma. J Neurosurg 97:408–414 
Sheehan JP, Kondziolka D, Flickinger J, Lunsford LD (2002): Radiosurgery for residual or 





Shin M, Kurita H, Sasaki T, Tago M, Morita A, Ueki K, Kirino T (2000) Stereotactic 
radiosurgery for pituitary adenoma invading the cavernous sinus. J Neurosurg 
93(Suppl 3):2–5 
Tomlinson, J.W., Holden, N., Hills, R.K., Wheatley, K., Clayton, R.N., Bates, A.S., Sheppard, 
M.C. & Stewart, P.M. (2001) Association between premature mortality and 
hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet, 
357, 425–431. 
Tsang, R.W., Brierley, J.D., Panzarella, T., Gospodarowicz, M.K., Sutcliffe, S.B. & Simpson, 
W.J. (1994) Radiation therapy for pituitary adenoma: treatment outcome and 
prognostic factors. International Journal of Radiation Oncology, Biology, Physics, 30, 
557–565 
Vance ML (1998) Endocrinological evaluation of acromegaly. J Neurosurg 89:499–500 
Witt TC (2003) Stereotactic radiosurgery for pituitary tumors. Neurosurg Focus 14:e10. 
Witt TC, Kondziolka D, Flickinger JC, Lunsford LD (1998) Gamma knife radiosurgery for 
pituitary tumors. In: Gamma knife brain surgery progress in neurological surgery. 
Lunsford LD, Kondziolka D, Flickinger J (eds) Karger, Basel, pp114–127. 
Wolffenbuttel BH, Kitz K, Beuls EM (1998) Beneficial gammaknife radiosurgery in a patient 
with Nelson’s syndrome. Clin Neurol Neurosurg 100:60–63.  
Wowra B, Stummer W (2002) Efficacy of gamma knife Radiosurgery for nonfunctioning 
pituitary adenomas: a quantitative follow up with magnetic resonance imaging-
based volumetric analysis. J Neurosurg 97:429–432  
Yildiz F, Zorlu F, Erbas T, Atahan L (1999) Radiotherapy in the management of giant 
pituitary adenomas. Radiother Oncol 52:233–237. 
Yoon SC, Suh TS, Jang HS, Chung SM, Kim YS, Ryu MR, et al. 1998 Clinical results of 24 
pituitary macroadenomas with linac based stereotactic radiosurgery. Int J Radiat 





Shin M, Kurita H, Sasaki T, Tago M, Morita A, Ueki K, Kirino T (2000) Stereotactic 
radiosurgery for pituitary adenoma invading the cavernous sinus. J Neurosurg 
93(Suppl 3):2–5 
Tomlinson, J.W., Holden, N., Hills, R.K., Wheatley, K., Clayton, R.N., Bates, A.S., Sheppard, 
M.C. & Stewart, P.M. (2001) Association between premature mortality and 
hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet, 
357, 425–431. 
Tsang, R.W., Brierley, J.D., Panzarella, T., Gospodarowicz, M.K., Sutcliffe, S.B. & Simpson, 
W.J. (1994) Radiation therapy for pituitary adenoma: treatment outcome and 
prognostic factors. International Journal of Radiation Oncology, Biology, Physics, 30, 
557–565 
Vance ML (1998) Endocrinological evaluation of acromegaly. J Neurosurg 89:499–500 
Witt TC (2003) Stereotactic radiosurgery for pituitary tumors. Neurosurg Focus 14:e10. 
Witt TC, Kondziolka D, Flickinger JC, Lunsford LD (1998) Gamma knife radiosurgery for 
pituitary tumors. In: Gamma knife brain surgery progress in neurological surgery. 
Lunsford LD, Kondziolka D, Flickinger J (eds) Karger, Basel, pp114–127. 
Wolffenbuttel BH, Kitz K, Beuls EM (1998) Beneficial gammaknife radiosurgery in a patient 
with Nelson’s syndrome. Clin Neurol Neurosurg 100:60–63.  
Wowra B, Stummer W (2002) Efficacy of gamma knife Radiosurgery for nonfunctioning 
pituitary adenomas: a quantitative follow up with magnetic resonance imaging-
based volumetric analysis. J Neurosurg 97:429–432  
Yildiz F, Zorlu F, Erbas T, Atahan L (1999) Radiotherapy in the management of giant 
pituitary adenomas. Radiother Oncol 52:233–237. 
Yoon SC, Suh TS, Jang HS, Chung SM, Kim YS, Ryu MR, et al. 1998 Clinical results of 24 
pituitary macroadenomas with linac based stereotactic radiosurgery. Int J Radiat 
Onc Biol Phys 41:849–853 
Pituitary Adenomas
Edited by Vafa Rahimi-Movaghar
Edited by Vafa Rahimi-Movaghar
Pituitary Adenomas is a comprehensive book about the most common pathology of the 
pituitary gland in the sellar region. The book chapters include epidemiology, symptoms 
and signs, clinical, imaging, immunohistochemical and ultrastructural pathological 
diagnosis, therapeutic approaches and outcome of the functional and non-functional 
pituitary tumors. Therapies include medications, endoscopic transphenoidal and 
open surgeries; radiotherapy includes gamma knife radiosurgery. Visual symptoms 
has important and characteristic patterns which has discussed in one specific chapter. 
Endocrine secretion is another characteristic in 40% of pituitary adenomas. Therefore, 
another chapter presents it. Stereotactic radiosurgery and endoscopic surgery both 
have special role in recent decades. Thus, they have considered specifically, too. 
Authors expect to give excellent insight in pituitary adenoma to the book readers.
Photo by SubstanceP / iStock
ISBN 978-953-51-0041-6
Pituitary A
denom
as
 6815 7
